Queen Victoria's childhood home now a hotel - equipped with bespoke Athanor kitchen

Now a five-star luxury hotel and award winning restaurant, Ynyshir Hall is the AA Hotel of the Year in Wales for the last two years running, and its restaurant holds a Michelin Star. With a cornucopia of high quality local ingredients, Ynyshir Hall’s menu showcases Welsh lamb, Welsh Wagyu beef and organic pork, with the kitchen gardens producing fruit, vegetables, herbs and salads for the restaurant, and with the foraging of wild foods providing an extra touch of something special. Ynyshir Hall’s restaurant serves innovative and award winning dishes under the experienced eyes of Head chef, Gareth Ward, who was Sous Chef at the two Michelin Star, Restaurant Sat Bains, Nottingham, for three years prior to arriving at Ynyshir. Previously, Ward also worked at the one star Hambleton Hall Rutland and Seaham Hall, Durham. Motivation for investment: Ynyshir’s existing kitchen was approaching the end of its lifetime, with increasing inefficiencies and energy consumption. Along with this, as it neared the end of its maintenance cycle and became increasingly cost prohibitive to repair and run, Ynyshir elected to invest in a new specially designed kitchen and suite tailored to the needs of the facility and its staff. The solution would be specified and provided by Grande Cuisine in conjunction with kitchen fit our specialists C&C Catering Equipment of Chester. Challenges identified: Ynyshir Hall is mainly a Victorian property and carries several idiosyncrasies and unique features that where challenging from a planning and design perspective. Varying floor heights, room shapes and using only the footprint of the previous kitchen meant that space considerations needed to be specially considered to maximise the efficiency and workflow of the new kitchen. Solutions: Grande Cuisine’s supplied solution was a unique hybrid of its three core brands, including components and equipment from its bespoke Athanor cook suites, modular CAPIC equipment and Adventys induction technology products. In addition, following guidance from C&C Catering Equipment the client accepted the proposal to extended the kitchen area, as well as the addition of a chef’s dining area, which was subsequently undertaken as part of the overall refurbishment.     The primary suite was supplied with a one-piece top crafted from 3mm stainless steel chrome titanium alloy, which was guaranteed to last the lifetime of the product. Set within this one-piece top are two multi-zoned multi-point induction hobs with variable power controls. Each ranging from 50W to a maximum of 5000W (5kW). A double Plaque Athanor provides the centrepiece, with two separate 4kW heating zones. The Plaque Athanor can be used both as a conventional heating surface - for pots and pans at preparation and mise-en-place or as a direct cooking surface during main service period. Able to reach temperatures of 450 degrees Celsius, the Plaque Athanor is ideal for use with large pans for stock and preparation work, with the added benefit that the cooking plate radiates far less heat than a conventional style gas solid tops. During service, when used as a direct cooking surface, the non-microporous solid steel cooking plate does not absorb oils, butters or flavours, meaning it is ideal for cooking meat, fish and vegetables without cross-contamination of flavours. The Athanor equipment’s reliability and consistent heat management means it provides a quality solution, while also significantly reducing pan traffic, as there is less time and labour being spent on cleaning pans and returning them to the suite during service. Supplied with a set of two removable cast iron searing plates, the Plaque Athanor cook plates can also be used to mark and char-grill produce, when required. A wall mounted CAPIC quick therm hi-light salamander grill was also supplied, and is powered by three ceran radiant heating elements for rapid heating. Reaching 200 degrees Celsius in 20 seconds once activated, this rapid heating means the unit can be switched on as needed, as opposed to being left on constantly radiating heat into the kitchen environment. The salamander can also able to be used at lower settings as a holding or resting surface, or at full power for browning. A final feature of the supplied solution is the three inset twin zone induction hobs manufactured by Adventys. With one located within the kitchen’s specialist pastry section, and the other two in the cold preparation and main service areas. The twin zone 6.4kW induction hobs are flush mounted with the surrounding with granite work tops, and are controlled by a remote touch control panel situated on the front fascia of the stainless steel fabrication within which they sit. Benefits for the customer: Grande Cuisine’s solution to Ynyshir Hall has more than enhanced its capabilities while also reducing its energy consumption and costs, along with reducing its long-term maintenance needs. The kitchen was overdue an upgrade, with the previous kitchen equipment increasingly proving costly and complicated to maintain and keep operating at full capability. The new layout of the kitchen is a huge success and ensures better workflows in the busy areas of the kitchen The supplied units from Grande Cuisine have enabled the kitchen an unprecedented degree of flexibility, with the different components each offering quality, high performance cooking and versatility. Each unit is easy to clean, and therefore, easy to maintain. For more information about Grande Cuisine’s range of products and services, please contact Grande Cuisine directly on 01908 745540, email info@grandecuisine.co.uk  (info@grandecuisine.co.uk%20)or visit the website www.grandecuisine.co.uk

Sprint Bioscience enters into collaboration with Bayer HealthCare on tumor metabolism program

Sprint Bioscience AB (publ) (Sprint Bioscience) and Bayer HealthCare (Bayer) have entered into a collaboration and license agreement for the research, development, and commercialization of oncological drug candidates. Under the agreement, Sprint Bioscience licenses an early-stage inhibitor program targeting tumor metabolism to Bayer. Subsequently, Bayer will have full control over further development and worldwide commercialization rights for potential cancer therapeutics and diagnostics. – “We are very happy to have entered into this agreement for one of our tumor metabolism projects. We are convinced that Bayer is a perfect partner to further develop this program. This agreement also gives us the opportunity to further invest in the expansion of our portfolio within the area of tumor metabolism,” said Dr Anders Åberg, CEO of Sprint Bioscience. “Bayer is committed to translating the findings of cancer research into effective therapies to improve the quality of life of patients. Addressing the metabolism of cancer cells is a promising approach in oncology and one of our focus areas in cancer research at Bayer,” said Professor Andreas Busch, Head of Global Drug Discovery and member of the Executive Committee of Bayer HealthCare. “We are looking forward to expanding our portfolio in this area through the agreement with Sprint Bioscience. This early research program has the potential to lead to new treatment options for cancer patients.” As a result of a tumor's uncontrolled growth, cancer cells exhibit an altered metabolism (tumor metabolism) and thereby are often resistant to conventional radiation- and chemotherapy. Sprint Bioscience has developed molecules inhibiting a novel metabolic target, which is vital for cancer cell survival. Such inhibitors can potentially lead to effective new treatments by selectively affecting cancer cells. Sprint Bioscience is eligible to receive up to approximately 190 Million Euro in potential preclinical, clinical and net sales based milestone payments, including an upfront payment from Bayer upon signing of the agreement. Furthermore, Sprint Bioscience is also eligible to receive royalties on worldwide net sales of any resulting products under the collaboration. About Sprint Bioscience Sprint Bioscience AB (publ) is part of the new Swedish pharmaceutical industry. The company has the goal to develop drug candidates for the global pharmaceutical market within the field of oncology in a more time- and resource-efficient manner. Sprint Bioscience is situated in Stockholm, Sweden. Sprint Bioscience share is listed on NASDAQ First North and traded under the name SPRINT. Additional information is available on the company website; www.sprintbioscience.com.Certified Advisor is Redeye, www.redeye.se. About Bayer HealthCare The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of around EUR 20.0 billion (2014), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 60,700 employees (Dec 31, 2014) and is represented in more than 100 countries. More information is available at www.healthcare.bayer.com. 

PA Resources submits Zarat Field Plan of Development

PA Resources is pleased to announce that it has submitted an updated Zarat Field Plan of Development to the Tunisian authorities. This Plan of Development is a technically and commercially robust plan which has been constructed by the Zarat Field joint development team; an integrated team comprising of staff from both PA Resources and the state oil company, ETAP (L’Entreprise Tunisienne d’Activités Pétrolières). The Zarat Field is a large, shallow-water, gas-condensate and oil field containing estimated recoverable reserves of 147 mmboe. It is Tunisia’s largest undeveloped field and production from Zarat Field will be critical in alleviating a forecast future gas supply deficit in Tunisia. Zarat Field is geologically similar to PA Resources’ nearby Didon Field and to other producing fields such as Ashtart and Hasdrubal fields in Tunisia and the giant El Bouri and Al Jurf fields in Libya. The Zarat Field extends across two license tracts; the Zarat license to the south and the Joint Oil block to the north. The parties in the Zarat license are PA Resources Tunisia as operator and ETAP. ETAP has the option to back-in to the southern tract for up to a 55% working interest, in which scenario PA Resources would retain 45%, and a decision on this back-in option follows shortly after acceptance of the Plan of Development. The northern tract is held by Joint Oil, which was formed as a joint entity between ETAP (Tunisia) and the National Oil Company (Libya). The proposed development is in two phases, with Phase 1 comprising four production wells and production facilities to process and export 20,000 bbls/d of oil and 100 mmscfg/d of raw gas.  Phase 2 comprises a further four development wells, with expanded facilities to increase capacity to 40,000 bbls/d and 200 mmscf/d of raw gas. First oil would be expected in 2020. The Plan of Development makes full use of existing Gulf of Gabes infrastructure for the reinjection of CO2, the export of sales gas to shore, onshore gas processing and extraction of the LPG stream. The Zarat facilities also have the potential to act as a hub to facilitate development of nearby stranded oil and gas fields in the eastern Gulf of Gabes, such as PA Resources’ Elyssa gas field. Following acceptance of the Zarat Field Plan of Development by the Tunisian authorities, the project will enter a front-end engineering design phase with project sanction during 2017. PA Resources CEO, Mark McAllister commented: “We are delighted to have reached this milestone on the Zarat Field. The Plan of Development is the result of dedicated work and close collaboration between PA Resources and ETAP, which has achieved total alignment on the optimum approach to maximise resource recovery and value from the Zarat Field. The phased approach to development allows reduced capital outlay to achieve commercial production from what is a most important field development for Tunisia”. Stockholm 28 July, 2015PA Resources AB (publ) For additional information, please contact: Mark McAllister, President & Chief Executive OfficerPhone:   +44 203 322 0100E-mail:   ir@paresources.se PA Resources AB (publ) is an international oil and gas group which conducts exploration, development and production of oil and gas assets. The Group operates in Tunisia, Republic of Congo (Brazzaville), United Kingdom, Denmark, Netherlands and Germany. PA Resources has oil production in Tunisia. The parent company is located in Stockholm, Sweden. PA Resources’ net sales amounted to SEK 603 million in 2014. The share is listed on the NASDAQ OMX in Stockholm, Sweden. For additional information, please visit www.paresources.se. The above information has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 08:30 CET 28 July 2015.

Todd Haushalter joins Evolution as Chief Product Officer

Haushalter will join Evolution by 1 September from MGM Resorts International, where he currently holds the Las Vegas-based role of Vice President of Gaming Operations. A gaming industry veteran in experience, knowledge and achievements, if not in years, Haushalter began his gaming career as a high limit casino dealer for London Clubs International in Las Vegas in 2000. His subsequent rapid rise through the ranks of some of the world’s biggest gaming companies included time with Wynn Las Vegas, where he was Senior Gaming Analyst, with Shuffle Master, first as Product Director Asia, based in Macau and then as global Director of Product Development, and with Bally Technologies, as Vice President of Business Strategy. Since 2011 Haushalter has also developed and patented several casino game innovations including a revolutionary, new Baccarat shuffler, a new method for displaying roulette game historical data and trends, and a system for projecting interactive betting spots onto gaming tables as well as new table games. Jens von Bahr, CEO of Evolution, said: “We are thrilled to have attracted such a well-respected star of the gaming world to Evolution. Todd’s vast experience in the land-based sector, his knowledge, his ideas and his US and global track record are all a perfect fit for Evolution as we move forward, and as many operators focus on convergence. He is a top addition to our team and will be instrumental in driving Evolution product innovation and delivery, and penetrating new markets in the Live Casino sector.” Haushalter added: “I’ve worked closely with Evolution before – on the Shuffle Master deal that resulted in side bets being integrated into Evolution’s Live Blackjack, and on other game content. I’m familiar with the company and the Evolution product portfolio and very excited to be joining up with the world’s leading Live Casino provider. This is a different challenge for me in a hugely important sector – and I can’t wait to get started.” 

Bright future for gut bacteria and donors after BBC endorsement, say specialists

Microbiologist Glenn Taylor, Founder of the Taymount Clinic, in Hertfordshire, which treats people from all over the world with pioneering Faecal Microbiota Transplants (FMT), comments come after the BBC referred to the treatment as ‘a doctors dream’ and, ‘almost a miracle’ in its Trust Me I’m a Doctor programme. “The world is sitting up and noting the power of the microbiome,” said Mr Taylor, whose clinic helps people with a range of gastrointestinal conditions, including Clostridium difficile (C Diff) and Crohn’s disease as well as neurological and other problems. “Those of us involved in this field of research have known for a long time that by normalising gut flora, many patients are reporting beneficial changes in accompanying conditions and as the demand grows we can see in the not-too-distant future, faecal donation being as normal as blood donation,” he said. In the Trust Me I’m a Doctor series, the feature focussed on FMT having a 90% or more success rate in treating Clostridium Difficile (C Diff), whilst also saying it held great possibilities for other diseases, such as Crohn’s and Multiple Sclerosis. Mr Taylor, whose clinic was featured on BBC Newsnight earlier this year, where the programme focused on the use of FMT to eradicate C Difficile, said there has been an increased interest in the subject over the last couple of years. “The fascinating world of the human microbiome is slowly but surely gaining a foothold as a serious component in delivering health.  The increased use of antibiotics combined with a decrease in the variety of diet, has resulted in a reduction in the diversity of beneficial bacteria that help to look after the human body.” he added.  “It is a fact that human beings and their gut flora are a complex ecosystem and this realisation is beginning to capture the imagination within the scientific world. This is not just good news for FMT specialists, but the whole of mankind.” Click here at 37 minutes to see Trust me I’m a Doctor on FMT http://www.bbc.co.uk/iplayer/episode/b063jzxq/trust-me-im-a-doctor-series-3-episode-2 Editors Notes Taymount Clinic – FMT Treatment & Gut Flora Experts The Taymount Clinic are known internationally as a specialist centre for the production of tested, certified, high quality gut bacteria and effective, efficient implant techniques. Researching intestinal bacteria since 2006, the Taymount Clinic is now a recognised world leader in applying Faecal Microbiota Transplant or FMT treatment procedures to create a “normal” bacterial environment in patients with a broad range of conditions. Dr Simon Greenfield (http://taymount.com/about-fmt/meet-chief-medical-officer) MD FRCP Consultant Gastroenterologist and Chief Medical Officer to the Taymount Clinic provides guidance and supervision to the management of patients undergoing FMT at the clinic. The Taymount clinic provides FMT treatment to normalise gut bacteria in patients with Clostridium difficile infection.  The Taymount clinic has also replaced gut bacteria in patients with Inflammatory Bowel Diseases (IBD) such as Crohn’s disease and Ulcerative colitis, post-antibiotic Dysbiosis, food intolerance, Multiple Sclerosis and Parkinson’s disease. The Taymount Clinic cannot at this this time supply statistics for any likely clinical outcome as clinical trials are ongoing for many conditions. For further information about Taymount Clinic at http://taymount.com/  For Press Enquiries, contact  Nolan PR mn@nolanpr.co.uk or tel 01564 822861/07505 133302

Dolphin announces East Campeche 2D Multi-Client project in Mexico

Dolphin has commenced the East Campeche 2D long offset Multi-Client survey in Mexico, utilizing the M/V Artemis Arctic. The licensed approved 19.597 line kilometer survey is well positioned towards the recent Mexican announced 5 year plan for leases and Dolphin will be able to deliver time processed seismic data products in time for the upcoming first Mexican license round. The survey is supported by industry pre-funding. Andy Phipps, President Dolphin Western Hemisphere commented; " Dolphin is very pleased to begin the acquisition of its first survey of this new era in Mexican petroleum exploration. We feel our survey is in a good location to make the most of the licensing rounds that the Mexican authorities have outlined for the next four calendar years " Dolphin survey map Please find Dolphin Mexico survey map attached, for further information contact: Atle Jacobsen, CEOMobile: +47 97 71 53 36E-mail: atle.jacobsen@dolphingeo.com Erik Hokholt, CFOMobile: +47 90 75 60 64E-mail: erik.hokholt@dolphingeo.com Dolphin Group ASAHelsfyr AtriumInnspurten 150663 OSLO Phone: +47 22 07 15 30Fax: +47 22 07 15 31 www.dolphingeo.com Dolphin Group ASA is the Parent company of Dolphin Geophysical AS, a global full-range, asset light supplier of marine Geophysical services. Dolphin operates a fleet of new generation, high-capacity seismic vessels and offers contract seismic surveys, Multi-Client projects and processing services on a worldwide basis. Dolphin Group ASA is listed at Oslo Stock Exchange(OSE ticker: DOLP)

GardenAware.com Sets Its Sites on New Generation of Gardeners

The new online gardening resource, Garden Aware is aiming to get more young readers gardening. It has set out to break the stereotype that green fingers are a hobby for the older generation with a colourful and engaging website offering interesting and attention-grabbing articles.   With a recent global gardening survey revealing that 47% of the UK population would like to introduce their children and/or grandchildren to the world of horticulture, it has never been a better time for families to grab their gloves and seed the passion for gardening. Research suggest that the younger generation is becoming more interested in gardening with a recent survey showing it is more popular than the cinema with some 25-35 year-olds.  This year, the Royal Horticulture Society also found that 89% of 16-25-year-olds have a garden or grow plants. Shad Zac, Owner of Garden Aware said, “The number of young gardeners is on the rise, however, many still believe that gardening is reserved for the elderly, the retired or those with too much time on their hands. Here at Garden Aware we aim to show budding horticulturalists that tackling a garden is not only relaxing, but rewarding.” It is never too early to experience the array of benefits that gardening offers both physical and psychological. These include a lowering of blood pressure, to lower chances of strokes and heart disease and a better diet free of too much processed food and full of fresh fruit and vegetables.   Zac added, “Our website offers a vast range of articles, techniques and tips for anyone who wishes to get their fingers green. There is something for everyone, and with years of experience, Garden Aware is designed to be accessible for young gardeners to pick up the tools they require.” To find out more about Garden Aware visit the website: http://www.gardenaware.com

Jordan selects Zircotec ceramic coating for Austin A40 Historic Touring Car

A blend of increased performance coupled with a period look has led Mike Jordan to specify Zircotec’s ThermoHold® thermal barrier coating for its Austin A40 historic touring car. The ability to squeeze more performance from the 1293cc A Series engine and ensuring a more period look under the bonnet led Jordan to use Zircotec and follows the use on both the Ford GT40 he prepared and son Andrew’s BTCC MG6. “Historic racing is very competitive and we are looking for every opportunity to get performance from the car,” says Mike Jordan. “The coating keeps heat levels down underbonnet and can offer a little bit extra performance. Every gain, especially when you only have 130bhp is worthwhile.” Alongside the performance and surface temperature reductions of up to 33 percent, aesthetics also played a key role in Jordan’s selection. “When we built the car, we had a shiny stainless manifold that wasn’t really period,” adds Jordan. “Increasingly historic events want classic race cars to look as they did in period. Zircotec’s black ceramic coating looks right and is so much neater than wraps or exhaust bandages.” Renowned for its high standards of preparation and with a string of successes, it’s unsurprising that the former British Touring Car racer’s outfit is already preparing more cars and planning to use Zircotec on the next car. “We’ve got a Lotus Cortina Touring Car coming next and we’ll be using Zircotec again on that.”


New Delhi (28 July 2015)—In a move that will spare the lives of millions of animals over coming years, animal sacrifice has been cancelled indefinitely at Nepal's Gadhimai festival, the world's biggest animal sacrifice event held every five years for around 265 years. The decision announced by the Nepal temple trust (http://www.hsi.org/assets/pdfs/gadhimai-temple-trust-statement-ram-chandra-shah.pdf) at a special press conference in Delhi today, follows rigorous negotiations and campaigning by Humane Society International/India and Animal Welfare Network Nepal. Gauri Maulekhi, HSI/India consultant & Trustee, People for Animals, who petitioned India’s Supreme Court against the movement of animals from India to the Gadhimai festival, said, “This is a tremendous victory for compassion that will save the lives of countless animals. HSI/India was heartbroken to witness the bloodshed at Gadhimai, and we've worked hard to help secure this ban on future sacrifice. We commend   the temple committee but acknowledge that a huge task lies ahead of us in educating the public so that they are fully aware. HSI/India and People for Animals will now spend the next three and a half years til the next Gadhimai educating devotees in the states of Bihar, Jharkhand, Uttar Pradesh and West Bengal on the temple trust’s decision not to sacrifice animals. Animal sacrifice is a highly regressive practice and no nation in the modern world should entertain it.” Manoj Gautam, founding member of AWNN and campaigner against the Gadhimai festival, said, “We applaud the temple committee’s decision to end this mass slaughter of innocent animals and hope that they will continue to support us in our future endeavors for protecting animals in the country. AWNN’s progressive move to work directly with the temple committee, with Humane Society International/India’s support has been the key that changed the whole face of the campaign and is the reason for the achievement we have now.” In 2014, HSI/India and AWNN's global campaign against the Gadhimai animal massacre captured the public imagination when thousands of national and international supporters expressed their ire and displeasure against the ruthless killing. Protests were held worldwide. With the Supreme Court of India’s intervention to prohibit the movement of animals from India to Nepal, AWNN and HSI/India saw a reduction of up to 70 percent in the number of animals sacrificed from 2009. The Supreme Court’s order resulted in more than 100 arrests of those breaching the order, and more than 2,500 animals saved. Earlier this month the Supreme Court of India issued directions to states to set up mechanisms to prevent animals from being taken to Gadhimai in future and create awareness against animal sacrifice.   Earlier this year, following the global outrage steming from the Gadhimai massacre, the temple committee also decided not to sacrifice any animals during the harvest festival (Sankranti). Instead, the temple officials have been confiscating the animals and caring for them until rescuers can rehome them. Mr Ram Chandra Shah, Chairman of the Gadhimai Temple Trust, issued a statement on the decision to stop holding animal sacrifices during the Gadhimai festival, which can be found here (http://www.hsi.org/assets/pdfs/gadhimai-temple-trust-statement-ram-chandra-shah.pdf). High resolution photos are available for download here. For access to the full Gadhimai photo library email nmukherjee@hsi.org or whiggins@hsi.org  Photo 1 (http://news.cision.com/humane-society-international/i/gadhimai-festival-2014,m10392) Photo 2 (http://news.cision.com/humane-society-international/i/gadhimai-festival-2014,m10393) Photo 3 (http://news.cision.com/humane-society-international/i/gadhimai-festival-2014,m10394) Photo 4 press conference  (http://news.cision.com/humane-society-international/i/temple-trust-with-hsi-july-2015,m10396) Facts: ·         It is estimated that more than 500,000 buffalo, goats, chickens and other animals were decapitated at Gadhimai in 2009, but in 2014 the numbers had reduced by 70 percent. ·       The origins of Gadhimai date back around 265 years ago, when the founder of the Gadhimai Temple, Bhagwan Chowdhary, had a dream that the goddess Gadhimai wanted blood in return for freeing him from prison, protecting him from evil and promising prosperity and power. The goddess asked for a human sacrifice, but Chowdhary successfully offered an animal instead, and this been repeated every five years since. ·       Among others, President Emeritus of the World Council of Arya Samaj and noted social activist, Swami Agnivesh, were at the forefront of urging Indian devotees to boycott the mass slaughter by holding a hunger strike at the heart of the temple ·        B. D. Sharma, director general of SSB was awarded with the ‘Leadership in Animal Welfare’ award for his exemplary contribution in curbing the illegal transport of animals during Gadhimai ENDS

Sustainable Fashion Co Putting Best Foot Forwards

There’s a new face of sustainable fashion coming to the UK – Croatian shoe brand Startas + Co. The manufacturer aims to lead the way in sustainable eco fashion by championing organic and natural fabrics, ethical trade practices and handmade luxury. Sustainability is a hot topic for businesses around the world, but the fashion industry is lagging behind. 5% of the UK’s total annual carbon and water footprints can be attributed to clothing consumption. Thousands of tonnes of used clothing is sent to landfill each year rather than being recycled, which is why Startas + Co is urging conscious consumers to buy less. Jelena Micunovic, Managing Director of Startas + Co said, “Every woman needs a staple pair of plimsole trainers – but we shouldn’t be buying a new pair each season to follow the ever changing trends. Buy an eco-friendly, sustainable pair of trainers which will stand the test of time, and you’ll be doing your bit for the planet.” Made from 100% organic materials, each pair of Startas is produced ethically in the company’s factory in Croatia, and handmade with love. It’s not just the environment Startas + Co strives to protect – it’s also the workers of the production industry. The profits from a typical non Fairtrade t-shirt which costs $10 are unfairly distributed – with 50% going to the retailer and just $0.03 given to the factory workers. The lifestyle brand is on a mission to fight unfair trade and production around the world by setting an example to all other fashion manufacturers. The first collection of classic and stylish trainers from Startas + Co are now available in the UK. The ethical footwear brand doesn’t compromise on style and has created its own design with detachable bows, soon to be hitting pavements from London to Llandudno. Jelena added, “We take pride in our sustainable way of producing each and every shoe. This doesn’t mean that the style of our luxury trainers take a backseat – fashion and ethical production go hand in hand.” For more information about Startas + Co and to view the brand new UK collection, visit: http://startasandco.com/

The OurSense Collection from Touched Interiors

Bring a touch of modern design and abstract glamour into your home with the new OurSense Collection – exclusively distributed by luxury retailers Touched Interiors. Revealing imaginative shapes, daring use of lines and an eclectic colour palette, this striking range will bring intrigue into your interiors and revitalise any home. The diverse collection encapsulates the very best of innovative European design. Collection highlights include the White Silver Leaf Sideboard, the Green Prism Cabinet and the Wood and Diamond Glass Sideboard. Each piece has been expertly created using bold use of colour and high quality workmanship, resulting in a striking contrast between design and quality. The company, founded in 2009, offers handcrafted furniture from all around the world, and boast an extensive range of opulent interior and exterior furnishings. This includes a vast selection of free-standing and hanging sofas, dining tables and chairs, and coffee and cocktail tables. For the full range visit www.touchedinteriors.co.uk For more details/images please contact: annabel@jwcpr.com / 0161 381 0173 Sent by jwc on behalf of Touched Interiors Note to Editors Images attached of: Vivid Armchair This flamboyant armchair will promise to liven up any space or corner. The sofa structure is made in beech wood and upholstered in a luxurious durable fabric. The seat comprises of springs for extra comfort and durability. £3,162.00 The Daydreams Sideboard A creative and abstract sideboard with a perfect interaction between wood, glass and steel. Created with cherry wood and marine plywood, with finishing lacquer, feet in steel and handmade diamond glass.  £10,755.00 White silver leaf grand feet sideboard A colourful, modern and abstract chest created in marine plywood, and artistically finished with lacquer and silver leaf.  £7,149.00 Vivid Three Seater Sofa This flamboyant three seater sofa will promise to liven up any space.The sofa structure is made in beech wood, upholstered in a luxurious durable fabric. The seat comprises of springs for extra comfort and durability.The legs are beautifully detailed in black lacquer.£5000.00 Deluxe Red Prism Bench This is a stunning prism bench with the structure made in beech wood, with an application of finishing lacquer.  The legs are intricately detailed and finished in gold leaf.£3,154.00 The Prism Cabinet Silver leaf green prism cabinet with drawers inside. Structure in beech wood, marine plywood and finishing lacquer with doors in silver leaf and leather.  £4,153.00 All available in bespoke sizes and finishes

Rebel opens its doors to public once more

To herald August in, Penryn’s own Rebel Brewing Co are having an open day to announce their member’s club. The membership club is set to launch on the Crowdfunder platform, and seeks to give fans merchandise and bargains on their award winning beers, through an annual membership. On the 1st of August, the company wish to invite all over 18s to come and see the new kit in action. Brewery tours will run continuously throughout the day, and anyone attending will get to sample the full Rebel range and learn about the Crowdfunding opportunities. Having got 4 years of brewing under their belt, the company recently invested profits in a brand new high quality brew kit, with an output of up to 18,000 pints of award winning ales every week. With 50 new signups in the last month, the new kit’s quality speaks for itself. It has also increased the quantity of ale produced; meaning the brewery are set to take on new pubs, bars and restaurants to hoist the sails of this craft ale, and continue to grow. With the delicate, refreshing Surfbum at just 3.5% giving citrusy peach notes, a cool summery beer with a lighter finish will make the perfect accompaniment to a hot day. Whereas if the unpredictable Cornish weather results in stormier skies, delicious thick and malty 80 Shilling is like a drinkable hug, and the 8.5% stout Mexi-cocoa transports drinkers to the centre of Mexico. Rebel make a core range of seven classic ales, and plan to continue to develop new beers using the subscription fees. Head brewer and founder of the company Rob Lowe said, “We have been looking to focus on getting the quality just right, and we’re now confident that our classic range is the best ever. We want to thank our loyal customers by offering benefits, and free tours.” Now stocked nationally, The Rebel Brewing Co have a strong following throughout Cornwall and the rest of the UK. There will be a burger van on site to provide sustenance for those in attendance, and the brewery is accessible by buses to ASDA. To find out more about Rebel, see their website at www.rebelbrewing.co.uk

Announcement from PA Resources’ Annual General Meeting on 28 July 2015

PA Resources AB (publ) held its Annual General Meeting on Tuesday 28 July 2015 in Stockholm. This is a summary of the most important decisions made by the Annual General Meeting. The annual report for the parent company and the consolidated group’s annual report, together with the auditor’s report for the fiscal year 2014, were presented. The income statement and the balance sheet for both the parent company and the group regarding the fiscal year 2014 were adopted by the meeting. The Meeting decided that no dividend would be paid out for the fiscal year 2014. The members of the Board and the CEO were granted discharge from liability for the fiscal year 2014. The Meeting decided that the Board would comprise of three ordinary members and re-elected Paul Waern and the company’s CEO Mark McAllister and elected the company’s CFO Tomas Hedström as new member.  Paul Waern was elected Chairman of the Board. The Meeting decided to re-appoint Ernst & Young as auditors with the chartered accountant Björn Ohlsson as head auditor. The fees to the Board of Directors were determined by the Meeting to a total of SEK 550,000 (last year 1,650,000) which in its entirety should be paid to the chairman (last year 550,000). No board fee would be paid to the other members since they are employed by the company (last year 275,000 to members who were not employed). The fees to the auditor would be paid according to reasonable and by the Company approved invoice. The Meeting decided to establish a Nomination Committee for the next AGM, whereby the three largest shareholders in the Company as per 30 September 2015 will be asked to appoint one representative each, who together with the Chairman of the Board will comprise the Nomination Committee. In the event that a shareholder does not appoint a member, the next largest shareholder will be asked. The composition of the Nomination Committee must be communicated at the latest six months before the AGM in 2016. The Meeting approved the guidelines proposed by the Board regarding remuneration to the CEO and other senior executives. The Meeting decided to reduce the company’s share capital with SEK 1,403,283,100.80 to SEK 11,316,799.20 for covering of losses and to adopt a new Articles of Association in connection thereto. The reduction will be made without redemption of shares and no permit from the Swedish Companies Registration Office will be required. The CEO of PA Resources, Mark McAllister, addressed the Meeting and reported on the Group’s development during the fiscal year 2014 and the first half year 2015. The presentation is available on the company’s website www.paresources.se. Stockholm, July 28, 2015PA Resources AB (publ) For additional information, please contact: Tomas Hedström, Chief Financial OfficerPhone:   +46 8 545 211 50E-mail:   ir@paresources.se PA Resources AB (publ) is an international oil and gas group which conducts exploration, development and production of oil and gas assets. The Group operates in Tunisia, Republic of Congo (Brazzaville), United Kingdom, Denmark, Netherlands and Germany. PA Resources has oil production in Tunisia. The parent company is located in Stockholm, Sweden. PA Resources’ net sales amounted to SEK 603 million in 2014. The share is listed on the NASDAQ OMX in Stockholm, Sweden. For additional information, please visit www.paresources.se. The above information has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 12:00 CET 28 July 2015.

Print Workz Launches 3D Aluminium Printing for Homes

Online print specialists, Print Workz are offering homes a unique and eye catching way to display photos with the launch of their new 3D aluminium prints. The photo is printed on a patented aluminium panel, which sits ½ inch off a unique background, giving a 3D effect. Prints are delivered to homes ready to hang on the wall using an innovative free invisible hanging system. Using Dibond high quality aluminium for each panel, prints are 3mm thick and are made of three solid layers. Two outer layers of aluminium cradle the centre layer, a hard piece of plastic designed to help keep prints strong and solid. Available in three sizes and dispatched within 7 to 10 working days via courier, the exclusive matte finish prints are UV resistant. They offer a fun, unique and attractive way to show off family photos in the home, bringing contemporary texture to a traditional medium. Prints are available in sizes; · 8" x 10" background with your photo on an 5" x 7" panel · 12" x 12" background with your photo on an 8" x 8" panel · 11" x 14" background with your photo on an 8" x 10" panel Charles Staddon, Production Manager said, “Our 3D aluminium prints are a one of a kind way to personalise any home. Perfect for family photos, the new prints are a great way to showcase stylish snaps this season. “We use only the best quality metal and printing products to ensure that all 3D prints meet the highest standards possible.” Print Workz are the only UK printer offering this type of service. Available in a wide range of designs, 3D prints are an attractive alternative to the traditional canvas print. Covered by a 100% satisfaction guarantee, customers who are not happy with their purchase can return prints within seven days for a full refund. Staddon added, “Our prints stand out in their own right and are a great addition to any home looking for an injection of personality.” For more information visit: http://www.printworkz.co.uk


28 July 2015 – Reports following the inquest into the death of a young mother, Kimberley Jones (25), who died in 2013 from carbon monoxide poisoning caused by a defective coal powered heater is a warning that it’s not just gas fired appliances that can result in death from ‘the silent killer’, and that essential safety measures are vital to help prevent such needless tragedies. Kimberley Jones was spending the first night in her new home purchased for her by Ms Jones’ parents; she moved into the semi-detached home in Cwmbach, South Wales, early to begin cleaning and decorating the house and nursery for her six-month-old son. South Wales Police had called in professional plumbing and heating engineer Howard Reed to undertake an incident investigation on their behalf, and conducted an examination of the heater and connected chimney flue.  It was his opinion that the heater’s airways had not been cleaned for 'probably four or five years' commenting that, “The fire appliance leaked lethal amounts of gas after debris blocked the fireplace's airway, meaning emissions could not escape.” The inquest heard that carbon monoxide levels were 16 times above the acceptable limit. B&ES (http://www.b-es.org/), the Building & Engineering Services Association, say that it’s vital that homeowners take precautions against the build up of potentially lethal levels of carbon monoxide in the home.  They say that such safety measures may have prevented the tragic death of this young mother.  Mark Oakes, spokesman for B&ES, said, “The first line of defence against CO poisoning and the most important thing you can do to keep you and your family out of harm’s way is to ensure that all fuel burning household appliances such as the boiler, cooker or fire and any connected flues or extraction systems in the home are regularly maintained to keep them operating in safe working order and subject to annual safety checks by a qualified engineer.  For gas this should be a Gas Safe Registered engineer, for oil an OFTEC member and for solid fuel a HETAS member. “Never attempt to install or service an appliance yourself and make sure that all chimneys and flues are swept regularly by a qualified sweep who is a member of the National Association of Chimney Sweeps (NACS) or one of the other associations representing professional chimney sweeps. “A second but important line of defence is to fit one or more CO alarms. As you cannot see or smell carbon monoxide fitting a European Standard certified audible carbon monoxide alarm is a low cost but potentially life saving device. CO alarms are widely available to buy online or through electrical, hardware and home improvement stores and cost as little as £15.” For information about the services offered by B&ES members in the residential sector visit: www.trustmark.org.uk. Ends

Zensar Technologies Shares Insight into Leveraging the Cloud for Business Transformation in New Thought Paper

Westborough, MA – July 28, 2015: Zensar Technologies (http://www.zensar.com), a leading software and infrastructure services provider, today announced the availability of a new thought paper titled ‘Transform Your Business – Get Cloud Ready’. The paper features Gartner research and highlights the value of cloud computing services for next- generation solutions and how IT service providers can enable the most effective adoption and management of cloud models. The paper can be downloaded at: https://info.zensar.com/GetCloudReady.html.Based on real-world insights from Zensar’s work with global enterprises, the thought paper provides insights on how enterprises can take advantage of a move to cloud computing as a step toward realizing next-generation solutions that incorporate cloud, social, mobile and information. The paper will share: · Is it realistic that a move to the cloud will keep your data as secure as when it was stored in your own data center? · Will cloud solutions optimize and enhance efficiencies across the organization and enable an improved end user experience? · Are there customizable Hybrid Cloud solutions for organizations to merge their public and private clouds and what are the business advantages of doing this? “As organizations continue to discover the value of the cloud to enable more flexible and agile IT environments while lowering costs, they are relying on partners to help manage their cloud migration. The self-service and on-demand nature of cloud computing has created new challenges for IT services providers, as well as opportunities to deliver innovative, next-generation solutions to clients,” said Ankit Ghosh, Senior Vice President and Head of Global IM Practices, Zensar Technologies. “Zensar has a wealth of experience in helping our customers successfully and seamlessly execute their journey to the cloud, and we are excited to publish this report to share our knowledge and expertise,” he said.Zensar provides clients with Cloud Consulting, Cloud Enablement, and Cloud Management services encompassing a full portfolio of Cloud Services and Solutions including: · Cloud Readiness Assessment – A solution which helps organizations determine how to evaluate, plan and build a successful cloud strategy. This is accomplished through a detailed discovery process, which gathers data on the organization’s current applications and infrastructure environment and reviews its business and technical objectives. · Hybrid Cloud Services – Industry-leading technologies combined with Zensar’s tested migration methodology enables organizations to transform their existing infrastructure to a private or hybrid cloud model. This allows organizations to leverage technology benefits while lowering their total cost of operation. · Cloud in a Box – An extensible appliance-based server/software stack with the ability to transform an x86 server into a cloud-enabled virtual computing platform. The Cloud in a Box provides users with visibility through a single pane of glass with hybrid cloud management capabilities including automation and orchestration. · Storage as a Service - Zensar’s Storage as a Service (STaaS) provides storage with enterprise class features and fully managed services without investing in traditional expensive SAN/NAS equipment. The offering includes options for private and public cloud with on premise or hosted scenarios. To learn more, about Zensar’s cloud solutions and services, please visit: http://www.zensar.com/cloud-services. To download ‘Transform Your Business – Get Cloud Ready’, please visit: https://info.zensar.com/GetCloudReady.html

ENISA publishes its Annual Report for 2014

ENISA releases its Annual Activity Report for 2014 (https://www.enisa.europa.eu/publications/programmes-reports/enisa-annual-activity-report-2014). The report provides an insight into ENISA’s operations and key programmes in the service of the EU’s cyber security.  Throughout this past year, the Agency (http://www.enisa.europa.eu/) has built on its renewed regulatory framework actively supporting: •       EU policy building and implementation of EU legislation: ENISA’s work in the context of Article 13a with National Telecom Regulators and European Electronic Communications Service Providers has provided deep insights on root causes of major incidents and best practices. All Member States use ENISA’s technical guidelines in their annual reporting. On standardisation ENISA contributes at the CEN CENELEC ETSI Cyber Security Coordination Group (CSCG) for the development of the CSCG white paper (https://www.enisa.europa.eu/media/news-items/white-paper-on-digital-security-published-by-european-standardisation-bodies). On Network and Information Security (NIS) the Agency has become a point of reference for European Trust Service Providers (TSPs) on eIDAS security requirements, and the data protection legislation with the reference document on privacy by design (https://www.enisa.europa.eu/media/news-items/deciphering-the-landscape-for-privacy-by-design). The Agency also supports the EU’s cloud computing strategy and partnership through its work on governmental clouds (https://www.enisa.europa.eu/media/press-releases/the-steps-for-going-cloud-for-governments-and-public-administration), and developing best practice in the public and private sector and in particular for SMEs (https://www.enisa.europa.eu/media/press-releases/enisa2019s-security-guide-and-online-tool-for-smes-when-going-cloud). •       Capacity building of EU Member States within the public and private sector, and raising the level of awareness among EU citizens. The ECSM (https://www.enisa.europa.eu/activities/stakeholder-relations/nis-brokerage-1/european-cyber-security-month-advocacy-campaign) (European Cyber Security Month) is a known example which takes place across 30 countries; with more than 184 activities and over 2000 twitter followers last year. Flagship programmes and achievements in 2014 include: •       The threat landscape (https://www.enisa.europa.eu/media/press-releases/enisa-draws-the-cyber-threat-landscape-2014) report, which consolidates and analyses the top cyber threats and their evolution, referencing over 400 sources on threats, to help navigate through the cyber landscape. The report has received around 25000 downloads and is widely referenced. In parallel, two thematic landscapes have been developed by the Agency on Internet Infrastructures (https://www.enisa.europa.eu/activities/risk-management/evolving-threat-environment/enisa-thematic-landscapes/threat-landscape-of-the-internet-infrastructure/iitl) and Smart Home Environments (https://www.enisa.europa.eu/media/press-releases/are-smart-homes-cyber-security-smart). •       The Cyber Exercises, define and test operational procedures (EU-SOPs) for all cybersecurity authorities in the EU, for handling cyber events. A new incarnation of "Cyber Europe 2014" (https://www.enisa.europa.eu/media/press-releases/biggest-ever-cyber-security-exercise-in-europe-today) took place in 2014, where 1556 players representing 483 public and private sector organisations from 29 EU and EFTA Member States, tested collaboration during large scale cyber incidents. •       CERTs (https://www.enisa.europa.eu/activities/cert) - the  EU’s Computer Emergency Response Teams – which assist public and private sector organizations, to provide a response to incidents and threats across an EU wide network through the exchange of experience and expertise while developing ‘baseline capabilities’. ENISA has developed, together with the CERT community, the training program for advanced skills for IT Security experts which is publically available (https://www.enisa.europa.eu/activities/cert/training) on the ENISA website. Commissioner Günther H. Oettinger (https://ec.europa.eu/commission/2014-2019/oettinger_en) said: “2014 has been another very successful year forENISA. It has been a year in which the Agency has further strengthenedrelations and outreach with stakeholders, both in the public and privatedomain. ENISA is providing solutions and expertise, and assistance forsignificant improvements to the state of cyber security throughout the EU. Itis important to ensure a high common level of network and information securityin the in the EU. ENISA’s role is decisive in this effort to establish acommon approach and understanding in the community, to develop cyber securitycapabilities in the Member States, and to promote a truly EU digital singlemarket for the benefit of citizens, governments and industry”. ENISA’s Executive Director Udo Helmbrecht (https://www.enisa.europa.eu/about-enisa) stated: “Emerging trends in cyber security in this past year markedthe different aspects to cyber security and cyber-attacks. We face a new typeof asymmetric warfare with a new paradigm and no taxonomy. Furthermore, thedevelopment of digital solutions, result to a more data driven approach,increasing vulnerability to cyberattacks. Applications of new technologiesalso highlight unchartered territories and whether society can tolerate theconsequences resulting from their use. ENISA will continue to deliver itsprogramme to reinforce and promote trust and security in digital services inthe EU”. In 2014 ENISA produced 37 reports (https://www.enisa.europa.eu/media/press-releases/enisa2019s-2014-work-programme-publications) in a variety of areas ranging from national level subjects such as the protection of critical infrastructure, to subjects affecting the individual citizen level such as privacy and data protection. ENISA’s 2014 reports are available online here (https://www.enisa.europa.eu/media/press-releases/enisa2019s-2014-work-programme-publications).

Beer Industry Contributes $14 Billion Annually to Florida Economy

FOR IMMEDIATE RELEASE: July 28, 2015 A new economic impact study (http://www.beerservesamerica.org) shows America’s beer industry, made up of brewers, beer importers, beer distributors, brewer suppliers and retailers, contributes more than $14 billion annually to Florida’s economy and is linked to 125,402 local jobs. Jointly commissioned by the National Beer Wholesalers Association (NBWA) (https://www.nbwa.org/) and the Beer Institute (http://www.beerinstitute.org/), the study shows that the industry generates 125,402 jobs in Florida—accounting for more than $5 billion in wages and benefits. The industry also contributed $3 billion in the form of business, personal and consumption taxes in 2014. “It can be said that beer truly serves America. Beer is more than our nation’s favorite adult drink – it is a powerhouse in job creation, commercial activity and tax revenue,” said Jim McGreevy, president and CEO of the Beer Institute, which released the study today jointly with NBWA. According to the study, the beer industry generates nearly $253 billion in economic activity, produces $48.5 billion in tax revenue and supports 1.75 million jobs. Brewers and beer importers directly employ 49,576 Americans. More than 70 percent of brewing jobs are linked to large and mid-sized brewers and beer importers, and the number of distributor jobs has increased by more than 20 percent in the last decade, to more than 131,307. NBWA President & CEO Craig Purser said, “As independent businesses, America’s licensed beer distributors are proud to provide more than 130,000 direct jobs with solid wages and great benefits to employees at more than 3,300 facilities, located in every state and congressional district across the country. These independent beer distributors provide significant economic benefits in their communities through local business-to-business commerce, investments in local infrastructure and capital assets and tax revenue.  They provide services that improve efficiency for trading partners, especially small brewers and retailers, and they ensure fair prices and a broad selection of products for consumers to enjoy.” The Beer Serves America study (http://www.beerservesamerica.org) was compiled by an independent economics firm, John Dunham & Associates (http://guerrillaeconomics.com/). It is the most comprehensive analysis of the industry available, using data collected directly from private companies, Dun & Bradstreet, the U.S. Bureau of Labor Statistics, the Alcohol Tobacco Tax and Trade Bureau, and the U.S. Bureau of Economic Analysis. ### The National Beer Wholesalers Association (NBWA) represents the interests of America’s 3,300 licensed, independent beer distributor operations in every state, congressional district and media market across the country. Beer distributors are committed to ensuring alcohol is provided safely and responsibly to consumers of legal drinking age through the three-tier, state-based system of alcohol regulation and distribution. To learn more about America’s beer distributors, visit www.AmericasBeerDistributors.com. For additional updates from NBWA, follow @NBWABeer (https://twitter.com/NBWABeer) on Twitter, watch NBWA videos on www.youtube.com/NBWABeer  and visit www.facebook.com/NBWABeer (https://www.facebook.com/pages/NBWABeer/75305414159). The Beer Institute is a national trade association for the American brewing industry, representing both large and small brewers, as well as importers and industry suppliers. First founded in 1862 as the U.S. Brewers Association, the Beer Institute is committed today to the development of sound public policy and to the values of civic duty and personal responsibility: www.BeerInstitute.org. Connect with us @BeerInstitute (http://www.twitter.com/beerinstitute) and on Facebook (http://www.facebook.com/beerinstitute).

The JORVIK Group takes a lighthearted look at historic vs. modern travel

What would a medieval knight make of modern day aircraft baggage allowances?  Or how would a Viking cope with restrictions on hand luggage when he has mead and livestock to take with him?  These scenarios are explored in a series of light-hearted video clips being released by the JORVIK Group to make the launch of its new PastPort ticket! The short clips take characters from the JORVIK Group’s five attractions and put them into situations that their modern contemporaries would recognise very well, but which even the most seasoned medieval traveller would not comprehend. “Over the centuries, the rules of travel have changed radically, and we wondered what kind of obstacles some of our historic characters might face if they were to undertake voyages today,” comments director of attractions for the JORVIK Group, Sarah Maltby.  “Today, we can hop on a ‘plane to the other side of the world without thinking twice, but for Vikings, a long journey meant planning ahead for every possible eventuality, and in the case of the Norse men and women who came to our part of the world, making sure they had all the paraphernalia required not only for the journey but also to create a new life for themselves on the banks of the Ouse.” The videos were mostly filmed at Leeds Bradford International Airport, where holidaymakers were bemused to see a host of historic characters and livestock wandering around the airport – and no doubt relieved that their journey through the check-in process would be substantially easier than their historic counterparts.  The films will be released over the coming weeks on the JORVIK Group’s website, at www.thejorvikgroup.com/historicairways and on the Group’s YouTube channel, www.youtube.com/JORVIKYork. For more details, please visit www.thejorvikgroup.com/pastport ENDS For further media information or photographs, please contact: Jay Commins Pyper York Limited Tel:         01904 500698 Email:    jay@pyperyork.co.uk

Binary Tree Recognizes Global Channel Partner Leadership

Binary Tree, a leading Microsoft Exchange and Office 365 migration solutions company, is pleased to announce the recipients of its annual partner awards, recognizing channel excellence around the globe. Walter Monasterio, Director of Strategic Alliances, recently officiated at the private ceremony for Binary Tree’s management team and representatives of its partner companies. The following partners received special recognition for their outstanding work with Binary Tree: Avanade (http://www.avanade.com/fr-fr/home) of Châtillon, France and HP (http://www.hp.com/) of Palo Alto, CA received the SMART Global SI Award, recognizing Global Systems Integrator Partners whose commitment to Binary Tree solutions and quality delivery create an excellent partnership benefiting customers around the world. The SMART Regional Systems Integrator award winners are from five territories across the globe, including: North America, French (EMEA) Territory, South (EMEA) Territory, United Kingdom and Asia Pacific Japan. In North America, KiZAN Technologies (http://www.kizan.com/) of Louisville, KY and Perficient (https://www.perficient.com/) of St. Louis, MO received the SMART Regional SI Award, recognizing a North American Systems Integrator Partner whose commitment to Binary Tree solutions and quality delivery creates an excellent partnership benefiting customers across North America. In the French (EMEA) territory, Neurones IT (http://www.neurones-it.com/) of Nanterre, France received the SMART Regional SI Award, recognizing an EMEA Systems Integrator Partner whose commitment to Binary Tree solutions and quality delivery creates an excellent partnership benefiting customers across EMEA. In the United Kingdom territory, LAN2LAN (http://www.lan2lan.com/) of Surrey, United Kingdom also received the SMART Regional SI Award, recognizing an EMEA Systems Integrator Partner whose commitment to Binary Tree solutions and quality delivery creates an excellent partnership benefiting customers across EMEA. In the Asia Pacific Japan territory, Go-IT (http://www.go-it.co/) of Sydney, Australia received the SMART Regional SI Award, recognizing an EMEA Systems Integrator Partner whose commitment to Binary Tree solutions and quality delivery creates an excellent partnership benefiting customers across Asia Pacific and Japan. In the South (EMEA) territory, GlobalTMS (http://globaltms.net/) of Madrid, Spain received the SMART Regional SI Award, recognizing an EMEA Systems Integrator Partner whose commitment to Binary Tree solutions and quality delivery creates an excellent partnership benefiting customers across South America. Presidio (http://www.presidio.com/) of New York, NY and Softchoice (http://www.softchoice.com/) of Toronto, ON received the SMART Rising Star Award (North America), recognizing those Partners who have accelerated the ability to sell and deliver Binary Tree solutions while growing the partnership to be a strategic part of their business. ai3 (http://www.ai3.fr/) of Boulogne, France received the SMART Rising Star Award (French Territory), recognizing a Partner who has accelerated its ability to sell and deliver Binary Tree solutions while growing the partnership to be a strategic part of their business. Contrail (http://www.contrail.se/) of Värmdö, Sweden received the SMART Rising Star Award (Nordic Territory), recognizing a Partner who has accelerated its ability to sell and deliver Binary Tree solutions while growing the partnership to be a strategic part of their business. Andrea Pichler, Director of Infrastructure & Security Services at 4ward (http://www.4ward.it/), received the SMART Technical Excellence Award (EMEA), recognizing an Individual who continually shows expertise on current Binary Tree solutions and delivering quality customer engagements utilizing Binary Tree solutions. Brian Ahearn, Senior Consultant at Agility Partners (http://www.agilitypartners.com/), received the SMART Technical Excellence Award (North America), recognizing an Individual who continually shows expertise on current Binary Tree solutions and delivering quality customer engagements utilizing Binary Tree solutions. Binary Tree’s Emory Camp, Senior Alliances Manager, North America, comments, “We congratulate each of our award winners in the North America region. Binary Tree and our partners continue to be a winning combination as market leaders for migration software solutions and professional services to assist our collective customers with their Active Directory and messaging transformations." Fabrice Barbier, Binary Tree Director of Sales, EMEA, stated, “It is a pleasure to recognize the quality, breadth of experience and dedication of the growing European partner ecosystem. Sharing the awards is acknowledging our partners’ capacity to continue to increase market shares both via legacy Binary Tree solutions as well as by embracing the latest Binary Tree SMART Active Directory Migrator product offering.” As Binary Tree’s Senior Account Executive in Asia Pacific Japan, James Yip states, “It’s my pleasure to work with Go-IT in the region as they show dedication on the projects we work together. We look forward to working much closer with Go-IT during the rest of the year to further enhance our coverage for Binary Tree in the region.” As messaging specialists for more than 20 years and a Microsoft Gold Messaging Partner, Binary Tree provides messaging and collaboration transformation technology and solutions for the Microsoft platform in the cloud, on-premises, or in hybrid environments.

AMETEK Adds DC Regenerative Sink Option Capability

SAN DIEGO, CA – AMETEK Programmable Power, the global leader in programmable AC and DC power test solutions (programmablepower.com), has added the ability to sink DC current to its California Instruments' RS and MX Series Power Sources The addition of this option to an RS or MX Series power source with AC Sink installed allows users to source and sink both AC and DC currents at up to 100 percent of the source's rated output power. When sinking current, the current is regenerated and returned to the electrical grid reducing the operating cost of electricity. There are many applications for sinking AC current, such as the prevalent need to regenerate current back to the electrical grid while testing grid-tied inverters. A common DC sink application, among others, is to simulate batteries connected to a bidirectional converter in hybrid electric vehicle motor drive systems. When purchasing a new RS or MX Series power source, customers can purchase the SNK option to sink only AC current, the SNK-DC option to sink only DC current, or both options for ultimate versatility. Upgrading an existing RS unit can be done by AMETEK, depending on the age of the unit.  Consult factory for further details. About AMETEK Programmable Power AMETEK Programmable Power designs, manufactures and markets precision, AC and DC programmable power supplies, electronic loads, application specific power subsystems, and compliance test solutions for customers requiring and valuing differentiated power products and services. It offers one of the industries' broadest portfolios of programmable power products under the Sorensen (http://www.programmablepower.com/brands/sorensen.htm), Elgar (http://www.programmablepower.com/brands/elgar.htm), California Instruments (http://www.programmablepower.com/brands/california-instruments.htm) and AMREL (http://www.programmablepower.com/brands/amrel.htm) brands. For more information on any of AMETEK’s programmable power supplies (http://www.programmablepower.com/) and programmable loads, contact an authorized AMETEK Programmable Power sales representative by visiting programmablepower.com/contact/ (http://www.programmablepower.com/contact/). You can also contact AMETEK Programmable Power directly toll free at 800-733-5427 or 858-458-0223, or by email: sales.ppd@ametek.com. AMETEK Programmable Power  (http://www.programmablepower.com/)is a business unit of AMETEK Electronic Instruments Group, a leader in advanced instruments for the process, aerospace, power and industrial markets and a division of AMETEK, Inc., a leading global manufacturer of electronic instruments and electromechanical devices with 2014 annual sales of $4.0 billion. For further information contact: Craig Frahm Tel: (858) 678-4459 E-mail: craig.frahm@ametek.com, Website: www.programmablepower.com

Happy Hamsters

Embargoed until 00.01 BST Wednesday 29 July 2015 Hamsters are the ubiquitous childhood pet: cute, cuddly, ready to sink their teeth deep into your finger … But how can you tell if your hamster is happy? And what can you do to improve their wellbeing? Scientists at Liverpool John Moores University (LJMU) have published a study in the journal Royal Society Open Science revealing that hamsters in cages enriched with hammocks, extra bedding, ledges and chews show shifts in their cognition similar to those seen in people when happy. Enriched hamsters made more optimistic judgements about ambiguous information than they did when the enrichment was removed. This is the first study to demonstrate that positive shifts in emotion can be objectively measured in hamsters. The scientists trained Syrian hamsters to expect sugar water in a drinker placed at one location in a test arena and to expect bitter quinine water at another location. Hamsters were quick to approach the sugar water location, but stopped approaching the quinine location. The scientists then gave half of the hamsters a range of enrichment devices including hammocks, extra bedding, ledges and chews to increase opportunities to express natural behaviours and improve their mood, and measured how often hamsters approached ‘ambiguous’ drinkers placed in locations in between the sugar and quinine locations. The enriched hamsters approached the ambiguous drinkers more often than did the unenriched hamsters, suggesting they were more optimistic that the drinkers might contain sugar water. Dr Emily Bethell, LJMU Senior Lecturer in Primate Behaviour: “This study shows that hamsters housed in enriched environments make more optimistic judgements about otherwise ambiguous information. The important note for pet owners is that ensuring pets have adequate opportunities to express natural behaviours in captivity improves their mood and is essential for their welfare.’ Dr Nicola Koyama, LJMU Senior Lecturer in Ethology: “Judgement bias studies let us examine the effect of emotions on cognitive processes and are important measures for improving animal welfare. Hamsters are often a child’s first pet and we’ve shown that what goes into a cage (ledges, chews, hammocks and material to dig in) has a positive impact on a hamster’s emotional state and thus, their well-being.” When live the paper will be at: http://rsos.royalsocietypublishing.org/lookup/doi/10.1098/rsos.140399 Dr Emily Bethell  and Dr Nicola Koyama  are based at the LJMU School of Natural Sciences and Psychology Interview contact details: Dr Emily Bethell,  +44 (0)151 231 2488 or +44 (0) 7702001272 E.J.Bethell@ljmu.ac.uk Images with credits on the media section of the LJMU Press Centre http://news.cision.com/liverpool-john-moores-university

Quarterly report Q2, April - June 2015

70,411  (44,104) · Net revenues -24,422 (-39,502) · Operating profit  Neg (Neg) · Operating margin -24,501 (-39,631) · Profit/loss after tax SEK -0.58 (-0.95) · Earnings per share Significant events during the second quarter · SEQR launches MyShop – the service that allows everyone to start-up a mobile e-commerce shop. The new MyShop feature in the SEQR app provides all users their own shop with a simple, secure and free of charge payment solution. To start using the store, it is as simple as taking a picture with your mobile device of what you want to sell, writing a brief description, and then attaching a price tag. Then create an advertisement with the QR code which is automatically delivered to your e-mail. The ad can then be disseminated in any and every media, such as advertising sites, Facebook, your own blog, or Tictail, or even printed out and hung up in a stairwell or on a bulletin board. The buyer scans the QR code and makes the purchase without the need to enter either his address or payment details, since this is already registered in the SEQR app. · SEQR is available in more than Colruyt, Okay, Bio-Planet, Cru, Dreamland, Dreambaby 500 stores as well as independent Spar stores. In autumn 2014, the Colruyt Group and SEQR began its cooperative efforts to work together. The first tests were made at selected e-commerce platforms and the cooperative efforts have now been expanded to include all physical stores. · SEQR continues to take advantage of its strengths in e-commerce and during the quarter Instant Checkout was released, which allows shopping on mobile devices with as few steps as possible. Along with the e-commerce provider E37, the solution has been integrated in mobile E37’s mobile-customized checkout, and SWEdala Outlet’s online store is a pilot customer. · SEQR goes live in Great Britain and the United States during the quarter.  Earlier this year, SEQR began its expansion into the U.S. market. In the past few months, with Daniel Bessmert, general manager of SEQR in the United States at the forefront, we have invested in building up our organization in the U.S. and establishing long-term strategic relationships with partners and resellers. SEQR is now one of very few providers in the world able to offer mobile payment solutions to companies operating in the global market, making it easier for both the retailer and consumer. With SEQR, merchants obtain a secure and more cost-effective alternative to traditional payment options, and consumers are able to shop both online and in physical stores - all with one single solution. · Seamless Vice President Ingrid Lindström will be leaving her position in autumn 2015. During the two years that Ingrid worked in the company, extensive development and structuring of work has been carried out in which Ingrid has played a prominent role and contributed in a decisive manner. CEO's Comment I am proud to announce that during the second quarter Seamless reports our highest quarterly revenue in a single quarter – 70 MSEK, which is an increase of 60% compared to same quarter 2014. All our three business divisions now show significant growth, after three years of heavy investment.  We also see a rapid decrease in our losses – down 39% compared to the second quarter 2014 – due both to higher revenues and to lower costs. The Transaction Switch division delivers a record result again with 23 MSEK in revenue and profit of 10 MSEK. This is an increase in profit of 326% compared to Q2 2014. The Distribution division has a revenue of 45 MSEK, showing growth of 45% on Q2 2014. For the first time, this division shows profit, 2 MSEK. Transactions through the SEQR interface increased with 48% compared to Q2 2014. Revenue from SEQR is lagging the increase in transactions and is still flat compared to Q2 2014. The revenue lag is partly because we made a choice to forgo advertisement revenue during the quarter. Instead of selling our advertisement space, we advertised our own SEQR rewards program during the whole period. If we had not made this choice, we could have had approximately half a million SEK more in revenue for SEQR, which would have meant that SEQR also would have posted a strong quarter. Our plan is to revert back to selling the advertisement space in the middle of Q3. We expect growth in revenue for 2015 compared to 2014 for SEQR. Overall, our revenue has increased from 44 MSEK in Q2 2014 to 70 MSEK in Q2 2015. This is the largest quarterly revenue that Seamless has ever reported and represents a growth of 60% compared to Q2 2014. Our losses have decreased significantly over the last two quarters from a peak of 51 MSEK in Q4 2014 to 24.5 MSEK in Q2 2015. Last year in Q2 2014, our losses were 40 MSEK, which means that we decreased our losses with 39% compared to Q2 2014 and with 52% from the peak loss in Q4 2014. This is a function of both a lower cost base and an increase in net revenue. The SEQR solution was launched and went into live production in the US and the UK during the quarter. These countries represent a large potential market for SEQR and we are now building our merchant and user base there. In the US, which has a different regulatory system compared to Europe, we need MTLs (money transfer license) to offer our full suite of products. Specifically our peer-to-peer (remittance) service. We have during the last year put considerable effort and investment into applying for MTLs which are necessary on a state by state basis. As I write this, we have received three MTLs, for Missouri, Iowa and Mississippi. We expect MTLs for the other states to be received one by one over the next twelve month period. A crucial component for our future success lies in always having a superior solution. The product development in all divisions is continuing at a strong pace, and we now can leverage on the architecture that has been built. This means that we can add products and features at a faster tempo with less investment than could be done earlier. This is key for going forward since every new feature and product means that we add new potential income streams. An example of this product development is in the SEQR business division, where we launched MyShop. This is a feature that lets any SEQR user create their own classified advertisement from within the SEQR app, with payment by SEQR built-in to the ad via a QR code. This solves a lot of problems that current classified ad channels have with payment logistics as well as with fraud and abuse. Maybe even more important is that MyShop is channel independent. Users can post this ad anywhere they want, whether on social media, on a classified ad site, or simply via emailing .This means that a MyShop ad can be displayed through any media such as Facebook, Pinterest, Tumblr or any of the existing classified channels such as Craigslist, Blocket, Ebay. With MyShop, everything becomes a classified ad channel. We also launched Instant Checkout which allows a SEQR user to buy from an online merchants with unprecedented speed and convenience, regardless of if the user is shopping through the mobile phone, PC, or any other electronic device. This increases conversion rate significantly for online merchants and therefore has a positive effect on the online merchants’ revenue, above and beyond the savings merchants receive by using SEQR over other payment methods When it comes to the financing of the company, we are constantly exploring the best solutions for our shareholders going forward. On this note, we launched a small convertible bond in a private placement the 17th of July. This issue should be seen as a limited part of a wider effort to fund the company for continued growth. Peter Fredell CEO Consolidated Revenues Seamless’ revenues increased during the First Quarter by 60 percent to SEK 70,411 thousand (44,104). The sales are distributed between the various business segments, with 33 percent (25) from the Transaction Switch business segment, 64 percent (71) from the Distribution business segment, and 3 percent (4) from the SEQR business segment. Financial Results · •           The consolidated operating loss amounted to SEK -24,422 thousand (-39,502) in the second quarter. · •           Second quarter net losses from financial items amounted to SEK -38 thousand (-108). · •           Earnings per share amounted to SEK -0.58 (-0.95) for the quarter. Personnel We had a total of 131 (160) employees at end of the quarter. In addition to this, Seamless has retained approximately 40 consultants – primarily in India, Ghana and Pakistan.  Investments During the quarter, investments have been made in a total amount of SEK 6,811 thousand (1,107). Product development costs have been capitalized at a value of SEK 5,126 thousand (5,514), while depreciation taken and amortization amounted to SEK -6,086 thousand (-4,138). Cash flow and financial position Cash flow from operating activities amounted to SEK -30,345 thousand (-27,822) for the second quarter. Bank deposits and cash equivalents at the end of the quarter amounted to SEK 21,019 thousand (224,807). The Group has interest-bearing liabilities in the form of leases for hardware amounting to SEK            -2,005 thousand (-3,152), divided between long-term debt of SEK -607 thousand (-1,231) and short-term debt of SEK -1,398 thousand (-1,921). The Company has no interest-bearing liabilities to banks or other credit institutions. Other than the above, the Group has no borrowings. Seamless has an equity ratio of 67 (84) percent. As announced in press releases and in the previous quarterly reports, savings measures have been implemented in the third and fourth quarter of 2014, which will result in an anticipated savings of approximately SEK 80 million on an annual basis. One of these savings measures has been to discontinue the Swedish part of the Seamless development department, which resulted in that about 30 people were not able to continue with the company. Additionally, Seamless has issued SEK 29 million of convertible debentures after the end of the period. The issue, which was fully subscribed, was sold to private and institutional investors, arranged by Evli Bank PLC, who acted as bookrunners for the deal. The successful completion of this issue gives Seamless an adequate working capital buffer. The board of directors of Seamless resolved to issue these bonds pursuant to the authorization granted at the latest annual general meeting of the company. The convertible loan amounts to a nominal value of not more than SEK 29 million and carries interest at an annual rate of seven (7) per cent. The convertible debentures have been subscribed at a value corresponding to 100 per cent of the nominal value and the conversion price is based on the VWAP of the Seamless share on 13 July 2015. The conversion price is SEK 8.55. The issue has been implemented with deviation from the shareholders’ preferential rights. The reason for the deviation is that the company wants to have a working capital buffer. A private placement of convertible debentures has, at this point in time, been deemed to be the most favourable way to obtain such financing for the company. The convertible loan will mature 364 days after the date of issue, unless conversion or distribution has occurred prior to this date. The payment for the convertible debentures shall be made in connection with the subscription, or such later date as the board of directors resolves. The issue of convertible debentures will entail, upon full conversion, a dilution for the current shareholders of Seamless of approximately 7.49 per cent after full dilution. Parent Company The parent company’s net sales for the quarter amounted to SEK 1,959 thousand (0) and net financial results amounted to a loss of SEK -2,231 thousand (-6,270). Net gains/losses in the parent company from financial items amounted to SEK 0 thousand (-52), and the parent company had bank deposits/cash on hand in the amount of SEK 736 thousand (198,758) at the close of the quarter. The parent company had 5 (5) employees at the close of the quarter.  For more information:  Daniel Hilmgård, CFO +46 709 968 333,  daniel.hilmgard@seamless.se Peter Fredell, CEO Seamless +46 8 564 878 00, peter.fredell@seamless.se This information is such information that Seamless Distribution AB (publ) is required to disclose pursuant to the Swedish Securities Market Act and/or the Swedish Financial Instrument Trading Act. The information was released for publication on 29 July 2015 at 07.50 am (CET)

The banknote and coin campaign is now underway

At the end of July, the Riksbank will launch the free app "Kolla pengarna" (Check your money):http://www.riksbank.se/en/Notes--coins/App-kolla-pengarna/This teaches how to recognise a genuine banknote and provides information on the banknote and coin changeover in Swedish, English and 29 other languages. There is also a game that involves sorting banknotes according to which are ne and the dates on which the old ones become invalid. The faster they are sorted, the more points are scored. The app also provides support for the visually-impaired, who can use it to scan a banknote and have the denomination read aloud by Governor of the Riksbank Stefan Ingves. "One-quarter of Sweden's population is still unaware that Sweden will be getting new banknotes and coins. We will be using several different channels to reach as many people as possible. The app will make it possible to haveinformation easily at hand and will provide assistance for the visually-impaired. A banknote game in the app offers a different and fun way to learn important dates in the changeover", says Christina Wejshammar, head of the Cash and Payment Systems Department. In September, every household in Sweden will receive a pamphlet on the banknote and coin changeover through its letterbox. Information on the new banknotes and coins is available at: www.riksbank.se/en/ andfacebook.com/kollapengarna In addition, there is an information film on the banknote and coin changeover, in Swedish: www.riksbank.se In August and September, the Riksbank will be holding exhibitions on the new banknotes at the six different locations in Sweden associated with the personalities on the new banknotes. Persons wishing to be reminded of important dates during the banknote and coin changeover can get push notifications via the app or reminders via text message by texting riksbanken start to 71120.

Eltel wins renewal of long-term contract with Orange Polska S.A.

The expected goals in the new contract are quality improvements to ensure high customer satisfaction, efficiency to gain cost reduction through synergies and to stay ahead of changing and increasing customer demands. The contract will also give Eltel improved position to win future business as service provider for fiber optics build and maintenance services. The new agreements enter into force in autumn 2015. The new service contracts in Poland are based on a geographical model where Eltel’s Communication segment will be the provider of copper lines installation services and fault repairs in the awarded regions. Peter Uddfors, President of Fixed Communication at Eltel comments: “We are proud to once again be selected as Orange main partner in Poland. Our focus and specialization with Fixed Communication provides excellent opportunities to enhance and improve end customer experience. Our coverage in Poland with over 1000 skilled employees ensures high connectivity for both copper and fiber based solutions.” About Orange Polska S.A. Orange Polska is Poland’s leading telecommunication provider, operating in all segments of the Polish telecom market. As at the end of 2014 Orange Polska had over 23 million customers of different services (mobile, fixed voice, broadband, TV). The company revenue achieved PLN 12.2 billion in 2014. Orange Polska is part of the French Orange Group. About Eltel Eltel is a leading European provider of technical services for critical infrastructure networks – Infranets – in the segments of Power, Communication and Transport & Defence, with operations throughout the Nordic and Baltic regions, Poland, Germany, the United Kingdom and Africa. Eltel provides a broad and integrated range of services, spanning from maintenance and upgrade services to project deliveries. Eltel has a diverse contract portfolio and a loyal and growing customer base of large network owners. The number of employees is approximately 8,600 and in 2014, Eltel net sales amounted to EUR 1,242 million. For more information, please contact Gunilla Wikman, Investor Relations Manager at Eltel AB, tel: +46 725 843 630 gunilla.wikman@eltelnetworks.se Hannu Tynkkynen, Senior Vice President, Group Communications at Eltel AB,    tel: +358 40 3114503 hannu.tynkkynen@eltelnetworks.com

New Diamyd Medical-licensed patent issued

“This new patent may very well bring substantial value to Diamyd Medical since various preproinsulin derived compounds are being developed by others as Antigen Based Therapies (ABTs) in parallel with Diamyd Medical’s development of the GAD-based ABT, Diamyd®, says Anders Essen-Möller, President and CEO of Diamyd Medical. “The diabetes vaccine Diamyd® is clearly today’s leading candidate ABT for type 1 diabetes but any synergistic reinforcement of its efficacy is important. Like in cancer therapy, incremental improvements by combining compounds that hit the disease from different angles, is likely the winning path forward in the forthcoming battle for this multibillion USD market.” Diamyd Medical is collaborating with Professor Kenneth McCormick, the University of Alabama at Birmingham, in a GABA/Diamyd® combo trial in 75 recent onset type 1 diabetes patients, ages 4-18 years. Recruitment has been ongoing since March this year. Gamma-Amino Butyric Acid (GABA) is a major neurotransmitter. GABA taken orally is widely considered safe with few side effects (Tian, 2011), and is available over the counter in the US. Diamyd® has been used in clinical studies with more than 1,000 patients and has shown a good safety profile. In a European Phase III study Diamyd® showed good clinical effect in several subgroups, and a limited overall 16% efficacy (p=0.10) in preserving endogenous insulin secretion. Diamyd® is easy to administer in any clinical setting. Tian, Kaufman, et al showed that combining GABA with GAD-alum (Diamyd®), synergistically prolongs transplanted beta cell survival in an animal model for type 1 diabetes (PLoS One, (http://www.ncbi.nlm.nih.gov/pubmed/21966502) 2011). More recently the same authors, (Tian, Kaufman et al, Diabetes, 2014), reported that combined treatment with GABA plus proinsulin synergistically restored normoglycemia and promoted beta cell replication in newly diabetic mice. In conclusion, GABA in combination with antigen based therapy (ABT) holds promise for type 1 diabetes intervention leading to restored or improved endogenous insulin production. Evidence is accumulating that GABA is an important compound for treatment and prevention for diabetes and other inflammatory diseases. GABA lowers the production of pro-inflammatory cytokines and stimulates beta cell proliferation while it inhibits apoptosis. (Ligon, Diabetologia, 2007; Soltani, Proc  (http://www.ncbi.nlm.nih.gov/pubmed/21709230)Natl Acad Sci USA, 2011; Birnir, Amino Acids 2013; Wan, 2015). Tian, Dang, Chen, Guan, Jin, Atkinson and Kaufman also showed that GABA regulates both the survival and replication of human beta cells. (Diabetes, 2013). Abstracts from related scientific articles are included in this press release as appendix further below. Ongoing studies with GABA and/or Diamyd® include: · GABA/ DIAMYD® – COMBINING GABA WITH DIAMYD® A placebo-controlled study, where Diamyd® is being tested in combination with GABA. The study comprises 75 patients between the ages of 4 and 18 recently diagnosed with type 1 diabetes, and will continue for a total of 12 months. The aim of the combination treatment is to preserve the body’s residual capacity to produce insulin. The study is led by Professor Kenneth McCormick at the University of Alabama at Birmingham, USA. The first patient was included in the study in March 2015. · DIABGAD-1 – COMBINING DIAMYD® WITH IBUPROFEN AND VITAMIN D A placebo-controlled study, where Diamyd® is being tested in combination with ibuprofen and vitamin D. The study comprises a total of 64 patients between the ages of 10 and 18 recently diagnosed with type 1 diabetes, and will continue for a total of 30 months. The aim of the combination treatment is to preserve the body’s residual capacity to produce insulin. The study runs at nine clinics in Sweden and is led by Professor Johnny Ludvigsson at Linköping University, Sweden. 15 month results from the study are due in the fourth quarter of 2015. · DIAGNODE – DIAMYD® IN LYMPH GLANDS IN COMBINATION WITH VITAMIN D An open label study, where Diamyd® is administered directly into lymph nodes in combination with treatment with vitamin D. The study comprises five patients between the ages of 18 and 30 newly diagnosed with type 1 diabetes, and will continue for a total of 30 months. The aim of the study is to evaluate the safety of the combination treatment and the effect on the immune system and the patients’ insulin producing capacity. The study is led by Professor Johnny Ludvigsson at Linköping University, Sweden. The first patient was included in the study in February 2015. · EDCR IIa – COMBINING DIAMYD® WITH ETANERCEPT AND VITAMIN D An open label study, where Diamyd® is combined with etanercept and vitamin D. The study comprises 20 patients between the ages of 8 and 18 who have been newly diagnosed with type 1 diabetes, and will continue for a total of 30 months. The aim of the study is to evaluate the safety of the combination treatment and the effect on the immune system and the patients’ insulin producing capacity. The study is led by Professor Johnny Ludvigsson at Linköping University, Sweden. The first patient was included in May 2015. · DiAPREV-IT 1 – DIAMYD® A placebo-controlled study, where Diamyd® is being tested in children at high risk of developing type 1 diabetes, meaning that they have been found to have an ongoing autoimmune process but do not yet have any clinical symptoms of diabetes. A total of 50 participants from the age of four have been enrolled in the study, which will last for five years. The aim of the study is to evaluate whether Diamyd® can delay or prevent the participants from presenting with type 1 diabetes. The study is led by Dr. Helena Elding Larsson at Lund University, Sweden. Five year results are expected at the end of 2016. · DiAPREV-IT 2 – COMBINING DIAMYD® WITH VITAMIN D A placebo-controlled study, where Diamyd® is being tested in combination with vitamin D in children at high risk of developing type 1 diabetes, meaning that they have been found to have an ongoing autoimmune process but do not yet have any clinical symptoms of diabetes. A total of 80 participants between the ages of 4 and 18 will be enrolled in the study, which will last for five years. The aim of the study is to evaluate whether Diamyd® can delay or prevent the participants from presenting with type 1 diabetes. The study is led by Dr. Helena Elding Larsson at Lund University, Sweden. The first patient was included in March 2015. About Diamyd MedicalDiamyd Medical is dedicated to working toward a cure for type 1 diabetes and LADA. The Company’s projects include development of combination regimens with the GAD-based diabetes vaccine Diamyd® for arresting the destruction of insulin-producing beta cells. The Company exclusively licenses UCLA-rights to GAD65, the active ingredient in the vaccine, for which the last patent expires in 2032. Additionally, the Company exclusively licenses UCLA patents for using GABA for the treatment of diabetes and other inflammation-related conditions. Diamyd Medical is one of the major shareholders in the stem cell company Cellaviva AB, which is establishing a Swedish commercial bank for private family saving of stem cells in umbilical cord blood and other sources of stem cells. Stem cells can be expected to be used in Personalized Regenerative Medicine (PRM), for example, to restore beta cell mass in diabetes patients where autoimmunity has been arrested. Remium Nordic AB is the Company’s Certified Adviser. APPENDIX Diabetes Metab Syndr Obes. 2015 Feb 3;8:79-87. doi: 10.2147/DMSO.S50642. eCollection 2015. GABAergic system in the endocrine pancreas: a new target for diabetes treatment. Wan Y, Wang Q, Prud'homme GJ. Excessive loss of functional pancreatic β-cell mass, mainly due to apoptosis, is a major factor in the development of hyperglycemia in both type 1 and type 2 diabetes (T1D and T2D). In T1D, β-cells are destroyed by immunological mechanisms. In T2D, while metabolic factors are known to contribute to β-cell failure and subsequent apoptosis, mounting evidence suggests that islet inflammation also plays an important role in the loss of β-cell mass. Therefore, it is of great importance for clinical intervention to develop new therapies. γ-Aminobutyric acid (GABA), a major neurotransmitter, is also produced by islet β-cells, where it functions as an important intraislet transmitter in regulating islet-cell secretion and function. Importantly, recent studies performed in rodents, including in vivo studies of xenotransplanted human islets, reveal that GABA exerts β-cell regenerative effects. Moreover, it protects β-cells against apoptosis induced by cytokines, drugs, and other stresses, and has anti-inflammatory and immunoregulatory activities. It ameliorates the manifestations of diabetes in preclinical models, suggesting potential applications for the treatment of diabetic patients. This review outlines the actions of GABA relevant to β-cell regeneration, including its signaling mechanisms and potential interactions with other mediators. These studies increase our understanding of the regenerative processes of pancreatic β-cells, and help pave the way for the development of regenerative medicine for diabetes. Diabetes. (http://www.ncbi.nlm.nih.gov/pubmed/25146474) 2014 Sep;63(9):3128-34. doi: 10.2337/db13-1385. Combined therapy with GABA and proinsulin/alum acts synergistically to restore long-term normoglycemia by modulating T-cell autoimmunity and promoting β-cell replication in newly diabetic NOD mice. Tian J, Dang H, Nguyen AV, Chen Z, Kaufman DL. Antigen-based therapies (ABTs) fail to restore normoglycemia in newly diabetic NOD mice, perhaps because too few β-cells remain by the time that ABT-induced regulatory responses arise and spread. We hypothesized that combining a fast-acting anti-inflammatory agent with an ABT could limit pathogenic responses while ABT-induced regulatory responses arose and spread. γ-Aminobutyric acid (GABA) administration can inhibit inflammation, enhance regulatory T-cell (Treg) responses, and promote β-cell replication in mice. We examined the effect of combining a prototypic ABT, proinsulin/alum, with GABA treatment in newly diabetic NOD mice. Proinsulin/alum monotherapy failed to correct hyperglycemia, while GABA monotherapy restored normoglycemia for a short period. Combined treatment restored normoglycemia in the long term with apparent permanent remission in some mice. Proinsulin/alum monotherapy induced interleukin (IL)-4- and IL-10-secreting T-cell responses that spread to other β-cell autoantigens. GABA monotherapy induced moderate IL-10 (but not IL-4) responses to β-cell autoantigens. Combined treatment synergistically reduced spontaneous type 1 T-helper cell responses to autoantigens, ABT-induced IL-4 and humoral responses, and insulitis, but enhanced IL-10 and Treg responses and promoted β-cell replication in the islets. Thus, combining ABT with GABA can inhibit pathogenic T-cell responses, induce Treg responses, promote β-cell replication, and effectively restore normoglycemia in newly diabetic NOD mice. Since these treatments appear safe for humans, they hold promise for type 1 diabetes intervention. Amino Acids. 2013 Jul;45(1):87-94. doi: 10.1007/s00726-011-1193-7. Epub 2011 Dec 13. GABA is an effective immunomodulatory molecule. Jin Z, Mendu SK, Birnir B. In recent years, it has become clear that there is an extensive cross-talk between the nervous and the immune system. Somewhat surprisingly, the immune cells themselves do express components of the neuronal neurotransmitters systems. What role the neurotransmitters, their ion channels, receptors and transporters have in immune function and regulation is an emerging field of study. Several recent studies have shown that the immune system is capable of synthesizing and releasing the classical neurotransmitter GABA (γ-aminobutyric acid). GABA has a number of effects on the immune cells such as activation or suppression of cytokine secretion, modification of cell proliferation and GABA can even affect migration of the cells. The immune cells encounter GABA when released by the immune cells themselves or when the immune cells enter the brain. In addition, GABA can also be found in tissues like the lymph nodes, the islets of Langerhans and GABA is in high enough concentration in blood to activate, e.g., GABA-A channels. GABA appears to have a role in autoimmune diseases like multiple sclerosis, type 1 diabetes, and rheumatoid arthritis and may modulate the immune response to infections. In the near future, it will be important to work out what specific effects GABA has on the function of the different types of immune cells and determine the underlying mechanisms. In this review, we discuss some of the recent findings revealing the role of GABA as an immunomodulator. Diabetes. 2013, 62:3760-5. γ-Aminobutyric acid regulates both the survival and replication of human β-cells. Tian J, Dang H, Chen Z, Guan A, Jin Y, Atkinson MA, Kaufman DL. γ-Aminobutyric acid (GABA) has been shown to inhibit apoptosis of rodent β-cells in vitro. In this study, we show that activation of GABAA receptors (GABAA-Rs) or GABAB-Rs significantly inhibits oxidative stress-related β-cell apoptosis and preserves pancreatic β-cells in streptozotocin-rendered hyperglycemic mice. Moreover, treatment with GABA, or a GABAA-R- or GABAB-R-specific agonist, inhibited human β-cell apoptosis following islet transplantation into NOD/scid mice. Accordingly, activation of GABAA-Rs and/or GABAB-Rs may be a useful adjunct therapy for human islet transplantation. GABA-R agonists also promoted β-cell replication in hyperglycemic mice. While a number of agents can promote rodent β-cell replication, most fail to provide similar activities with human β-cells. In this study, we show that GABA administration promotes β-cell replication and functional recovery in human islets following implantation into NOD/scid mice. Human β-cell replication was induced by both GABAA-R and GABAB-R activation. Hence, GABA regulates both the survival and replication of human β-cells. These actions, together with the anti-inflammatory properties of GABA, suggest that modulation of peripheral GABA-Rs may represent a promising new therapeutic strategy for improving β-cell survival following human islet transplantation and increasing β-cells in patients with diabetes. Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11692-7. doi: 10.1073/pnas.1102715108. GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. Soltani N, Qiu H, Aleksic M, Glinka Y, Zhao F, Liu R, Li Y, Zhang N, Chakrabarti R, Ng T, Jin T, Zhang H, Lu WY, Feng ZP, Prud'homme GJ, Wang Q. Type 1 diabetes (T1D) is an autoimmune disease characterized by insulitis and islet β-cell loss. Thus, an effective therapy may require β-cell restoration and immune suppression. Currently, there is no treatment that can achieve both goals efficiently. We report here that GABA exerts antidiabetic effects by acting on both the islet β-cells and immune system. Unlike in adult brain or islet α-cells in which GABA exerts hyperpolarizing effects, in islet β-cells, GABA produces membrane depolarization and Ca(2+) influx, leading to the activation of PI3-K/Akt-dependent growth and survival pathways. This provides a potential mechanism underlying our in vivo findings that GABA therapy preserves β-cell mass and prevents the development of T1D. Remarkably, in severely diabetic mice, GABA restores β-cell mass and reverses the disease. Furthermore, GABA suppresses insulitis and systemic inflammatory cytokine production. The β-cell regenerative and immunoinhibitory effects of GABA provide insights into the role of GABA in regulating islet cell function and glucose homeostasis, which may find clinical application. PLoS One. (http://www.ncbi.nlm.nih.gov/pubmed/21966502) 2011;6(9):e25337. doi: 10.1371/journal.pone.0025337. Epub 2011 Sep 22. Combining antigen-based therapy with GABA treatment synergistically prolongs survival of transplanted ß-cells in diabetic NOD mice. Tian J, Dang H, Kaufman DL. Antigen-based therapies (ABTs) very effectively prevent the development of type 1 diabetes (T1D) when given to young nonobese diabetic (NOD) mice, however, they have little or no ability to reverse hyperglycemia in newly diabetic NOD mice. More importantly, ABTs have not yet demonstrated an ability to effectively preserve residual ß-cells in individuals newly diagnosed with type 1 diabetes (T1D). Accordingly, there is great interest in identifying new treatments that can be combined with ABTs to safely protect ß-cells in diabetic animals. The activation of γ-aminobutyric acid (GABA) receptors (GABA-Rs) on immune cells has been shown to prevent T1D, experimental autoimmune encephalomyelitis (EAE) and rheumatoid arthritis in mouse models. Based on GABA's ability to inhibit different autoimmune diseases and its safety profile, we tested whether the combination of ABT with GABA treatment could prolong the survival of transplanted ß-cells in newly diabetic NOD mice. Newly diabetic NOD mice were untreated, or given GAD/alum (20 or 100 µg) and placed on plain drinking water, or water containing GABA (2 or 6 mg/ml). Twenty-eight days later, they received syngenic pancreas grafts and were monitored for the recurrence of hyperglycemia. Hyperglycemia reoccurred in the recipients given plain water, GAD monotherapy, GABA monotherapy, GAD (20 µg)+GABA (2 mg/ml), GAD (20 µg)+GABA (6 mg/ml) and GAD (100 µg)+GABA (6 mg/ml) about 1, 2-3, 3, 2-3, 3-8 and 10-11 weeks post-transplantation, respectively. Thus, combined GABA and ABT treatment had a synergistic effect in a dose-dependent fashion. These findings suggest that co-treatment with GABA (or other GABA-R agonists) may provide a new strategy to safely enhance the efficacy of other therapeutics designed to prevent or reverse T1D, as well as other T cell-mediated autoimmune diseases. Fig 1. Synergistic effects of combined GAD/alum+GABA treatment to prolong transplanted syngenic ß-cell survival in diabetic NOD mice (Tian 2011 e25338) Diabetologia. (http://www.ncbi.nlm.nih.gov/pubmed/17318626) 2007 Apr;50(4):764-73. Epub 2007 Feb 22. Regulation of pancreatic islet cell survival and replication by gamma-aminobutyric acid. Ligon B, Yang J, Morin SB, Ruberti MF, Steer ML. AIMS/HYPOTHESIS: Pancreatic islets have evolved remarkable, though poorly understood mechanisms to modify beta cell mass when nutrient intake fluctuates or cells are damaged. We hypothesised that appropriate and timely adjustments in cell number occur because beta cells release proliferative signals to surrounding cells when stimulated by nutrients and 'bleed' these growth factors upon injury. MATERIALS AND METHODS: In rat pancreatic islets, we measured DNA content, insulin content, insulin secretion after treatment, immunoblots of apoptotic proteins and the uptake of nucleoside analogues to assess the ability of gamma-aminobutyric acid (GABA), which is highly concentrated in beta cells, to act as a growth and survival factor. This focus is supported by work from others demonstrating that GABA increases cell proliferation in the developing nervous system, acts as a survival factor for differentiated neurons and, interestingly, protects plants under stress. RESULTS: Our results show that DNA, insulin content and insulin secretion are higher in freshly isolated islets treated with GABA or GABA B receptor agonists. Exposure to GABA upregulated the anti-apoptotic protein B-cell chronic lymphocytic leukaemia XL and limited activation of caspase 3 in islets. The cellular proliferation rate in GABA-treated islets was twice that of untreated controls. CONCLUSIONS/INTERPRETATION: We conclude that GABA serves diverse purposes in the islet, meeting a number of functional criteria to act as an endogenous co-regulator of beta cell mass.

Estranged daughter overturns mothers will

Heather llott went through a long court battle after her mother Melita Jackson left her £486,000 estate to animal charities when she died just over a decade ago. However, the Court of Appeal has ruled she should receive a third of the estate. Candice Jones, a wills expert at QualitySolicitors David Roberts & Co said the ruling will possibly weaken people's right to leave money to those they want to inherit it. She said the ruling would mean people could still disinherit their own children but would need to explain why they have decided to leave their money or assets to others. The court heard Mrs Ilott, 54, had eloped at the age of 17 with her boyfriend and, as a result, her mother had never forgiven her and did not want her to receive a penny of her estate, which was left to animal charities, the RSPCA, RSPB and Blue Cross charities. Mrs Ilott married her partner, and the couple live in the Home Counties. They have five children and the court heard Mrs Ilott planned to use the inheritance to buy their home. This week she was awarded a third of the estate because her mother hadn't left "reasonable provision" for her in the will. She'll now be able to buy her housing association property and won't lose her state benefits. Mrs Jones, whose firm are based in New Brighton  said ”This ruling means you can still disinherit your children but you'll have to explain in more detail what connects you to those you do leave money to. “This will make it easier for adult disinherited children to challenge wills and claim greater sums and this will almost certainly lead to a tidal wave of contested wills.” Mrs Jackson made her last will two years before her death in 2004 with a letter to explain why she had disinherited her daughter, referring to the fact she had walked out of her home as a teenager to live with her boyfriend. Mrs Ilott, who was an only child, had in 2007 won the right to an inheritance of £50,000 after a district judge concluded she had been "unreasonably" excluded by Mrs Jackson. That ruling was reversed, before Appeal Court judges ruled she was entitled to a share. When Mrs Ilott appealed to get the amount increased, Mrs Justice Parker dismissed this at the High Court in London, ruling in March 2014 that the previous decision that £50,000 was appropriate could not "be said to be wrong". However, in the latest hearing Lady Justice Arden said Mrs Ilott's mother had been "unreasonable, capricious and harsh" and ruled she should therefore receive a greater proportion of the estate. Pic: Candice Jones, Wills Expert at QualitySolicitors David Roberts & Co Any queries call Nolan PR on 01564 822861/ 07505 133302

Cenex chooses Chargemaster to take over Plugged-in Midlands electric vehicle charging network

Cenex, the Loughborough-based Centre of Excellence for Low Carbon and Fuel Cell Technologies, has chosen Chargemaster, the largest UK supplier and operator of chargepoints, to run the Plugged-in Midlands Network (PiM) following a competitive selection process. The Plugged-in Midlands estate of more than 870 chargepoints will be merged with Chargemaster’s POLAR network, which already comprises over 4,000 chargepoints across the country. The addition of the PiM chargepoints to the extensive POLAR network will make EV motoring even easier across the UK. Developments planned for the PiM network include access to chargepoints via smartphone app and a choice of tariffs, with many chargepoints remaining free to use. Across the UK, more than 80% of POLAR chargepoints are free. The agreement with Chargemaster, which has been approved by the Office for Low Emission Vehicles (OLEV), will consolidate the Midlands chargepoints within a wider national network. This will help improve customer service for motorists and chargepoint hosts.  Chargemaster, together with shareholders including BMW and wireless charging pioneer Qualcomm, has committed to transforming the PiM chargepoints through investment in supporting management systems. The company will also expand the network, with a short-term goal of adding over 100 new chargepoints in the coming months. Robert Evans, CEO of Cenex, commented: “Cenex has successfully grown the PiM network over the past five years to serve electric vehicle owners in the Midlands, and we are very proud of what has been achieved. Now is the time for the PiM network to transition to a specialist network operator that can expand the scope of the network, unify networks for national coverage, and invest in new services and an improved customer experience.  “Having reviewed Chargemaster’s track record, we are delighted that they have offered to invest in and grow the PiM network. We are convinced that electric car users will benefit from this step, as Chargemaster continues to maintain the chargepoints to the highest standards.” David Martell, Chargemaster CEO, said: “We are excited to be given the opportunity to take the excellent work that Robert and his team at Cenex have achieved over the last five years, together with the support of OLEV, and advance it to a new level with significant investment from the private sector. “We will be investing in many new chargepoints and back-end server technologies. We will also be working closely with existing stakeholders to make the Midlands a showcase that facilitates and promotes the ownership and operation of electric vehicles.” Originally established as part of the government-backed Plugged-in Places (PiP) initiative in 2010, the PiM scheme exceeded all expectations by part-funding more than 870 chargepoints across the Midlands. Following financial support from Government over the last three years, public sector operators have been opting to transfer operation of the chargepoints to self-sustaining business models, often with private sector partnerships. In 2013, Chargemaster won a competitive tender to take over the management of the Milton Keynes PiP network. It has successfully expanded the chargepoint network, many of which are rapid chargers that enable electric vehicles to charge in under 30 minutes. About Chargemaster Chargemaster Plc is the UK’s leading provider of electric vehicle-charging infrastructure. Benefiting from over 25 years of experience working within the telematics and vehicle-orientated industry, Chargemaster provides a comprehensive, flexible and practical range of electric vehicle-charging solutions. Its charging stations are specially developed to accommodate new technological advances and the growing demands of the electric vehicle industry. Chargemaster works in partnership with leading energy providers, vehicle manufacturers, government agencies, management consultancies, and property development and blue chip companies. Chargemaster is the largest UK supplier of public and workplace charging units in the UK, and has supplied over 10,000 charging points across Europe. The company operates its own manufacturing facility at Luton Airport, which currently produces over 2,000 charging units per month and operates to ISO9001 quality standards. Chargemaster Rachel Burgess, Torque AgencyTel: 020 7952 1070rburgess@torqueagencygroup.com About Cenex Cenex (www.cenex.co.uk), the UK’s first Centre of Excellence for Low Carbon and Fuel Cell Technologies, is a UK independent not-for-profit company. Cenex operates as a research and consultancy organisation, and has established its position as the leading independent expert in low carbon vehicles and energy infrastructure through the delivery of a range of research and demonstration trials.  Cenex has been a leading facilitator of e-mobility in the UK through support of early EV trials and for taking a lead in infrastructure deployment. Cenex launched the Plugged-in Midlands (PiM) project in December 2010 as one of the eight original OLEV-funded Plugged-in Places. The PiM project provided grants for organisations to install charging points across the East and West Midlands. The PiM project led to the installation of more than 870 charging points in a diverse range of locations, from town and city centres through to hotels, retail outlets and motorway service areas.  Cenex also manages the UK’s largest Low Carbon Vehicle Event (www.cenex-lcv.co.uk). Cenex Sue Glanville/Cate Bonthuys, Catalyst CommunicationsTel: +44 (0)771 581 7589/ +44 (0)774 654 6773sue@catalystcomms.co.uk / cate@catalystcomms.co.uk

BYD and ADL partner to supply Go-Ahead London with capital’s first, large-scale pure electric bus fleet

The move follows confirmation by Go-Ahead London that they are to introduce 51 emission-free, pure electric buses on routes 507 and 521, which operate between Waterloo and Victoria. The vehicles will be built on BYD chassis and powered by BYD’s technology-leading electric drivetrain. All 51 buses will be bodied by ADL, incorporating their market-leading Enviro200-like midi bus design. The Enviro200 is the world’s best-selling midi bus and renowned for its lightweight, easy access, manoeuvrability and fuel efficiency.   Go-Ahead London said today that it expects to introduce all 51 of the revolutionary new vehicles into service by August 27, 2016, signalling the introduction of London’s first, large-scale pure electric bus fleet. The move follows an announcement from Transport for London (TfL) earlier this month that it would electrify central London routes 507 and 521 as part of its drive to make all of its single deck buses emission-free by 2020. The new deal, worth £19 million, includes a full on-site repair and maintenance programme for the term of the contract and combines the strengths of ADL’s Enviro200 12m single deck (with 18,000 units sold worldwide) and BYD’s own design of Iron-Phosphate Battery technology and drivetrain system. The latter has been proven to deliver outstanding range and reliability in multiple international markets, covering millions of kilometres of passenger-carrying service. The decision by the two manufacturers to collaborate on this first fleet is a significant step. It brings together the proven, safe and long range capabilities of BYD’s pure electric buses (the company has 3,500 in service worldwide) with the outstanding and high quality vehicle design and UK build capability of ADL. The resulting vehicles, capable of carrying up to 90 passengers, will offer Londoners some of the most advanced zero emission buses in the world and provide opportunities for the two partner bus builders to work together in the future for the benefit of other bus operators, their passengers and the wider community. Both BYD and ADL see this latest development as a major step towards bus operations in the UK and around the world making a bold statement and major contribution on which to base clean air initiatives. Isbrand Ho, Managing Director of BYD Europe, said: “Working together with our partners and friends at ADL we can provide a truly optimised blend of expertise. Our deep experience of not only battery technology but the critical battery management systems and driveline components necessary to deliver unequalled range and reliability are matched to ADL’s strong track record in building low weight, attractive and durable buses. This combination will deliver a unique vehicle which we believe will have a strong appeal in London and elsewhere in the UK”. Colin Robertson, CEO of ADL, commented: “Technology is at the forefront of everything we do and this unique alliance with BYD represents a quantum leap into the future. Our combined strengths and, critically, the unified aftermarket support we are putting in place to support Go-Ahead London in the long-term, represents a fundamental of our combined business philosophy. The backing of Go-Ahead – in the form of this £19m contract – is a huge confidence booster and we are delighted to have emerged alongside BYD as the preferred bidder in what was a highly competitive process involving a raft of global competitors. I see this new initiative as a major turning point for ADL and our new technology partner, BYD.”  Richard Harrington, Engineering Director of Go-Ahead London, commented: “We are delighted to have placed this order with BYD and have every confidence that along with ADL they will deliver exactly what they promise, that is, the world’s most advanced, zero-emission, pure electric bus fleet – and one that will match the rigorous demands of the London operating environment. Go-Ahead is constantly striving to stay at the forefront of technology and to make a major contribution in the reduction of emissions and pollutants. This is a considerable step towards a cleaner, greener London bus fleet.” About BYD BYD Company Ltd. is the world’s largest maker of pure electric buses. Its vehicles have been trialled by 147 cities worldwide and proved to have significant operational cost benefits, as well as being totally environment friendly. Two of its single decks have been in service with Go-Ahead in London for 18 months and the successful in-service experience of these vehicles – which are able to complete a day’s route service on a single battery charge – has been instrumental in securing this latest contract. The world’s first pure electric double deck is also being developed by BYD and TfL recently announced that five will enter trial service with Metroline in London later this year. BYD is one of China’s largest companies to have successfully expanded globally. Specializing in battery technologies, their green mission to “solve the whole problem” has made them industry pioneers and leaders in several High-tech sectors including High-efficiency Automobiles, Electrified Public Transportation, Environmentally-Friendly Energy Storage, Affordable Solar Power and Information Technology and Original Design Manufacturing (ODM) services. As the world’s largest manufacturer of rechargeable batteries, their mission to create safer and more environmentally  friendly  battery  technologies  has  lead  to  the  development  of  the  BYD  Iron Phosphate (or "Fe") Battery. This fire-safe, completely recyclable and incredibly long-cycle technology has become the core of their clean energy platform that has expanded into automobiles, buses, trucks, utility vehicles and energy storage facilities. BYD and all of their shareholders, including the great American Investor Warren Buffett, see these environmentally and economically forward products as the way of the future. BYD has made a strong entrance to the North, Central and South American markets with their battery electric buses, and lineup of automobiles. Their mission lies not just in sales growth, but also in sociological integration and local job creation as they have poured incredible investments into developing offices, dealerships and manufacturing facilities in the local communities they now call home, truly a first for Chinese companies. For more information, please visit www.byd.com (http://file:///C:/Users/penny/AppData/Local/Microsoft/Windows/Temporary%20Internet%20Files/Content.Outlook/A22LX4IU/www.byd.com) or www.facebook.com/bydcompany. About ADL Alexander Dennis Limited, known as ADL, is the UK’s biggest bus and coach manufacturer. It employs 2,500 people and supports a further 1,500 jobs in build partnerships around the world. It is a business that has enjoyed spectacular growth in recent years, quadrupling turnover and extending its global reach beyond the UK into Hong Kong, where it is market leader, China, Singapore, Malaysia, New Zealand, the USA and Canada. ADL is an acknowledged world-leader in the design, engineering and manufacture of both two-axle and three-axle double decks. It also produces the world’s best-selling midi bus, the Enviro200. Further information from: Penny Peng, at BYD, on +31 -102070888 (office) penny.peng@byd.com Martin Hayes, at BYD, on +44 (0) 7836 21009 (mobile) martin@mchassociates.org Bill Simpson, at ADL, on +44 (0)1483 571271 (office) or 0776699 5000 (mobile) bill.simpson@alexander-dennis.com

Bulk Document Management Made Easy

With over 10 million tonnes of paper used each year, more and more businesses are digitising their documents. Scanning solutions company, Pearl Scan is at the forefront of the paperless office revolution, urging businesses with a plethora of paper to make the switch this summer and let Pearl Scan take care of all digitalisation and archival needs. HBP Group claim companies that make the switch can save themselves between £3000-£10,000 thanks to increased productivity, slashed operational costs and better time management. For over a decade Pearl Scan solutions has delivered many fully searchable digital archives, and the bulk scanning bureau is able to scan over 15 million images a month. All bulk scanning services are accredited to the best quality, security and environmental standards including ISO 9000, 27001 and 14001. Tackling the issue of shrinking office space, bulk scanning documents ensures fast access, a reduction in outgoing costs and a potential boost in staff morale – as well as improving green credentials and environmental impact. Companies without bulk document or archive management services can benefit from free document management software, Halogen. As well as providing documents in standard PDF file formats, data can be hosted on Halogen or uploaded to the secure cloud based document storage service, Pearl Cloud portal. Naveen Ashraf, Managing Director of Pearl Scan said, “Our scanning service is completely bespoke and can be tailored to meet all individual business needs. Regardless of where in the UK a business is, we will fully manage the entire project conversion at our secure facilities. “We provide support of scoping, inventory creation and batch preparation – as well as creating files and folders for the collection process. From the moment a project begins we will create a plan which clearly defines schedules, times and deadlines.” Ashraf added, “There has never been a better chance for businesses to embrace the digital change. No matter their size, any companies can start to benefit from digitising their documents with us.” To find out more about Pearl Scan and its wide range of scanning solutions, visit:https://www.pearl-scan.co.uk Facebook: https://www.facebook.com/pages/Pearl-Scan-Solutions/208624582495681 Twitter: https://twitter.com/pearlscan Google+: https://plus.google.com/u/0/+Document-scanning-companyUk/posts

Pirelli unveiled as sponsor of Salon Privé’s inaugural ‘Prestige & Performance’ Competition

Salon Privé is proud to announce its partnership with one of the greatest global brands, Pirelli, who will sponsor the exciting new ‘Prestige & Performance’ Competition on Saturday 5th September at Blenheim Palace. As the first Concours of its kind in the UK to uniquely pay homage to post-1975 supercars, this event allows spectators to see stunning cars from the last 40 years. Presented in The Great Court and paraded through Blenheim Palace’s beautiful grounds, it offers the opportunity to experience the sights, sounds and smells of these fabulous vehicles first-hand. The innovative new competition is the centrepiece of The Salon Privé Supercar Show, the event’s first ever public day. Visitors on the Saturday will be dazzled by up to eighty motors, and the opportunity to get up close and personal with some of the most beautiful cars ever made promises to the be the highlight of any car fan’s calendar. Pirelli UK Managing Director Dominic Sandivasci said: “We are delighted to be working with Salon Privé for 2015. The event attracts owners of elite vehicles making it a perfect fit for us as we feature as Original Equipment on an abundance of the most prestigious and high performance cars in the world. Pirelli will be sponsoring Saturday’s proceedings at Blenheim Palace, namely the Pirelli 'Prestige & Performance’ Competition, which will see some of the world’s best supercars and hypercars being crowned the winners on the day." Salon Privé co-founder and Managing Director Andrew Bagley commented: “This is a hugely exciting new addition to Salon Privé for which we have a host of impressive cars taking part. “Pirelli’s sponsorship of the ‘Prestige & Performance’ Competition further underlines the importance of Salon Privé on the automotive events calendar and we are delighted to have yet another premium brand joining our growing list of sponsors, and headlining this competition.  This is the first time we’ve offered a weekend option and public day ticket for visitors and it promises to introduce a whole new generation to the passion and beauty of the world’s greatest cars.” Entrance tickets into the ‘Prestige & Performance’ area cost £20 and include access to the stunning grounds of Blenheim Palace. For those wishing to have the full Salon Privé experience, there is the opportunity to upgrade to the Salon Privé exclusive enclosure. This includes luncheon and refreshments as well as full access to the fabulous Concours entries, stunning Super, Hyper and Concept cars and an amazing range of high-end luxury brands and products. With an entrance roster for the Pirelli Competition expected to include all the big luxury marques including Audi, BMW, Ferrari, Maserati, Pagani, Porsche and more, participants of ‘Prestige & Performance’ can enjoy a range of classes including ‘Blink and it’s Gone’, ‘Road or Race or Both’ and ‘Feel the Breeze’. The full list of classes are: Celebrating 40 Years of the Iconic Ferrari 308 GTBCelebrating 10 Years in Production of the Bugatti VeyronRoad or Race or BothBuilt for SpeedFeel the BreezeGrace & PacePre-Millennium SupercarsBlink and it’s Gone Car owners wishing to enter their supercar are invited to register their interest here (http://www.jotformpro.com/form/50272645915962). Tickets are now on sale at www.salonpriveconcours.com  ENDS Media contactsMatt Sanger: 0207 952 1079 or msanger@torqueagencygroup.comRachel Burgess: 0207 952 1076 or rburgess@torqueagencygroup.com Editors’ notes About Salon Privé: Now in its 10th year, Salon Privé takes place from Thursday 3rd to Saturday 5th September at the stunning Blenheim Palace and is firmly established as the UK’s most prestigious Luxury Supercar Show & Concours d’Elégance. The three-day event incorporates the Chubb Insurance Concours d’Elégance, Boodles Ladies’ Day and The Salon Privé Supercar Show, also showcasing The Pirelli ‘Prestige & Performance’ Competition, the EFG Art and Memorabilia Fair and The Salon Privé Sale in association with Silverstone Auctions.  The Tour d’Elégance takes place for Concours owners only on Wednesday 2nd September.  Salon Privé takes pride and place amongst the leading automotive shows of the world including the U.S.’s Pebble Beach and Italy’s Villa d’Este.  Visit www.salonpriveconcours.com Facebook: https://www.facebook.com/SalonPriveUK About Pirelli Founded in 1872, Pirelli has a presence in over 160 countries, with 22 manufacturing facilities on four continents and 38,000 employees. Involved in motor racing since 1907 it is currently the exclusive Formula 1® tyre manufacturer for the 2014-2016 championship seasons. Being among the main tyre makers globally Pirelli is world leader in the Premium segment where it has consolidated partnerships with top premium car manufacturers. Facebook: https://www.facebook.com/PirelliUK?fref=ts Instagram: https://instagram.com/pirelli_uk/

An Analysis of the True Cost of Data Loss

Within the digital age that we currently inhabit we are surrounded by computers, software and technology along with the data it produces. Valuable and sensitive digital data is held and stored by nearly every business in operation and is a valuable commodity. Often, businesses rely on technology and software to support their day-to-day running procedures and compliance obligations. However, computers and software are prone to malfunctioning which can result in the loss of critical business and sensitive data. Information gathered from a number of sources highlights the far-reaching effects data loss can have upon a business and also indicates the various pitfalls and oversights made by businesses when it comes to protecting their data. Worryingly, research shows that 60% of small to medium businesses do not routinely back up their business-critical data and that 72% of businesses that do experience a major data breach ultimately shut down within 24 months. With an estimated 20% of small to medium businesses expected to suffer a major disaster causing substantial loss of critical data every 5 years, LE&AS has devised an infographic to help raise awareness of this potentially devastating occurrence. Director of Legal Escrow and Arbitration Services Jim Mills understands the true cost of data loss for a business Having worked in this industry for over 20 years I have seen the devastating effects that data loss can bring upon a business. LE&AS urges businesses to evaluate their data protection procedures and disaster recovery plans to ensure their business is sufficiently protected in the event of a hardware or software malfunction. The infographic is fully shareable from the LE&AS website (http://www.leaas.co.uk/blog/true-cost-data-loss/) and has been created to highlight the real need faced by modern businesses to devise a data protection and recovery plan. Having worked with businesses who have felt the effects of a data breach or loss, the experts at Legal Escrow and Arbitration Services wish to aid businesses through educating them. Information to create the infographic has been gathered from various sources including the Department for Business Innovation & Skills 2013 Information Security Breaches Survey and the Guardian.   

Investment from Simon Goodenough Spurs Next Phase of Growth at dsp

Award winning IT services provider dsp (http://www.dsp.co.uk/) is set to enjoy fast-tracked growth as it welcomes Simon Goodenough on-board as its new Executive Chairman. Simon Goodenough is part of a Private Investment Group that has agreed to fund the next phase of growth at dsp. Since 1999 dsp has been providing UK businesses with bespoke database and application managed services.  They support complex Oracle and Microsoft implementations for an array of mid-market, corporate and public sector clients. Now, DSP is setting its sights on further expansion with the appointment of Simon Goodenough (https://www.linkedin.com/profile/view?id=5311092) as company Chairman. As former Managing Director of Quantix and later Interoute, Simon brings a wealth of experience and expertise to the board in growing Oracle and Microsoft Managed Services companies. Phil (https://www.linkedin.com/profile/view?id=1772461) Huntley, Managing Director says, “It’s a coup in our industry to get Simon onto the team and are anticipating significant growth within the coming months. We have already used the funds to make our first acquisition by acquiring the Oracle Managed Services contract base from FSR Management. We have also invested the funds by implementing next generation proactive monitoring software and processes so our customers will also see an immediate win too.” Boasting a foundation of 16 years commercial success developing and delivering Oracle and Microsoft solutions, dsp is a major player in the mid-market space.  As well it’s first acquisition and new monitoring infrastructure, dsp will also use the cash injection to acquire the services of Bobby Singh (https://www.linkedin.com/profile/view?id=22581383) as Managed Services Sales Director. With over 17 years of experience in providing solutions and services to organisations running mission critical databases, applications and infrastructure, Bobby has an in-depth understanding of how to augment sales strategies and manage successful sales organisations. Over the past 12 months dsp has enjoyed contract growth of over 100%. With Simon Goodenough as Chairman and Bobby Singh as Sales Director and a pool of cash to fund growth, the trend is only set to continue. Together the pair plan to roll out both organic and inorganic strategies designed to cement the company’s status as a global leader in innovative Managed Services and Cloud solutions. In the wake of its ongoing growth dsp has recently relocated its offices to Canary Wharf, London’s most prestigious business district to be closer to its current and prospective client base. To find out more about dsp and how its latest appointments and investment funds are set to help its clients save cash while streamlining operations, go to: http://www.dsp.co.uk

Acquisition strengthens Beijer Ref’s position in New Zealand and Australia

The Swedish refrigeration group, Beijer Ref AB, strengthens its operation in New Zealand and Australia by acquiring the refrigeration wholesale company, Realcold, which has its head office in Auckland, New Zealand, and around 20 branches in New Zealand and Australia. Beijer Ref is one of the largest refrigeration wholesalers in the world and the acquisition of Realcold is a significant step forward in the company’s strategy to grow outside Europe. Realcold was founded in 1955, reports annual sales of more than SEK 260M and is the second largest refrigeration wholesaler in New Zealand. With the acquisition, Beijer Ref becomes the largest refrigeration wholesaler in New Zealand. “New Zealand and Australia are interesting growth markets for Beijer Ref. With the large food exports and growing tourism industry of these countries, there is a significant need for efficient refrigeration plants”, says Per Bertland, CEO of Beijer Ref. In New Zealand, Realcold has 10 branches, 68 employees and sales of SEK 135M. In Australia, the company has established an operation since 1999. Realcold has its distribution centre in Brisbane, eleven branches, 52 employees and sales of 157M. “The company has a broad product portfolio with brands such as Mitsubishi Heavy Industries, Tecumseh, Emerson Copeland and Gree. However, the range will now be complemented with Beijer Ref’s product programme. In addition to synergies on the purchasing side, we will contribute our European refrigeration-technology expertise and contribute with new eco-friendly refrigeration technology in New Zealand and Australia”, continues Per Bertland. The acquisition of Realcold together with our acquisition of the refrigeration wholesale companies, RNA Engineering & Trading in Malaysia and Patton in New Zealand, Australia, Thailand and India, during the spring has given Beijer Ref a stable foothold in the Australasia region, with total sales approaching SEK 800M. Realcold will be integrated into Beijer Ref’s organisation and is expected to be included in the consolidated accounts from October 2015. The acquisition is expected to have a marginal positive effect on Beijer Ref’s net income in 2015. The acquisition is subject to approval by the competition authorities in New Zealand. Malmö, 29 July 2015 Beijer Ref AB (publ) For further information, please contact: Per Bertland, CEO Telephone +46 40-35 89 00 Mobile +46 705-98 13 73 or Jonas Lindqvist, CFO Telephone +46 40-35 89 00 Mobile +46 705-90 89 04 BEIJER REF AB is a technology-oriented trading Group which, through added-value products, offers its customers competitive solutions within refrigeration and climate control. Beijer Ref is one of the largest refrigeration wholesalers in the world, and is represented in Belgium, Denmark, Estonia, Finland, France, Ireland, Italy, Latvia, Lithuania, Poland, Holland, Norway, Romania, Switzerland, Slovakia, Spain, United Kingdom, Sweden, the Czech Republic, Germany, Hungary, South Africa, Mozambique, Zambia, Botswana, Namibia, Malaysia, Thailand, India, Australia and New Zealand. www.beijerref.com

Securitas AB to publish Interim Report on Wednesday, August 5, 2015

App. 13.00 Report release. The report will be sent as a press release from Cision (www.cision.se) and will automatically be published on www.securitas.com when released. 14.00 Presentation slides available. For presentation slides, follow the link www.securitas.com/presentations 15.00 Telephone conference and audio cast Analysts and media are invited to participate in a telephone conference at 15.00 p.m. (CET) where Securitas CEO Alf Göransson will present the report and answer questions. The telephone conference will also be audio casted live via Securitas’ website. Please note! No information meeting will take place at Securitas headquarters at Lindhagensplan in Stockholm. To participate in the telephone conference, please dial in five minutes prior to the start of the conference call: The United States: + 1 855 269 2605 Sweden:   + 46 (0) 8 519 993 55 United Kingdom:  + 44 (0) 203 194 0550 To follow the audio cast of the telephone conference via the web, please follow the link www.securitas.com/webcasts. A recorded version of the webcast will be available on the same web page after the telephone conference. Subscribe to press releases and financial information. To receive press releases and financial reports from Securitas, please follow the link  www.securitas.com/subscribe and follow the instructions. Information: Micaela Sjökvist, Head of Investor Relations    Phone: +46 10 470 30 13. Mobile: +46 (0) 76 116 7443 Gisela Lindstrand, Senior Vice President Corporate Communications and Public Affairs Phone: +46 10 470 30 11. Mobile: +46 (0)70 287 86 62

An Innovative New Toilet Seat Bidet Uses NO Electricity

In Europe, bidets have often been seen as luxury items, only fitted in the biggest and most lavish of bathrooms. A water efficiency distribution company has changed those misconceptions, by stocking the UK’s first 2-in-1 toilet seat bidet without the need for electricity or a separate water supply – as it draws water from the current cistern supply. The exclusive Lavalino Toilet Seat with Built-in Bidet is the ultimate space saving solution for those who require that fresh feeling of cleanliness but don’t have the room for a traditional bidet. The retro-fit solution is easy to fit, does not require a separate water supply or electricity and is ideal for home and business bathrooms. This innovative bidet seat is new to the UK market, sold exclusively by Every Drop Is Precious. Previous products of this type have only been available by import from other areas of the world, causing issues with compatability. The Lavalino bidet seat is German manufactured, offering premium efficiency and German manufacturing standards which are famous around the globe. Tamsin Johnson, Director of Every Drop Is Precious said, “We are absolutely thrilled to introduce this state-of-the-art product to the UK market. It is only available in the UK through the Every Drop is Precious brand, and we are very excited to be stocking Lavalino, a highly regarded German manufacturer. ”This bidet seat offers a whole new experience for many Brits, who have often snubbed the bidet as a hygiene product. It is ideal for the elderly, anyone who is less mobile or suffers from medical conditions, or simply wants to feel instantly fresh and clean.” Bidets are most popular in Asia (Over 70% of households in Japan have a bidet fitted) the Middle East and certain parts of Europe, but they are also gaining popularity in the USA – especially amongst high-end bathrooms. A bidet offers a cleansing experience far superior than that offered by toilet paper, and those who have tried it often don’t look back. Regardless of how small a bathroom is, homeowners can now indulge in the bidet experience thanks to the affordable Lavalino toilet seat with built-in bidet function. There are no complicated remote controls to use, and the seat has been designed to fit onto most toilet pans. The device is easy to fit for any plumber or experienced DIY-er, due to the fact it uses the current cistern supply, so no separate water supply or electricity is needed. For more information about the toilet seat with bidet function or other eco-friendly water saving products, visit: http://www.everydropisprecious.com/

Hair Development on the Search for New Face of Brand

Selfie sticks at the ready - one of the leading names in permanent and fashion hair extensions and professional hair replacement solutions has launched a competition to find the face of the brand. London based Hair Development is looking for its HD Girl 2016, and the lucky lady will win an extension makeover worth £795 and become the face of the brand. The search for the poster girl began last month and the competition is open until October 31. Any British woman aged 18-45 can enter, and the directors at Hair Development want to stress they are not only appealing to aspiring models. Janis Levy, Creative Director of Hair Development said, “If we wanted a classic model we could have hired one, but this competition is about the everyday woman channelling her inner beauty and finding confidence. We want to see entries from a variety of ages from all walks of life – our HD Girl 2016 could be a student, a lawyer, an engineer or a full time mum. It’s going to be so exciting choosing our poster girl and giving them a hair makeover – the hunt is on!” The winner of the HD Girl competition will take part in a photoshoot once they have had their professional hair extensions fitted by a HD specialist. These images will be used for all promotional materials and on the Hair Development website, meaning the woman will be the face of the brand for the entire year. In addition, they will have the opportunity to make personal appearances at industry events to represent the brand. Entering the online competition is fast and easy and women wanting to be in with a chance of winning the special prize can enter on social media. The HD Girl competition is open across Facebook, Twitter and Instagram and all entrants need to do is snap a selfie and upload it, use the hashtag #HDGirlCompetition and tag Hair Development in it. Finalists will be chosen later in the year and invited to HD headquarters in London, where the HD Girl 2016 will be announced. Janis added “A lot of people post selfies regularly on social media – just tag us in it and you could end up being the face of HD!” To find out more about Hair Development and its range of natural looking extensions, visit: http://www.hair-development.com/ Facebook: https://www.facebook.com/HairDevelopment Twitter: https://twitter.com/HairDevelopment Instagram: https://instagram.com/hairdevelopment1/

Medivir announces start of a phase I clinical trial of the nucleotide polymerase inhibitor AL-704 for treatment of hepatitis C

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces the start of a phase I clinical trial with AL-704, also known as JNJ-54257099, by Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies. AL-704 is a nucleotide based NS5B polymerase inhibitor intended for the treatment of chronic hepatitis C virus (HCV) infection in combination with other direct acting antiviral agents.Medivir entered a Research & Development agreement in the field of HCV polymerase with Janssen Products LP in May 2008. AL-704 is the second candidate drug under this agreement that enters into clinical development, and thus no additional milestone payment is due for this specific step of development.This phase I study is a randomized, double-blind, placebo-controlled, 3-part study of orally administered AL-704 to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses (Part 1) and food-effect (Part 2) in healthy volunteers, and multiple doses (7 days) in subjects with chronic hepatitis C infection of genotype 1 and 3 (Part 3).Approximately 150 million people are chronically infected with HCV globally*. When left untreated, HCV causes progressive liver disease in many of those who are chronically infected, and this can lead ultimately to cirrhosis, hepatocellular carcinoma and a requirement for liver transplantation. However the infection is curable with combinations of antiviral agents, and nucleotide inhibitors of the viral polymerase have been shown to be central to some of the most effective drug combinations for treating HCV.Further information about the study can be found at www.clinicaltrials.govFor further information, please contact:Ola Burmark, CFO Medivir AB, mobile: +46 (0)725-480 580.Medivir is required under the Securities Markets Act to make the information in this press release public.The information was submitted for publication at 17.00 CET on 29 July 2015.About MedivirMedivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List. *http://www.who.int/mediacentre/factsheets/fs164/en/

VinSolutions integrates desking tool with Autosoft DMS

MISSION, Kan. (July 29, 2015) — VinSolutions today announced the integration of its VinConnect Desking tool and the Autosoft dealership management system (DMS). Duplicate entry remains a pain point for dealers. The push-and-pull functionality available with the VinConnect Desking and Autosoft FLEX F&I integration eliminates redundancies and enables dealers to save time and increase efficiencies. With real-time integration between VinConnect Desking and Autosoft FLEX F&I, Autosoft data is automatically pulled and stored in the VinConnect CRM database when dealers are desking a deal. This push-and-pull functionality eliminates the need for double data entry and improves data accuracy for critical decision-making. “This integration between two leading software companies reinforces our commitment to providing seamless solutions for our customers,” said Sean Stapleton, vice president of sales and marketing at VinSolutions. “As technology evolves, dealership software solutions will only communicate with each other more. We look forward to helping our customers enhance dealership processes, increase efficiency and better serve their customers.” This integration also enhances a dealership’s overall visibility between its departments and its DMS solution. “Our FLEX Connect integration program opens up exciting opportunities for our customers,” said Christopher Morris, senior vice president at Autosoft. “The close integration between our FLEX DMS and VinConnect Desking reduces inefficiencies in the F&I process, driving more productivity and, ultimately, more profitability for our dealers.” For more information about the VinConnect Desking and Autosoft FLEX F&I integration, visit vinsolutions.com/contact (http://www.vinsolutions.com/contact)

The end of an era – York explores the legacy of Richard III during JORVIK Medieval Festival

Few historic kings have received as much coverage and discussion over the last two years as the last medieval monarch, Richard III, and stories from his recent rediscovery, to the myths surrounding his life will be explored during a series of highlight events and lectures during the JORVIK Medieval Festival. One of the headline events of this year’s festival will be a lecture by Philippa Langley – the screenwriter who led the ‘Looking for Richard Project’ which successfully unearthed the long-lost Sovereign. The event, which takes place at York Guildhall on 25 August, will explore the years of research – and a long battle to actually dig where the team thought Richard might be buried – that led to his discovery. “We were delighted when Philippa agreed to contribute exhibits to the Richard III Experience in Monk Bar, so it is wonderful to be welcoming her back for this lecture when she can tell the story of this remarkable investigation in her own words,” comments Sarah Maltby, director of attractions for the JORVIK Group, which organises the festival. “When you hear of all the obstacles faced by the team before they broke the first piece of ground, this discovery really was like finding a needle in a haystack, and yet it has such huge ramifications for our understanding of this often maligned monarch.” Indeed, the mythology surrounding Richard III will be explored and examined by historian and author Dr John Ashdown-Hill on 22 August at York Explore. As a member of the University of Leicester’s Richard III Project, Dr Ashdown-Hill will share unique insights into the monarch, addressing some of the contemporary stories which the recent discovery has proved to be inaccurate, and looking at what some of the new findings have revealed about the King’s lifestyle. The relationship of Richard III to his beloved city of York throughout his life will be reviewed by Dr Sarah Rees Jones of the University of York on 23 August at York Explore, whilst his son – Edward of Middleham – will be the focus of a lecture at Barley Hall on 24 August by Ricardian historian, Peter Hammond. The only legitimate son of Richard III was created Prince of Wales in York Minster in 1483, but sadly died the following year. Other events relating to the Plantagenet monarch include a living history encampment at The Crooked Billet in Saxton, near Tadcaster on 3 August (12 noon until 3.00pm), and a series of walks around York’s city walls, starting from the Richard III Experience at Monk Bar and finishing at the Henry VII Experience at Micklegate Bar, with an expert guide bringing tales of one of the most turbulent periods on English history – the Wars of the Roses – to life. The 90 minute walk takes place daily from 24 – 28 August at 2.30pm. Full details of all of the events in the JORVIK Medieval Festival, including how to book, are available online at www.jorvikmedievalfestival.com ENDS For further media information or photographs, please contact: Jay Commins Pyper York Limited Tel:         01904 500698 Email:    jay@pyperyork.co.uk Photographs are available by following the links at the bottom of this email, or from http://news.cision.com/the-jorvik-group-of-attractions 

Leading surgeon, researcher Jack A. Roth, MD, named 2015 ASTRO Honorary Member

The American Society for Radiation Oncology (ASTRO) has selected leading surgeon and researcher Jack A. Roth, MD, as the 2015 Honorary Member, the highest honor ASTRO bestows on distinguished cancer researchers, scientists and leaders in disciplines other than radiation oncology, radiobiology or radiation physics. Dr. Roth will be inducted as the 2015 ASTRO Honorary Member during the Awards Ceremony on Tuesday, October 20, at ASTRO’s 57th Annual Meeting, October 18-21, 2015, at the Henry B. Gonzalez Convention Center in San Antonio. The first ASTRO Honorary Membership was awarded in 1989. The selection of Dr. Roth tallies the number of individuals to receive an Honorary Membership in ASTRO to 32. “Throughout his renowned career, Dr. Roth has demonstrated leadership and commitment to multidisciplinary approaches for treating lung cancer,” said Bruce G. Haffty, MD, FASTRO, chair of ASTRO’s Board of Directors. “Patients should benefit from his pivotal work comparing the use of stereotactic ablative radiation therapy [SABR] versus surgery for operable clinical stage I non-small cell lung cancer [NSCLC]. He and colleagues found that SABR may improve outcomes for stage I NSCLC patients compared to standard lobectomy in their study. Dr. Roth is an excellent surgeon and clinician, as well as an inspiring mentor. ASTRO thanks him for his outstanding achievements.”         Dr. Roth has received numerous grants and awards, including an NCI SPORE Grant in lung cancer, published more than 560 articles in peer-reviewed journals and 116 book chapters, and has 59 issued and 22 pending U.S. and foreign patients. He cited his and colleagues’ study “Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomized trials,” published in Lancet Oncology in May 2015, as his most recent career highlight. “This was the culmination of 10 years of work from many international multidisciplinary groups,” Dr. Roth said. He said the topic caught his interest in 2005, when he attended presentations by Robert Timmerman, MD, and Hiroshi Onishi, MD, PhD, on the first SABR clinical trials in stage I lung cancer at the International Association for the Study of Lung Cancer (IASLC) World Conference in Barcelona. “The potential to reduce treatment-related morbidity and mortality and for organ preservation was obvious,” he said. He organized a workshop sponsored by the IASLC in 2006 to discuss the feasibility of a clinical trial comparing SABR to lobectomy for operable clinical stage I NSCLC. “Implementation faced many obstacles, including rejection of the protocol by clinical trials cooperative groups, difficulty in obtaining funding and the refusal of thoracic surgeons at academic medical centers around the world to participate,” Dr. Roth said. “A turning point was the suggestion by Suresh Senan, MBBS, PhD, that the data from our two trials [STARS and ROSEL] be combined, which resulted in the Lancet Oncology publication.” He was also an early innovator in the development of gene therapy for cancer, and led the first tumor suppressor gene therapy clinical trials approved by the National Institutes of Health Recombinant DNA Advisory Committee and the U.S. Food and Drug Administration. The approval for the protocols came from his demonstration of feasibility and efficacy through laboratory and preclinical studies. His work was the first gene therapy in cancer approved for human use. “Cancer is a disease of dysfunctional genes,” Dr. Roth said. “A direct way to address this is to correct the genetic abnormalities through gene transfer. The first tumor suppressor gene therapy patient was treated by our group in 1995. This has been a long journey as well, with many technical challenges. However, during the past 5 years, real progress has been made in systemic gene delivery.” Dr. Roth has not only worked on the research and surgical sides himself, but he has also trained the next generation of surgical oncologists and laboratory researchers. “I hope this research will inspire physicians of all oncologic disciplines to work together to improve outcomes for cancer patients with the understanding that the best way to achieve this is through rigorous scientific investigation,” he said. “It is always a great feeling to be recognized by your peers,” Dr. Roth concluded. “My first thought was that this is a tribute to all the outstanding colleagues that I have been privileged to work with over the years.” Dr. Roth is professor, Department of Thoracic and Cardiovascular Surgery, Division of Surgery, MD Anderson Cancer Center, Houston, and chief, Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, Division of Surgery, MD Anderson Cancer Center, Houston. For more information about ASTRO’s 57th Annual Meeting, visit www.astro.org/AnnualMeeting. For press registration and media policies for ASTRO’s 57th Annual Meeting, visit www.astro.org/AMPress.

Montgomery College Partners with Lockheed Martin and Industry Leaders to Launch Healthcare Technology Alliance

The alliance will foster collaboration with industry and academic partnersLockheed Martin (NYSE: LMT) announced Tuesday the formation of a new healthcare technology alliance, combining the expertise of leading health IT providers, medical technology companies, and academic institutions to advance public health.The Lockheed Martin Healthcare Technology Alliance’s founding members include: Cisco, Cloudera, Illumina, Intel and Montgomery College.“Federal health IT is a dynamic and growing sector,” said Horace Blackman, vice president of Health & Life Sciences at Lockheed Martin. “Through collaboration between health IT industry and academic partners, this team will develop and refine technologies that will help guide decisions for care, diagnosis and treatment of disease while protecting critical health information.”The members of the Lockheed Martin Healthcare Technology Alliance will collaborate on technology solutions that help improve care in rapidly evolving and growing areas of health technology such as those that: secure patient medical information; leverage advances in genomic research; and apply big data solutions to improve public health.Alliance partners are already making progress on complex health information technology solutions. Lockheed Martin and Illumina are collaborating to develop tailored solutions for national-scale genomics programs. Lockheed Martin systems integration and data analytics experience compliments Illumina's recognized leadership in genomic sequencing and analysis. This collaboration has the potential to create a complete offering for customers — the most advanced tools and best practices in large-scale genomic solutions.“We are so pleased to be a part of this forward-thinking alliance; joining industry and academic research is the best way to spark innovation,” said Dr. DeRionne P. Pollard, president of Montgomery College. “Together, we can do great things.”For additional information, visit the Lockheed website at www.lockheedmartin.com/hta.About Montgomery College Montgomery College is a public, open admissions community college with campuses in Germantown, Rockville, and Takoma Park/Silver Spring, plus workforce development/continuing education centers and off-site programs throughout Montgomery County, Md. The College serves nearly 60,000 students a year, through both credit and noncredit programs, in more than 130 areas of study. About Lockheed MartinHeadquartered in Bethesda, Maryland, Lockheed Martin is a global security and aerospace company that employs approximately 112,000 people worldwide and is principally engaged in the research, design, development, manufacture, integration and sustainment of advanced technology systems, products and services. The Corporation’s net sales for 2014 were $45.6 billion.

Exercise of the over-allotment option in the IPO of Capio and end of stabilisation period

In connection with the initial public offering of Capio, Ygeia granted the banks an over-allotment option of up to 4,812,261 shares to be used to cover potential over-allotments of shares. During the stabilisation period, which commenced on June 30, 2015 and ended today, stabilisation has been carried out by SEB as stabilisation manager at the prices specified below. The banks have exercised the over-allotment option in full in respect of 4,812,261 shares. Following the exercise of the over-allotment option, and taking into consideration the sale of 1,197,176 shares to certain members of Capio’s group management and board of directors on July 24, 2015, Ygeia will hold 84,608,473 shares in Capio, corresponding to approximately 59.9 percent of the total number of shares in Capio. Stabilisation prices per day +-------------+---------+|June 30, 2015|SEK 48.50|+-------------+---------+|July 1, 2015 |SEK 48.50|+-------------+---------+|July 3, 2015 |SEK 48.50|+-------------+---------+|July 6, 2015 |SEK 48.50|+-------------+---------+ For information, please contact: Thomas Berglund, President and CEO of CapioPhone: +46 73 388 8600Email: thomas.berglund@capio.com Henrik Brehmer, SVP Corporate Communications and Public AffairsPhone: +46 76 111 3414Email: henrik.brehmer@capio.com ---------------------------------------------------------------------- [1] Ygeia Equity AB is owned by Nordic Capital Fund VI, the Apax Europe VI fund (advised by Apax Partners LLP) and the Apax France VII fund (managed by Apax Partners S.A) [2] Pro forma net sales after adjustments MSEK 12,960

Half Yearly Report

30 July 2015 H1 2015 Results Financial Summary +---------------------+------+----+------++-----+----+------+| |H1 2015 ||Q2 2015 |+---------------------+------+----+------++-----+----+------+| |$m |% change ||$m |% change |+---------------------+------+----+------++-----+----+------+| | |CER1|Actual|| |CER1|Actual|+---------------------+------+----+------++-----+----+------+|Total   Revenue2 |12,364|1 |(6) ||6,307|2 |(7) |+---------------------+------+----+------++-----+----+------+| | | | || | | |+---------------------+------+----+------++-----+----+------+|Core3 Op. Profit |3,618 |(4) |(9) ||1,813|(4) |(11) |+---------------------+------+----+------++-----+----+------+|Core   EPS |$2.29 |- |(7) ||$1.21|3 |(8) |+---------------------+------+----+------++-----+----+------+| | | | || | | |+---------------------+------+----+------++-----+----+------+|Reported   Op. Profit|1,856 |1 |(5) ||923 |(10)|(17) |+---------------------+------+----+------++-----+----+------+|Reported   EPS |$0.99 |2 |(4) ||$0.55|(4) |(13) |+---------------------+------+----+------++-----+----+------+ · Total H1 Revenue up 1%; Core Gross margin over 83%, up 1% point · Robust top-line performance, supported by externalisation, underpins accelerated investment in R&D to progress pipeline, up 24% in H1 · Core SG&A efficiency programme - early progress: Core SG&A 35% of Q2 Total Revenue (Q4 2014: 44%) -         Sales & marketing effectiveness, centralisation of functions, process improvements, third-party spend, further efficiencies across support areas, footprint optimisation · Core H1 EPS stable, up 3% in Q2, enhanced by one-off tax benefit · FY 2015 Total Revenue guidance at CER improved: Now expected to decline by low single-digit percent (prior guidance - mid single-digit). Core EPS guidance at CER is unchanged: Expected to increase by low single-digit percent, reflecting the continued accelerated investment in R&D · The Board recommends an unchanged first interim dividend of $0.90 H1 Commercial Highlights Growth platforms grew by 11%, representing 56% of Total Revenue: 1. Brilinta/Brilique: +42%. Achieved 10% new-to-brand prescription market share in the US 2. Diabetes: +32%, including 88% sales growth in Emerging Markets 3. Respiratory: +9%, ahead of market growth. Q2 sales up 11% 4. Emerging Markets: +14%. China sales growth of +19% 5. Japan: +2%, with Q2 sales growth of +6% Achieving Scientific Leadership: Progress since the prior results announcement +---------------------------------+--------------------------------------------+|Regulatory   Approvals |Iressa - lung   cancer (US) Faslodex 500mg -|| |  breast cancer (China) |+---------------------------------+--------------------------------------------+|Regulatory   Submissions* and/or |saxagliptin/dapagliflozin   - diabetes ||Regulatory Submission Acceptances|(EU)AZD9291 -   lung cancer (US*, EU) || |cediranib -   ovarian cancer (EU)Ceftazidime|| |  Avibactam (CAZ AVI) - serious infections || |(EU) |+---------------------------------+--------------------------------------------+|Phase III   Read-outs |selumetinib   - uveal melanoma: Primary || |endpoint not met |+---------------------------------+--------------------------------------------+|Other Key   Developments |Brilinta/Brilique - post-myocardial   || |infarction (MI):Granted FDA   Priority || |Review |+---------------------------------+--------------------------------------------+ Pascal Soriot, Chief Executive Officer, commenting on the results said: “We made good progress in the period, delivering a robust underlying business performance. This represents six successive quarters of top-line growth. The initiatives introduced to increase efficiency are starting to reduce SG&A costs, supporting our continued strategic investment in science and the acceleration of our pipeline which has positive momentum across all key areas. I’m particularly pleased by the pace of progress in Oncology, with new approvals for both Iressa and Faslodex accompanied by regulatory submissions for AZD9291 and cediranib. The strong performance of the growth platforms and the subsequent upgrade to top-line guidance, together with increased R&D productivity reaffirm the confidence we have in our ability to navigate the final impacts from the loss of exclusivity and meet our revenue targets.” Notes 1. All growth rates are shown at constant exchange rates (CER) unless specified otherwise. 2. Total Revenue defined as Product Sales and Externalisation Revenue. For further details on the presentation of Total Revenue, see the announcement (http://www.astrazeneca.com/Investors) published by the Company on 6 March 2015. 3. See the Operating and Financial Review for a definition of Core financial measures and a reconciliation of Core to Reported financial measures. Results Presentation A presentation for investors and analysts, hosted by management, will begin at midday BST today. The accompanying live webcast can be accessed via www.astrazeneca.com/investors. Reporting Calendar The Company intends to publish its nine months and third quarter financial results on 5 November 2015. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Media EnquiriesEsra   Erkal-Paler UK/Global +44 20 7604 8030Vanessa   Rhodes UK/Global +44 20 7604 8037Ayesha   Bharmal UK/Global +44 20 7604 8034Jacob   Lund Sweden +46 8 553 260 20Michele   Meixell US +1 302 885 2677 Investor EnquiriesUKThomas Kudsk Larsen +44 20 7604 8199 +44 7818 524185Eugenia Litz RIA +44   20 7604 8233 +44 7884 735627Nick Stone CVMD +44 20 7604 8236 +44 7717 618834Karl Hård Oncology +44   20 7604 8123 +44 7789 654364Craig Marks ING +44   20 7604 8591 +44 7881 615764Christer Gruvris +44   20 7604 8126 +44 7827 836825USDial / Toll-Free +1 301 398 3251 +1 866 381   7277 Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease, ING - Infection, Neuroscience and Gastrointestinal Research and Development Update ________________________________________________________________________________ A comprehensive update of the AstraZeneca development pipeline is presented in conjunction with this announcement and can be found later in the document. Progress since the prior results announcement on 24 April 2015: Regulatory   2 -         Iressa   - lung cancer (US)Approvals -         Faslodex 500mg - breast   cancer (China)Regulatory   4 -       saxagliptin/dapagliflozin -Submissions* diabetes (EU)-         AZD9291 - lungand/or cancer (US*, EU) -         cediranib -Regulatory ovarian cancer (EU)-         CAZ AVI -Submission serious infections (EU)AcceptancesPhase   III Read 1 -         selumetinib - uveal   melanoma:-outs Primary endpoint not metOther   Key 1 -         Brilinta/Brilique - post-MIDevelopments (PEGASUS trial):                                   Granted   FDA Priority ReviewForthcoming 3 -         brodalumab - psoriasis, PT003 -Regulatory   COPD, AZD9291 - lung cancer   (JP)SubmissionsForthcoming 5 -         lesinurad - gout,Regulatory   saxagliptin/dapagliflozin,Decisions Brilinta/Brilique, AZD9291, CAZ-AVIPivotal   Trial 6 -         PT010 - COPD-        Starts anifrolumab - lupus-         durvalumab (MEDI4736)   + tremelimumab - 2nd-line SCCHN** (CONDOR trial), 2nd   and 3rd -line gastric cancer, 1st-line NSCLC (MYSTIC trial)-         AZD9291 - 2nd -line   EGFRm NSCLC (CAURAL trial)New   Molecular 15 RIA-         lesinurad - gout-        Entities (NMEs) in PT003 - COPD-         PT010 - COPD (new)Pivotal Studies or -         brodalumab - psoriasis-        under Regulatory benralizumab - severe asthma-        Review tralokinumab - severe asthma-         anifrolumab - lupus (new)CVMD-         roxadustat - anaemiaOncology -         AZD9291 - lung cancer-         cediranib - ovarian cancer -         selumetinib - lung   cancer-         tremelimumab -   mesothelioma -         durvalumab - lung cancer -         moxetumomab pasudotox - leukaemia ING -         CAZ AVI - serious   infectionsProjects   in 119clinical pipeline **Squamous Cell Carcinoma of the Head and Neck In the period 2015-2016 AstraZeneca anticipates 12-16 Phase II starts, 14-16 NME and major line-extension regulatory submissions and 8-10 NME and major line-extension approvals. 1. Respiratory, Inflammation and Autoimmunity (RIA) Significant progress continues to be made in the RIA pipeline, which now includes seven programmes in pivotal studies or under registration. AstraZeneca holds a unique position in respiratory disease, including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), with a range of differentiated potential medicines in development by leveraging novel combinations, biologics and devices. The pipeline also has a number of promising assets in inflammatory and autoimmune diseases within areas such as psoriasis, psoriatic arthritis, gout, systemic lupus and rheumatoid arthritis. AstraZeneca and Ardea Biosciences had a strong presence at the recent European League Against Rheumatism annual meeting, with 24 abstracts accepted. Data were presented on several investigational molecules including lesinurad (gout), mavrilimumab (rheumatoid arthritis) and brodalumab (psoriatic arthritis). a)     PT010 (COPD) The first patient has been dosed in the Phase III programme for PT010, a combination of budesonide, glycopyrronium and formoterol fumarate (BGF) in development for patients with moderate to severe COPD. PT010 has the potential in a number of markets to be the first fixed-dose triple-combination medicine to be delivered in a pressurised metered-dose inhaler using the unique porous particle co-suspension technology developed by Pearl Therapeutics, acquired by AstraZeneca in 2013. The Phase III ETHOS trial is assessing a twice-daily investigational formulation in more than 8,000 patients with moderate to severe COPD over the course of 52 weeks. More than 750 centres in over 25 countries are expected to participate in the trial. ETHOS is a randomised, double-blind, multi-centre, parallel group trial assessing efficacy and safety of BGF relative to two active comparators - a fixed-dose combination of the budesonide and formoterol fumarate and a fixed-dose combination of glycopyrronium and formoterol. The primary endpoint is the rate of moderate or severe COPD exacerbations. b)    Anifrolumab (lupus) The first patient has been dosed in the Phase III programme for anifrolumab, a first-in-class investigational medicine for patients with moderate to severe systemic lupus erythematosus (SLE, or lupus), and the only anti-type-I IFN receptor approach currently in development. The Phase III TULIP programme includes two clinical trials that will evaluate the efficacy and safety of anifrolumab versus placebo in subjects with moderately to severely active, autoantibody-positive SLE, while receiving standard of care (SoC) treatment. The programme will assess the effect of anifrolumab in reducing disease activity (as measured by the SRI-4), decreasing use of oral corticosteroids, improving skin manifestations (as measured by CLASI) and reducing flares. Anifrolumab has been developed with a biomarker test based on the type-I IFN-inducible gene signature, which is also being investigated as part of the clinical programme. The Company intends to present full anifrolumab Phase IIb data at the American College of Rheumatology congress in November 2015. c)     Benralizumab (severe asthma) The Phase III benralizumab trials CALIMA and SIROCCO have completed enrolment. These trials are designed to evaluate safety and effectiveness in actively reducing exacerbations in patients with uncontrolled asthma. The trials also assess lung function, asthma symptoms and other asthma-control measures, as well as emergency room and hospitalisation rates. d)    Tralokinumab (severe asthma) In May 2015 AstraZeneca announced that it had entered an agreement with Abbott Laboratories, Inc. (Abbott) to develop companion diagnostic tests to identify patients with severe asthma most likely to benefit from tralokinumab. No companion diagnostic blood tests have yet been approved for use in asthma. Under the terms of the agreement, Abbott will develop and commercialise diagnostic tests to measure serum levels of the proteins periostin and dipeptidyl peptidase-4 (DPP-4), identified as potential predictive biomarkers of up-regulated IL-13 in severe asthma. The tests will be developed in conjunction with the Phase III trials of tralokinumab as a potential treatment for patients with severe, inadequately-controlled asthma. e)     Brodalumab (psoriasis) In May 2015 Amgen, Inc. (Amgen) announced the termination of its co-development and commercialisation agreement with AstraZeneca for brodalumab, an investigational IL-17 receptor monoclonal antibody in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. AstraZeneca has conducted an initial evaluation of the data, which confirms that brodalumab demonstrated strong efficacy in psoriasis and indicates that the observations of suicidal ideation and behaviour are unlikely to be causally related to brodalumab therapy. Whilst continuing the transfer of the programme from Amgen, the Company is proceeding with a full analysis and evaluating potential partnering options in parallel. AstraZeneca will communicate its definitive decision in due course. 1. Cardiovascular and Metabolic Disease (CVMD) AstraZeneca's strategy in CVMD focuses on ways to reduce morbidity, mortality and organ damage by addressing multiple risk factors across cardiovascular (CV) disease, diabetes and chronic kidney-disease indications. The patient-centric approach is reinforced by science-led life-cycle management programmes and technologies, including early research into regenerative methods. Reporting results of the Company’s research and development in diabetes, AstraZeneca presented 86 abstracts at the recent American Diabetes Association (ADA) annual meeting. These abstracts included clinical trial data evaluating Farxiga/Forxiga, Bydureon, Byetta and Onglyza, as well as the investigational combination of Onglyza and Farxiga/Forxiga. Notable late-breaking abstracts included data from a positive Phase III trial comparing the efficacy and safety of Farxiga/Forxiga versus placebo as an add-on to Onglyza and metformin immediate release in adults with type-2 diabetes who had inadequate glycaemic control. The trial met its primary endpoint. a)     Brilinta/Brilique (CV disease) In April 2015, AstraZeneca announced that the FDA had accepted a supplemental new-drug application (sNDA) and granted Priority Review for Brilinta for patients with a history of prior MI. The sNDA was based on the results of PEGASUS-TIMI 54, a large-scale outcomes trial in more than 21,000 patients that investigated Brilinta plus low-dose aspirin, compared to placebo plus low-dose aspirin, for the chronic secondary prevention of atherothrombotic events in patients who had experienced a heart attack one to three years prior to trial enrolment. A Priority Review designation is granted to medicines that the FDA determines have the potential to provide significant improvements in the treatment, prevention or diagnosis of a disease. b)    Onglyza (type-2 diabetes) AstraZeneca is working closely with regulators as part of the ongoing review of the full SAVOR dataset. The Company is currently awaiting a forthcoming decision from the FDA on a possible label update for Onglyza and Kombiglyze XR respectively. At the recent ADA meeting AstraZeneca announced results from an observational, retrospective trial which found no evidence of increased risk of hospitalisation for heart failure (hHF) with Onglyza, compared with sitagliptin, both of which are DPP-4 inhibitors, in patients with type-2 diabetes. A similar finding was obtained when comparing the overall DPP-4 class to sulfonylureas. The analysis included patients with and without prior CV disease and concluded that, among the latter, DPP-4 treatment was associated with a statistically-significant lower risk of hHF compared to treatment with sulfonylureas. c)     SGLT2 Inhibitors (type-2 diabetes) In May 2015, the FDA posted a Drug Safety Communication warning that sodium/glucose co-transporter-2 (SGLT2) inhibitors, the class to which Farxiga/Forxiga belongs and is used to treat type-2 diabetes, may lead to diabetic ketoacidosis (DKA), a medical condition where the body produces high levels of blood acids called ketones that may require hospitalisation. Last month the European Medicines Agency (EMA) announced a review of SGLT2 inhibitors to evaluate the risk of DKA. The regulatory authorities will continue to investigate this safety issue and will determine whether changes are needed in the prescribing information for this class of drugs. AstraZeneca is committed to working with the FDA and EMA during their respective reviews of the data. The DECLARE outcomes trial for Farxiga/Forxiga recently completed its global patient enrolment around one year ahead of plan. The DECLARE trial is a large CV outcomes trial designed to assess the impact of Farxiga/Forxiga on CV risk/benefit, when the medicine is added to a patient’s current anti-diabetes therapy, on CV events such as heart attack, ischemic stroke and CV-related death, compared with placebo. The trial involves the enrolment of around 26,000 patients with type-2 diabetes in more than 30 countries with the aim of randomising over 17,000 patients. It is an event-driven trial and is estimated to be completed in 2019. d)    Tenapanor (chronic kidney disease) In June 2015 Ardelyx, Inc. (Ardelyx) announced that it had entered into a termination agreement with AstraZeneca. Under the agreement all rights to Ardelyx’s portfolio of NHE3-inhibitors, including Ardelyx’s lead product candidate, tenapanor will be returned to Ardelyx. 1. Oncology AstraZeneca’s vision in Oncology is to help patients by redefining the cancer-treatment paradigm, with the aim of bringing six new cancer medicines to patients between 2013 and 2020. A broad pipeline of next-generation medicines is focused principally on four disease areas - breast, ovarian, lung and haematological cancers. As well as other tumour types, these are being targeted through four key platforms - immunotherapy, the genetic drivers of cancer and resistance, DNA damage repair, and antibody drug conjugates, underpinned by personalised healthcare and biomarker technologies. AstraZeneca hosted an investor science event during the 2015 American Society of Clinical Oncology (ASCO) meeting in Chicago. Key presentations included: · Data presented on durvalumab (formerly MEDI4736) as monotherapy in heavily pre-treated patients with non-small cell lung cancer (NSCLC) or SCCHN were encouraging and suggested that patients with PD-L1 positive tumours may have an improved overall response rate (ORR) compared to patients with PD-L1 negative tumours, highlighting the unmet medical need for the majority of tumours that are PD-L1 negative · Data presented on durvalumab plus tremelimumab confirmed the Phase III trial dose and schedule for this combination. The combination demonstrated an ORR of 38% at doses selected for the Phase III trials versus a 5% ORR for patients receiving durvalumab monotherapy in the 1108 trial. The combination was well tolerated with a very low 7% drug-related discontinuation rate · In addition, durvalumab is demonstrating strong potential to combine with small molecules AstraZeneca has an extensive development programme underway across multiple tumour types and stages of disease, assessing the potential for immunotherapy to either replace or combine with traditional targeted and chemotherapy treatment.  Today there are six AstraZeneca Oncology NMEs in pivotal studies or under regulatory review. Highlights from the late-stage portfolio include: +------------+--------------+--------------------------------------------------+|  Medicine  |  Indication  |  Status   |+------------+--------------+--------------------------------------------------+|Iressa |Lung cancer |Earlier this month the Company   announced that || | |the FDA had approved Iressa   (gefitinib) tablets,|| | |a 250mg once-daily 1st-line treatment for patients|| | |with   metastatic epidermal growth-factor receptor|| | |(EGFR) mutated NSCLC. Iressa was granted Orphan || | |Drug Designation by the FDA   in 2014. |+------------+--------------+--------------------------------------------------+|AZD9291 |Lung cancer |In   June 2015, the Company submitted the rolling || | |new-drug application (NDA) for AZD9291 as a || | |potential   medicine for the 2nd-line treatment of|| | |patients with advanced or metastatic   T790M || | |-mutated NSCLC. The EMA also accepted the || | |regulatory submission for   AZD9291.CAURAL, a || | |randomised Phase III trial in 2nd-line metastatic || | |EGFR   T790M-mutation positive NSCLC testing || | |AZD9291 plus durvalumab versus AZD9291   || | |monotherapy is being prepared for dosing. The || | |trial has a primary endpoint of   progression-free|| | |survival (PFS).At the ASCO meeting,   preliminary || | |efficacy and safety data for AZD9291 in the 1st || | |-line treatment of   EGFRm-positive advanced NSCLC|| | |were presented. Data showed that 81% (95%   || | |confidence interval (CI) 68% to 89%) of patients || | |on a once-daily dose of   AZD9291 were progression|| | |-free at nine months; the ORR was 73% (95% CI 60% || | |to   84%). The longest duration of response was || | |ongoing at 13.8 months at the time   of data cut || | |-off. These data support the ongoing development || | |of AZD9291 in   1st-line lung cancer, including || | |the Phase III FLAURA trial. |+------------+--------------+--------------------------------------------------+|Cediranib |Ovarian cancer|The Company received   acceptance from the EU this|| | |month for the marketing authorisation application || | |  for cediranib with an intended indication in || | |platinum-sensitive relapsed   ovarian cancer. The || | |application was based on the ICON6 trial. ICON6 || | |results   showed that, compared to platinum || | |chemotherapy alone, cediranib given with   || | |platinum-based chemotherapy and continued as || | |maintenance, significantly   improves PFS in women|| | |with recurrent ovarian cancer. Subsequent   || | |secondary-efficacy measures supported significant || | |sustained efficacy, leading   to a strong overall || | |survival trend. |+------------+--------------+--------------------------------------------------+|Selumetinib |Uveal melanoma|The Phase III SUMIT trial of selumetinib (MEK   || | |inhibitor) in combination with dacarbazine did not|| | |meet its primary endpoint   of PFS. This || | |combination therapy showed an adverse event || | |profile generally   consistent with current || | |knowledge of the safety profiles of dacarbazine || | |and   selumetinib. A full evaluation of the data || | |is ongoing.Outside uveal melanoma, selumetinib is || | |in a Phase   III trial in 2nd-line KRAS-mutant || | |advanced NSCLC in combination with   docetaxel, in|| | |a Phase III trial in differentiated thyroid cancer|| | |and in a   Phase II registration trial in patients|| | |with neurofibromatosis Type 1. These   trials have|| | |a different scientific rationale and selumetinib || | |is being tested   in alternative combinations. The|| | |findings from SUMIT are not expected to have   any|| | |impact on the other studies. |+------------+--------------+--------------------------------------------------+ +----------+----------------+--------------------------------------------------+|Durvalumab|Lung cancer |ATLANTIC, a Phase II trial in PD-L1   positive 3rd||  | |-line metastatic NSCLC, is now fully recruited and|| | |scheduled to   deliver data in the second half. || | |This trial could potentially, if positive,   || | |support the first regulatory submission for || | |durvalumab. ARCTIC, a Phase III trial in 3rd-line || | |metastatic NSCLC is recruiting patients and || | |contains a   randomised durvalumab monotherapy sub|| | |-study for PD-L1 positive patients   versus SoC || | |and a sub-study with a concurrent-combination || | |treatment with   tremelimumab versus the || | |contribution of components and SoC in PD-L1 || | |negative   patients.MYSTIC, which is being || | |prepared for dosing,   is a 1st-line NSCLC || | |durvalumab-tremelimumab trial in PD-L1 unselected,|| | |EGFR/ALK wild-type patients and includes   a sub || | |-group analysis of PD-L1 positive and PD-L1 || | |low/negative patients. The   primary endpoint is || | |PFS and the trial includes durvalumab monotherapy || | |and the   durvalumab-tremelimumab combination || | |versus SoC. NEPTUNE, a further durvalumab || | |-tremelimumab versus SoC trial with overall || | |survival (OS) as the   primary endpoint || | |complements the MYSTIC PFS trial and will commence|| | |in due   course.A third 1st-line NSCLC trial of || | |durvalumab   plus chemotherapy in PD-L1 || | |unselected, EGFR/ALK   wild-type NSCLC will also || | |be initiated after a lead-in phase.PD-L1 status is|| | |being assessed by a proprietary (SP263)   || | |immunohistochemistry diagnostic test jointly || | |developed with Ventana Medical   Systems, Inc., a || | |member of the Roche Group. |+----------+----------------+--------------------------------------------------+|Head and |In the CONDOR ||Neck |trial for ||cancer |patients with   || |recurrent or || |metastatic SCCHN|| |the first   || |patient was || |dosed in the || |quarter. The || |CONDOR trial is || |a Phase II, || |randomised,   || |global trial of || |durvalumab || |monotherapy, || |tremelimumab || |monotherapy and || |  durvalumab in || |combination with|| |tremelimumab in || |PD-L1 negative || |patients. It is || |designed to || |complement the || |HAWK trial which|| |  targets PD-L1 || |positive || |patients. |+----------+----------------+--------------------------------------------------+|Gastric |A Phase II trial||cancer |in 2nd and 3rd || |-line gastric   || |cancer was also || |initiated in the|| |period. This || |trial explores  || |durvalumab || |-tremelimumab || |versus || |durvalumab || |versus || |tremelimumab. |+----------+----------------+--------------------------------------------------+|Pancreatic|A pancreatic ||cancer |cancer || |uncontrolled || |Phase II   trial|| |will   explore || |combinations of || |immunotherapies,|| |in particular || |durvalumab plus || |  tremelimumab, || |in 2nd-line || |metastatic || |pancreatic || |ductal || |adenocarcinoma || |(PDAC).   In || |addition, the || |programme will || |explore || |combinations of || |immunotherapy || |with   both || |chemotherapy in || |1st-line PDAC || |and with || |targeted || |therapies in 2nd|| |-line   PDAC; || |the first || |targeted therapy|| |included in this|| |trial is AZD5069|| |(CXCR2). |+----------+----------------+--------------------------------------------------+|Bladder |A 1st-line ||cancer |bladder cancer || |Phase III,   || |randomised and || |controlled trial|| |will evaluate || |both durvalumab || |monotherapy and || |  durvalumab || |-tremelimumab in|| |metastatic, || |urothelial || |bladder cancer. |+----------+----------------+--------------------------------------------------+ Durvalumab and Ramucirumab (advanced solid tumours) In May 2015, AstraZeneca and Eli Lilly & Company (Lilly) announced a clinical-trial collaboration to evaluate the safety and preliminary efficacy of durvalumab, in combination with ramucirumab, Lilly’s VEGF receptor-2 anti-angiogenic cancer medicine. The planned trial will assess the combination as a treatment for patients with advanced solid tumours. A Phase I trial is expected to establish the safety and a recommended dosing regimen, with the potential to open expansion cohorts in various tumours of interest for the combination of durvalumab and ramucirumab. Under the terms of the agreement, the trial will be sponsored by Lilly. 1. Infection, Neuroscience and Gastrointestinal (ING) a)     CAZ-AVI (serious infections) In May 2015 the EU submission for CAZ-AVI was validated and accepted by the EMA. CAZ-AVI is being developed to treat adult hospitalised patients with complicated intra-abdominal infections, complicated urinary tract infections or nosocomial pneumonia (including hospital acquired pneumonia and ventilated patients). Full Phase III results evaluating the safety and efficacy of CAZ-AVI for the global RECLAIM-1 and RECLAIM-2 studies and the global REPRISE trial were presented at the 25th European Congress of Clinical Microbiology and Infectious Diseases. CAZ-AVI is anticipated as the first choice for the treatment of Gram-negative pathogens that are increasingly becoming resistant to prevailing standards of care, leading to greater numbers of life-threatening infections and additional healthcare costs. b)    AZD3293 (Alzheimer’s disease) AZD3293 is an oral, potent and selective small-molecule inhibitor designed as a novel treatment for patients suffering from early Alzheimer’s disease. A global co-development and co-commercialisation agreement was established with Lilly in 2014 for this important potential medicine. Under the terms of the agreement, Lilly will pay AstraZeneca up to $500m in development and regulatory milestone payments. The first progress milestone was met in July 2015 and, as such, $50m of Externalisation Revenue from Lilly to AstraZeneca will be recognised in the third quarter. Scientific Collaborations ______________________________________________________________________________ Montreal Heart Institute AstraZeneca announced in May 2015 a collaboration with the Montreal Heart Institute in Quebec, Canada, to search the genomes of up to 80,000 patients for genes associated with cardiovascular diseases and diabetes, their complications and treatment outcomes. This is one of the largest such screens of its type to date and will drive understanding of the biological mechanisms underlying these conditions and their complications. The analysis will also uncover which genetic traits are linked to better treatment outcomes. Corporate and Business Development Update ___________________________________________________________________________ a)    Haematology Collaboration with Celgene In April 2015 AstraZeneca announced an exclusive collaboration agreement with Celgene Corporation (Celgene), a global leader in haematological cancers, for the development and commercialisation of durvalumab across a range of blood cancers including non-Hodgkin’s lymphoma, myelodysplastic syndrome and multiple myeloma. Under the terms of the agreement, Celgene made an upfront payment of $450m in the second quarter to AstraZeneca. Celgene will lead on development across all clinical trials within the collaboration and will take on all research and development costs until the end of 2016, after which it will take on 75% of these costs. Celgene will also be responsible for global commercialisation of approved treatments. AstraZeneca will continue to manufacture and book all sales of durvalumab and will pay a royalty to Celgene on worldwide sales in haematological indications. The royalty rate will start at 70% and will decrease to approximately half of the sales of durvalumab in haematological indications over a period of four years. AstraZeneca may elect to opt out of funding part of any clinical study prior to its initiation, resulting in an increase of future royalty rates or a subsequent re-opt in payment. Within the collaboration, durvalumab will be assessed both as monotherapy and in combination with other AstraZeneca and Celgene potential and existing cancer medicines. Over time, the collaboration has the potential to expand and include other assets. b)    NKG2A Antibody Collaboration with Innate AstraZeneca entered into a collaboration in the second quarter with Innate Pharma SA (Innate) to accelerate and broaden the development of Innate’s proprietary NKG2A antibody, IPH2201, including in combination with durvalumab. Currently in Phase II development, IPH2201 is a potential first-in-class humanised IgG4 antibody against NKG2A. NKG2A is a checkpoint receptor that inhibits the anti-cancer functions of Natural Killer and cytotoxic T-cells. Under the terms of the agreement, AstraZeneca made an initial payment to Innate of $250m, which included the consideration for exclusive global rights to co-develop and commercialise IPH2201 in combination with durvalumab, as well as access to IPH2201 in monotherapy and other combinations in certain treatment areas for which AstraZeneca has the option to pay a further $100m prior to initiation of Phase III development. The agreement also includes additional regulatory and sales-related milestones. AstraZeneca will book all sales and will pay Innate double-digit royalties on net sales. The arrangement includes the right for Innate to co-promote in Europe for a 50% profit share. c)    Joint Venture with Fujifilm Kyowa Kirin Biologics In July 2015 AstraZeneca entered into an agreement with Fujifilm Kyowa Kirin Biologics Co., Ltd to establish a joint venture for the development and commercialisation of FKB238, a biosimilar version of bevacizumab, currently in Phase I development for the treatment of multiple solid tumours. The Company plans to use the biosimilar in combination with its portfolio of innovative oncology investigational and on-market medicines, across a range of cancers and at different stages of disease. By developing an interchangeable biosimilar to support the Company’s combination-focused oncology strategy, AstraZeneca will explore potential new treatment options for patients, while at the same time keep the cost of those combination therapies low enough to enable access for the majority of patients. d)    Entocort Divestment In July 2015 AstraZeneca completed an agreement entered into with Tillotts, part of the Zeria Group, for the divestment of global rights, outside the US, to Entocort (budesonide), a gastroenterology medicine for patients with mild-moderate Crohn’s disease and ulcerative colitis. Entocort is currently available in over 40 countries, with total product sales of $53m outside the US in 2014. A regulatory submission for Entocort in Japan is anticipated in the coming months. Under the terms of the agreement, Tillotts made an upfront payment to AstraZeneca of $215m upon completion of the transaction to acquire the rights to sell and develop Entocort capsules and enema formulations outside the US. The payment will be shown within Other Operating Income in the Company’s financial statements in the third quarter. e)    Benralizumab: Japan The Company recently announced an agreement with Kyowa Hakko Kirin Co. Ltd (Kyowa Hakko Kirin) for an exclusive option to commercialise benralizumab for asthma and COPD in Japan. Benralizumab is a monoclonal antibody in Phase III development for the treatment of severe uncontrolled asthma and COPD. The results for benralizumab in severe asthma are expected to read out in 2016, with regulatory submissions anticipated later that year. Phase III results and regulatory filing in COPD are expected in 2018. Under the terms of the agreement, the Company will make a $45m up-front option payment and may make subsequent payments for regulatory filing, approval and commercial milestones, and sales royalties should the option be exercised. Kyowa Hakko Kirin will continue to be responsible for the research and development of benralizumab in Japan. On exercising the option, AstraZeneca will be responsible for all sales and marketing in asthma and COPD in Japan. Kyowa Hakko Kirin will retain the rights to participate in certain commercial activities alongside AstraZeneca. f)     Caprelsa Divestment This month AstraZeneca announced that it had entered into a definitive agreement with Genzyme Corporation (Genzyme), part of Sanofi S.A., to divest Caprelsa (vandetanib), a rare-disease medicine. Caprelsa was granted Orphan Drug Designation by the US FDA in 2005 and is currently available in 28 countries for the treatment of aggressive and symptomatic medullary thyroid carcinoma, with global product sales of $48m in 2014. Under the terms of the agreement, Genzyme will pay AstraZeneca up to $300m, including an upfront payment of $165m to acquire the global rights to sell and develop Caprelsa, and further development and sales milestone payments of up to $135m. The transaction does not include the transfer of any AstraZeneca employees or facilities. As an asset divestment, the upfront receipt and any subsequent payments will be reported in Other Operating Income in the Company’s financial statements. g)    Creation of Antibiotics Business Unit The Company recently announced the intention to create a new antibiotics business unit focused on the development of the late-stage pipeline of small molecules (CAZ-AVI, ATM-AVI and CXL) and on maximising the commercial potential of the portfolio of small molecule antibiotics (Merrem and Zinforo) across a number of prioritised markets. The creation of a new, focused business unit is the best way to enable these important medicines to reach patients while further increasing the focus on the Company’s three main therapy areas. The creation of this new internal structure will have no impact on either the presentation of the Company’s financial statements or the Company’s biologics Infection business. h)     Change In Senior Executive Team Briggs Morrison, formerly Executive Vice President, Global Medicines Development and Chief Medical Officer, left the Company in June having accepted offers to become the Chief Executive Officer of Syndax Pharmaceuticals, Inc., a privately-held oncology company, and a Managing Director of venture capital firm, MPM Capital, Inc. Pending the appointment of Dr Morrison’s successor, Elisabeth Björk, Vice President and Head of Development, Cardiovascular, Metabolism and Diabetes was appointed Interim Chief Medical Officer and took over operational leadership of Global Medicines Development, and Pascal Soriot became temporary Co-Chairman of the Late Stage Product Committee, the governance body accountable for post-Phase II investment decisions. i)      Future Infrastructure In the half the Company continued both with the construction of its new Global R&D Centre and Corporate Headquarters on the Cambridge Biomedical Campus and the move of employees to Cambridge from other UK locations. AstraZeneca announced in the half that it will invest approximately $285m in a new high-tech facility for the manufacture of biological medicines in Södertälje, Sweden. The new plant will be focused on the filling and packaging of protein therapeutics. It is anticipated that the new facility will supply medicines for clinical-trial programmes from the end of 2018 and will deliver finished products for commercial use once fully operational by 2019. Södertälje is home to AstraZeneca’s largest global tablets and capsules manufacturing facility and is also a launch-platform site for the Company, with specialist capabilities on-site that allow large-scale production of new medicines, working closely with the research and development organisation. By locating the new manufacturing plant in Södertälje, the Company will combine its expertise in biologics with the well-established culture of operational excellence that exists within the Sweden Operations unit. Operating and Financial Review _____________________________________________________________________________ All narrative on growth and results in this section relates to Core performance, based on constant exchange rates (CER) unless stated otherwise. Financial figures are in $millions ($m). The performance shown below covers the six and three month periods to 30 June 2015 (the half and the quarter respectively) compared to the six and three months to 30 June 2014 (the half and the quarter respectively). Core measures, which are presented in addition to Reported financial information, are non-GAAP measures provided to enhance understanding of the Company’s underlying financial performance. Core financial measures are adjusted to exclude certain significant items, such as: − amortisation and impairment of intangibles, including impairment reversals but excluding any charges relating to IT assets − charges and provisions related to our global restructuring programmes (this will include such charges that relate to the impact of our global restructuring programmes on our capitalised IT assets) − other specified items, principally comprising legal settlements and acquisition-related costs, which include fair value adjustments and the imputed finance charge relating to contingent consideration on business combinations More detail on the nature of these measures is given on page 72 of the 2014 Annual Report (http://www.astrazeneca.com/investors) and Form 20-F Information. Total Revenue Total Revenue grew by 1% in the half to $12,364m. Based on actual exchange rates, Total Revenue declined by 6% reflecting the particular weakness of key trading currencies against the US dollar. Product Sales Product Sales declined by 2% in the half (Q2 2015: down by 1%) reflecting the US market entry of a Nexium generic product from February 2015 as well as an adverse impact from the change in accounting for the US Branded Pharmaceutical Fee following issuance of final regulations in Q3 2014. Externalisation Revenue Externalisation Revenue of $780m in the half (H1 2014: $352m) primarily reflected income from completion of the collaboration agreement in haematology with Celgene ($450m), together with income from the co-commercialisation agreement with Daiichi Sankyo Co, Ltd. (Daiichi Sankyo) for Movantik in the US ($200m), plus the co-commercialisation of Nexium in Japan ($55m), also with Daiichi Sankyo. Product Sales ________________________________________________________________________________ The performance of a selection of key medicines is shown below. A geographical split of the performance is shown in Notes 6 and 7. +----------------------+-----+------+------++-----+------+------+| |H1 2015 ||Q2 2015 |+----------------------+-----+------+------++-----+------+------+| | |% Change || |% Change |+----------------------+-----+------+------++-----+------+------+| |$m |CER |Actual||$m |CER |Actual|+----------------------+-----+------+------++-----+------+------+| | | | || | | |+----------------------+-----+------+------++-----+------+------+|Respiratory,   | | | || | | ||Inflammation and | | | || | | ||Autoimmunity | | | || | | |+----------------------+-----+------+------++-----+------+------+|Symbicort |1,687|- |(9) ||842 |- |(9) |+----------------------+-----+------+------++-----+------+------+|Pulmicort |518 |18 |10 ||232 |19 |11 |+----------------------+-----+------+------++-----+------+------+|Tudorza/EkliraDaliresp|8539 |n/mn/m|n/mn/m||5532 |n/mn/m|n/mn/m|+----------------------+-----+------+------++-----+------+------+|Duaklir |7 |n/m |n/m ||5 |n/m |n/m |+----------------------+-----+------+------++-----+------+------+| | | | || | | |+----------------------+-----+------+------++-----+------+------+|Cardiovascular and | | | || | | ||Metabolic Disease | | | || | | |+----------------------+-----+------+------++-----+------+------+|Brilinta/Brilique |275 |42 |27 ||144 |38 |23 |+----------------------+-----+------+------++-----+------+------+|Onglyza |391 |4 |(2) ||208 |(7) |(13) |+----------------------+-----+------+------++-----+------+------+|Bydureon |263 |41 |37 ||140 |29 |25 |+----------------------+-----+------+------++-----+------+------+|Byetta |172 |8 |4 ||82 |(1) |(7) |+----------------------+-----+------+------++-----+------+------+|Farxiga/Forxiga |205 |n/m |n/m ||129 |n/m |n/m |+----------------------+-----+------+------++-----+------+------+| | | | || | | |+----------------------+-----+------+------++-----+------+------+|Legacy: | | | || | | |+----------------------+-----+------+------++-----+------+------+|Crestor |2,477|(5) |(11) ||1,310|(3) |(10) |+----------------------+-----+------+------++-----+------+------+|Seloken/Toprol-XL |378 |7 |(2) ||184 |6 |(5) |+----------------------+-----+------+------++-----+------+------+|Atacand |194 |(11) |(26) ||99 |(13) |(29) |+----------------------+-----+------+------++-----+------+------+| | | | || | | |+----------------------+-----+------+------++-----+------+------+|Oncology | | | || | | |+----------------------+-----+------+------++-----+------+------+|Iressa |273 |(3) |(14) ||129 |(1) |(12) |+----------------------+-----+------+------++-----+------+------+|Lynparza |30 |n/m |n/m ||21 |n/m |n/m |+----------------------+-----+------+------++-----+------+------+| | | | || | | |+----------------------+-----+------+------++-----+------+------+|Legacy: | | | || | | |+----------------------+-----+------+------++-----+------+------+|Zoladex |409 |9 |(11) ||215 |14 |(9) |+----------------------+-----+------+------++-----+------+------+|Faslodex |333 |5 |(5) ||172 |9 |(4) |+----------------------+-----+------+------++-----+------+------+|Casodex |139 |(5) |(16) ||69 |(5) |(17) |+----------------------+-----+------+------++-----+------+------+|Arimidex |126 |(9) |(19) ||64 |(6) |(18) |+----------------------+-----+------+------++-----+------+------+| | | | || | | |+----------------------+-----+------+------++-----+------+------+|Infection,   | | | || | | ||Neuroscience and | | | || | | ||Gastrointestinal | | | || | | |+----------------------+-----+------+------++-----+------+------+|Nexium |1,291|(27) |(32) ||647 |(27) |(33) |+----------------------+-----+------+------++-----+------+------+|Seroquel   XR |526 |(7) |(12) ||264 |(8) |(13) |+----------------------+-----+------+------++-----+------+------+|Synagis |270 |(28) |(28) ||66 |40 |40 |+----------------------+-----+------+------++-----+------+------+|Losec/Prilosec |181 |(6) |(16) ||85 |(9) |(19) |+----------------------+-----+------+------++-----+------+------+|FluMist/Fluenz |21 |75 |75 ||14 |180 |180 |+----------------------+-----+------+------++-----+------+------+|Movantik/Moventig |4 |n/m |n/m ||1 |n/m |n/m |+----------------------+-----+------+------++-----+------+------+ H1 Product Sales Summary ________________________________________________________________________________ During 2014, final regulations relating to the US Branded Pharmaceutical Fee were issued, affecting how the fee is recognised; AstraZeneca consequently accrues for the obligation as each sale occurs. As the fee is based on actual Product Sales in the current year, the fee is recognised as a deduction from Product Sales rather than a charge to SG&A, impacting individual brand sales by an average of 2%. RIA Symbicort Product Sales in the half were stable at $1,687m. The brand continues to demonstrate strong differentiation in asthma reinforced by guidelines and ongoing lifecycle management in milder conditions. In the US, the decline in the half to $717m was limited to 1% with continued lower net prices reflecting additional access and co-pay assistance. Symbicort’s share of total prescriptions for fixed-combination medicines increased in the half, growing by 0.7% points. In Europe, Product Sales declined by 8% to $582m, reflecting increased competition from recently-launched analogue medicines. This performance contrasted with growth of 28% in Emerging Markets to $187m, notably with 64% growth in China where Product Sales reached $63m. Pulmicort Product Sales of Pulmicort in the first half were $518m, up 18%. Growth was driven primarily by the performance of Pulmicort Respules in Emerging Markets, which were up 37% at $303m. China Product Sales increased by 43% to $240m, reflecting sustained investment in supporting asthma and COPD patients for several years, both in hospitals and more recently at home. In February 2015, the US District Court for the District of New Jersey ruled the patent protecting Pulmicort Respules in the US was invalid. The US Court of Appeals for the Federal Circuit subsequently affirmed the decision (see Note 5). Consequently a reduced level of sales-related receipts was realised in the second quarter (within Other Operating Income) from Teva Pharmaceutical Industries, Ltd. Tudorza/Eklira Product Sales in the half were $85m. This included $45m in the US, where the brand name is Tudorza, following the completion of the acquisition of the Actavis plc product rights in March 2015. Rights were also acquired at that time for Daliresp, for which sales amounted to $39m in the half. CVMD Brilinta/Brilique Product Sales in the half were $275m, up 42%, with consistent strong growth in each quarter. Brilinta Product Sales in the US were $101m, up 60%. The brand’s weekly new-to-brand prescription market share achieved a new high of 10% in June 2015. In Europe, Brilique continued to perform well, with an increase in Product Sales of 21% to $110m, reflecting indication leadership across a number of European markets. Emerging Market sales grew by 80% to $47m as the medicine remains in launch phase. Onglyza Product Sales were up 4% in the half to $391m. Growth of 19% in Q1 was offset by a 7% decline in Q2, reflecting a reallocation of promotional activities to Farxiga/Forxiga. In the US, H1 Product Sales were down 16% at $211m driven primarily by destocking and competition in the DPP-4 class, as well as the aforementioned changes in promotional activities. Product Sales in the Rest of World (ROW) were $180m, with growth in all key markets, notably in Europe where sales were $71m, up 23%. Product Sales in the half in Emerging Markets grew by 56% to $77m. Bydureon/Byetta Combined sales were $435m in the half, up 26%, with Bydureon representing 60% of total Bydureon/Byetta sales. Product Sales in the US were $343m, up 28%. Bydureon total prescriptions grew 22% in the second quarter, reflecting the launch of the Bydureon Pen in September 2014. Most of the remaining sales of Bydureon/Byetta reside in Europe, where sales growth of 19% in the half reflected the ongoing successful Pen launch. Farxiga/Forxiga Product Sales were $205m in the half following the recent launch of the brand. In the US, Product Sales of $115m compared to $26m in the comparative period. Additional promotional activity underpinned the growth of Farxiga, which continued to face market share pressures in the period, due to formulary-access changes. Product Sales in Europe, at $53m in the half, more than doubled while Emerging Markets sales stood at $26m. Crestor Product Sales declined by 5% in the half to $2,477m. The performance reflected ongoing generic competition and price pressures. In the US, Crestor’s H1 Product Sales declined by 7% to $1,374m, with price pressures exacerbated by lower volumes that were in line with total prescription share; inventory movements also impacted the performance. Market share was maintained in the second quarter however, with a 1% point growth in new-to-brand share since the start of the year. In Europe, Product Sales declined by 7% to $469m, reflecting prevailing competitive trends. Crestor consolidated its position as the leading statin in Japan, growing its sales by 6% in the half. Emerging Markets delivered sales growth of 5% at $352m, including 21% in China. Oncology Iressa H1 Product Sales declined by 3% to $273m, primarily a function of the competitive environment in Europe where sales were down by 5%, and in Japan down by 14%. The latter territory saw a material swing in performance from quarter to quarter, with year-on-year growth of 9% in Q2. Emerging Markets grew by 3% with Product Sales of $139m, with particular growth in China, up 5% and Russia, up 23%. Lynparza Product Sales reached $30m following the launch in the US at the end of 2014. Growth has been driven by the pool of eligible patients awaiting treatment as well as patients newly-tested for BRCA mutation. Over 1,000 patients have already been treated with Lynparza in the US for germline BRCA-advanced ovarian cancer with three or more lines of chemotherapy. Zoladex Product Sales in the half were up 9% to $409m. Notable performances included growth of 36% in China where Product Sales reached $60m. Faslodex Product Sales for the half were up 5% to $333m. A 1% rise in European sales to $101m was complemented by 2% growth in the US where Product Sales reached $165m. The notable performance was in Emerging Markets, where sales of $42m represented a growth rate of 32%, an encouraging result alongside the approval of 500mg Faslodex in China in May 2015. ING Nexium Overall H1 Product Sales fell 27% to $1,291m, with Q2 sales similarly down 27% at $647m. The decline was particularly felt in the US, where sales in the half fell 49% to $479m, reflecting the loss of exclusivity in February 2015 which directly impacted both pricing and volumes. In Q2 this resulted in an increase to the estimate for pipeline inventory returns, although the value of the level of business and volume maintained remains at a high level. Sales in Europe fell 10% in the half to $143m. Product Sales in markets outside the US delivered a positive result, with H1 Latin American sales up 17%, Japan sales up 16% and China sales up 3%. Emerging Markets represent a key opportunity for Nexium, with the brand’s sales totalling $397m in the half. Seroquel XR Product Sales declined by 7% in the half to $526m, with similar falls in each quarter. In the US H1 sales were up 2% to $353m where the performance was mainly driven by a higher underlying net price. The majority of the remainder of the brand’s sales are in Europe, where a H1 sales decline of 25% to $113m was driven primarily by competition from generic products. Synagis Product Sales fell 28% in the half to $270m, reflecting the 38% decline in the US where the majority of sales are made. A significant factor was lower demand related to the American Academy of Pediatrics Committee on Infectious Disease guidelines issued in mid-2014. These further restricted patients eligible for preventative therapy with Synagis. While these guidelines were inconsistent with the approved label, demand was significantly impacted; this is anticipated to continue in the second half. Product Sales in Europe fell 6% to $110m. Regional Product Sales ________________________________________________________________________________ ++++----------+------+----+------++-----+----+------+++|| |H1 ||Q2 ||||| |2015 ||2015 |||++++----------+------+----+------++-----+----+------+++|| | |% Chang || |% Chang ||||| | |e || |e |||++++----------+------+----+------++-----+----+------+++|| |$m |CER |Actual||$m |CER |Actual|||++++----------+------+----+------++-----+----+------+++||US |4,525 |(9) |(9) ||2,356|(3) |(3) |||++++----------+------+----+------++-----+----+------+++|| | | | || | | |||++++----------+------+----+------++-----+----+------+++||Europe |2,601 |(5) |(20) ||1,261|(5) |(23) |||++++----------+------+----+------++-----+----+------+++|| | | | || | | |||++++----------+------+----+------++-----+----+------+++||Established |1,491 |(2) |(15) ||785 |- |(14) |||||  ROW1 | | | || | | |||++++----------+------+----+------++-----+----+------+++|||Japan |977 |2 |(12) ||522 |6 |(10) |||++++----------+------+----+------++-----+----+------+++|||Canada |273 |6 |(5) ||138 |5 |(6) |||++++----------+------+----+------++-----+----+------+++|||Other |241 |(23)|(33) ||125 |(22)|(34) ||||||Established| | | || | | ||||||ROW | | | || | | |||++++----------+------+----+------++-----+----+------+++|| | | | || | | |||++++----------+------+----+------++-----+----+------+++||Emerging   |2,967 |14 |2 ||1,434|9 |(2) |||||Markets2 | | | || | | |||++++----------+------+----+------++-----+----+------+++|| |China |1,309 |19 |18 ||583 |10 |11 |||++++----------+------+----+------++-----+----+------+++|| |Ex.China |1,658 |10 |(7) ||851 |8 |(10) |||++++----------+------+----+------++-----+----+------+++|| | | | || | | |||++++----------+------+----+------++-----+----+------+++||Total |11,584|(2) |(10) ||5,836|(1) |(10) |||++++----------+------+----+------++-----+----+------+++|1 Establishe |||d ROW |||comprises |||Japan, |||Canada,   |||Australia |||and New |||Zealand.2   |||Emerging |||Markets |||comprises |||all |||remaining |||Rest of |||World |||markets, |||including   |||Brazil, |||China, |||India, |||Mexico, |||Russia, and |||Turkey. ||++++----------+------+----+------++-----+----+------+++||++++----------+------+----+------++-----+----+------+++|||| | | | || | | |||++++----------+------+----+------++-----+----+------+++ US Product Sales in the half were down 9% to $4,525m, with an encouraging trend in sales illustrated by only a 3% fall in the second quarter. Excluding the impact of the change in accounting related to the Branded Pharmaceutical Fee, Product Sales in the quarter were down 1% versus the comparative period. The headline decline in sales however reflected the loss of Nexium patent exclusivity, competition facing Crestor from therapeutic substitution by generic statins, the adverse impact of the Synagis guideline changes and the aforementioned change in accounting related to the Branded Pharmaceutical Fee. Onglyza sales also declined in the second quarter due to ongoing competition in the diabetes market. These declines were partly offset by growth in Brilinta, Bydureon, Farxiga, Lynparza and the inclusion of Tudorza and Daliresp. Brilinta growth was driven by strong consecutive quarters of growth in total and new-to-brand prescription market share gains. Bydureon continues to benefit from the launch of the Bydureon Pen as well as growth in demand in the overall GLP-1 class. A strong acceleration in Farxiga sales reflected continued growth in demand underpinned by additional promotional activity. With Lynparza exceeding the 1,000 patient milestone, it was encouraging to see the early benefit to patients from a pipeline due to launch a number of important medicines in the US in the near term. Europe Product Sales in the half were down 5% to $2,601m. Strong growth from Forxiga and Onglyza was more than offset by continued generic competition facing Crestor and Seroquel XR. An 8% decline in Symbicort sales reflected adverse pricing movements driven by competition from analogues in key markets. Established ROW Product Sales were down 2% in the first half to $1,491m. Following a decline in the first quarter, Japan Q2 sales increased by 6%, reflecting the passing of the anniversary of the mandated April 2014 biennial price cut. Nexium and Crestor continue to grow strongly in Japan, growing by 16% and 6% in the half, respectively. Crestor’s growth reflected a continued increase in the usage of the 5mg dosage. Canada Product Sales grew by 6% to $273m in the half, driven by the performances of Onglyza and Symbicort. Emerging Markets The Company continues to focus on delivering innovative medicines by accelerating investment in its Emerging Markets’ capabilities, with a focus on China and other leading markets, such as Russia and Brazil. Product Sales were up 14% to $2,967m in the half with growth across the region. China sales in the half increased by 19% to $1,309m, more in line with recent trends, with the Company’s medicines for respiratory, cardiovascular and diabetes diseases delivering particularly strong results. Russia sales were up 30% to $116m, while Brazil sales were up 15% to $206m. Q2 Product Sales were up 9% to $1,434m. China sales were up 10% to $583m, with slower growth after a 28% growth in Product Sales in the first quarter. Financial Performance ________________________________________________________________________________ H1 2015 Reported Restructuring IntangibleAmortisation Diabetes Other1 Core % Chang & Impairments Alliance eH1 2015 H1 20142 CER ActualProduct Sales 11,584 - - - - 11,584 12,870 (2) (10)Externalisation 780 - - - - 780 352 124 122RevenueTotal Revenue 12,364 - - - - 12,364 13,222 1 (6) Cost of Sales (2,336) 101 317 - - (1,918) (2,349) (7) (18) Gross Profit 10,028 101 317 - - 10,446 10,873 3 (4)Gross Margin3 79.8% 83.4% 81.7% +1.0 +1.7 Distribution (161) - - - - (161) (149) 23 8% Total Revenue 1.3% 1.3% 1.1% -0.2 -0.2 R&D (2,822) 124 62 - - (2,636) (2,306) 24 14% Total Revenue 22.8% 21.3% 17.4% -3.8 -3.9 SG&A (5,765) 223 444 216 298 (4,584) (4,777) 4 (4)% Total Revenue 46.6% 37.1% 36.1% -0.9 -1.0 Other Operating 576 - 135 - (158) 553 342 77 62Income% Total Revenue 4.7% 4.5% 2.6% +1.9 +1.9 Operating 1,856 448 958 216 140 3,618 3,983 (4) (9)Profit% Total Revenue 15.0% 29.3% 30.1% -1.5 -0.8 Net (513) - - 204 59 (250) (267)FinanceExpenseJoint Ventures (7) - - - - (7) - Profit Before 1,336 448 958 420 199 3,361 3,716 (3) (10)TaxTaxation (88) (94) (193) (95) (2) (472) (600)Tax Rate 6.6% 14.0% 16.1%Profit After 1,248 354 765 325 197 2,889 3,116 - (7)Tax Non-controlling (1) - - - - (1) (3)InterestsNet Profit 1,247 354 765 325 197 2,888 3,113 - (7) Weighted 1,263 1,263 1,263 1,263 1,263 1,263 1,261Average Shares Earnings Per 0.99 0.28 0.60 0.26 0.16 2.29 2.47 - (7)Share 1 Other adjustments include provision   charges and settlement income relatedto certain legal matters (see Note 5)   and fair value adjustments tocontingent consideration liabilities arising on   business combinations (seeNote 4).2 2014 comparatives   have been restated to reflect the reclassification ofExternalisation Revenue   from Other Operating Income.3 Gross Margin   reflects Gross Profit derived from Product Sales, divided byProduct Sales. Q2   2015 Reported Restructuring IntangibleAmortisation Diabetes Other1 Core % Chang & Impairments Alliance eQ2 2015 Q2 20142 CER ActualProduct Sales 5,836 - - - - 5,836 6,454 (1) (10)Externalisation 471 - - - - 471 308 54 53RevenueTotal Revenue 6,307 - - - - 6,307 6,762 2 (7) Cost of Sales (1,067) 58 44 - - (965) (1,156) (7) (16) Gross Profit 5,240 58 44 - - 5,342 5,606 4 (5)Gross Margin3 81.7% 83.5% 82.1% +1.1 +1.4 Distribution (84) - - - - (84) (77) 27 10% Total Revenue 1.3% 1.3% 1.1% -0.3 -0.2 R&D (1,466) 62 48 - - (1,356) (1,208) 23 12% Total Revenue 23.2% 21.5% 17.9% -3.7 -3.6 SG&A (2,966) 115 242 108 285 (2,216) (2,460) (1) (10)% Total Revenue 47.0% 35.1% 36.4% +1.2 +1.3 Other Operating 199 - 86 - (158) 127 170 (12) (25)Income% Total Revenue 3.2% 2.0% 2.5% -0.3 -0.5 Operating 923 235 420 108 127 1,813 2,031 (4) (11)Profit% Total Revenue 14.6% 28.7% 30.0% -1.7 -1.3 Net (263) - - 100 31 (132) (141)FinanceExpenseJoint Ventures (2) - - - - (2) - Profit Before 658 235 420 208 158 1,679 1,890 (2) (11)TaxTaxation 38 (49) (104) (47) 2 (160) (247)Tax Rate -5.8% 9.5% 13.1%Profit After 696 186 316 161 160 1,519 1,643 3 (8)Tax Non-controlling 1 - - - - 1 (1)InterestsNet Profit 697 186 316 161 160 1,520 1,642 3 (8) Weighted 1,264 1,264 1,264 1,264 1,264 1,264 1,262Average Shares Earnings Per 0.55 0.15 0.25 0.13 0.13 1.21 1.30 3 (8)Share 1 Other adjustments include provision   charges and settlement income relatedto certain legal matters (see Note 5)   and fair value adjustments tocontingent consideration liabilities arising on   business combinations (seeNote 4).2 2014 comparatives   have been restated to reflect the reclassification ofExternalisation Revenue   from Other Operating Income.3 Gross Margin   reflects Gross Profit derived from Product Sales, divided byProduct Sales. Gross Profit Core gross profit increased by 3% in the half to $10,446m. Excluding the impact of externalisation, the Core gross profit margin increased by 1% point. Drivers of the margin increase included the mix of Product Sales, the contribution from the growth platforms and additional manufacturing efficiencies. Operating Expenses Core R&D costs were up 24% in the half to $2,636m as the Company continued its accelerated investment in the pipeline. The Company anticipates a lower growth rate in the second half of the year. Core SG&A costs were up 4% to $4,584m in the half as the Company continued to invest in the product launch programme and the growth platforms; costs declined by 1% in the second quarter, reflecting the third successive quarter of falling Core SG&A costs as a proportion of Total Revenue. In the second quarter, Core SG&A costs represented 35% of Total Revenue, compared to 39% in Q1 2015 and 44% in Q4 2014. The Company is committed to reducing Core SG&A costs in 2015 versus the prior year, both in terms of absolute value and, importantly, relative to Total Revenue. A number of programmes designed to meet this target are in progress. These initiatives are centred on: -         Sales, marketing and medical-cost effectiveness -         Centralisation of selected functions and process improvements -         Reduced third-party spend -         Additional efficiencies gained across support functions and IT -         Continued footprint optimisation, including presence in the UK and US Resources are being deployed more opportunistically to meet changing customer needs and the evolving portfolio, while driving top-line growth more efficiently. Other Operating Income Core Other Operating Income of $553m in the half included gains on the disposal of Myalept ($193m) and other disposals amounting to $120m, including the US rights to Tenormin. Operating Profit Core Operating Profit was down 4% to $3,618m in the half. Core Operating Margin declined by 1.5% points to 29.3% of Total Revenue as the Company continued to invest in the pipeline and the growth platforms. Finance Expense Core net finance expense was $250m versus $267m in the first half of 2014. Reported net finance expense of $513m included a charge of $263m relating to the discount unwind on contingent consideration creditors recognised on business combinations, principally relating to the acquisition of BMS’s share of the global diabetes alliance last year. Taxation Excluding the one-off tax benefit of $186m following settlement of past years’ US federal tax liabilities, both the Core and Reported tax rates for the half year were around 20%. Including the impact of this benefit, the Core and Reported tax rates for the half year were 14% and 7% respectively. The cash tax paid for the half year was $782m, which is 59% of Reported Profit Before Tax and 23% of Core Profit Before Tax. The Core and Reported tax rates for the first half of 2014 were 19% and 21% respectively when excluding the impact of a one-off tax benefit of $117m in respect of prior periods following the inter-governmental agreement of a transfer pricing matter. Including the impact of this benefit, the Core and Reported tax rates for the first half of 2014 were 16% and 13% respectively. The cash tax paid for the first half of 2014 was $736m, which was 49% of Reported Profit Before Tax and 20% of Core Profit Before Tax. Earnings Per Share (EPS) Core EPS in the half was stable at $2.29, a favourable performance versus Core Operating Profit due to a one-off tax benefit in the second quarter. Reported Operating Profit of $1,856m was 1% higher than the first half of 2014. Reported EPS was up by 2% at $0.99. Productivity Restructuring charges of $448m were taken in the first half of 2015, including $101m incurred on initiatives identified since the announcement of the fourth wave of restructuring. The Company continues to make good progress in implementing the fourth wave of restructuring that was announced in 2013 and expanded in 2014. It remains on track to incur $3.2bn in one-time restructuring costs and to deliver annualised benefits of $1.1bn by the end of 2016. In addition to the fourth wave of restructuring an additional $600m of costs are estimated to be incurred by the end of 2016 (of which $362m has been incurred to date) associated with previously-announced site exits (including Avlon in the UK) and the integration of businesses acquired since the beginning of 2014. It is anticipated that, once completed, the total annualised benefits of these additional actions will be $200m, bringing the total annualised benefit of all ongoing restructuring activities to $1.3bn by the end of 2016. Cash Flow The Company generated a cash inflow from operating activities of $1,008m in the half, compared with an inflow of $3,266m in the first half of 2014, reflecting the operational performance of the business. Net cash outflows from investing activities were $1,234m compared with $4,955m in the first half of 2014, primarily reflecting the acquisition of the BMS share of the global diabetes alliance last year. The Company has embarked upon an initiative to further improve cash generation from the business including standardisation of global processes and payment terms. Net cash distributions to shareholders were $2,337m through dividends of $2,357m, offset by proceeds from the issue of shares of $20m due to the exercise of stock options. Debt and Capital Structure At 30 June 2015, outstanding gross debt (interest-bearing loans and borrowings) was $11,008m (30 June 2014: $10,074m). Of the gross debt outstanding at 30 June 2015, $2,705m was due within one year (30 June 2014: $2,500m). The Company’s net debt position at 30 June 2015 was $5,994m (30 June 2014: $3,959m). Shares in Issue During the half, 0.5 million shares were issued in respect of share option exercises for a consideration of $20m. The total number of shares in issue at 30 June 2015 was 1,264 million. Dividends The Board has recommended an unchanged first interim dividend of $0.90 (57.5 pence, 7.71 SEK) per Ordinary Share. For holders of the Company’s American Depositary Shares (ADSs) this equates to $0.45 per ADS. Following the ratio change to the Company’s NYSE-listed sponsored Level 2 American Depositary Receipt programme on 27 July 2015, two ADSs equal one Ordinary Share. The level of the dividend per share reflects the Board’s aim of setting the first interim dividend at around a third of the prior-year dividend, which for FY 2014 was $2.80 per Ordinary Share. The Board has adopted a progressive dividend policy, by which the Board intends to maintain or grow the dividend per share each year. In adopting this policy, the Board recognises that some earnings fluctuations are to be expected as the Company’s revenue base transitions through a period of exclusivity losses and new-product launches. In setting the distribution policy and the overall financial strategy, the Board’s aim is to continue to strike a balance between the interests of the business, financial creditors and the Company’s shareholders. After providing for business investment, funding the progressive dividend policy and meeting debt-service obligations, the Board will keep under review the opportunity to return cash in excess of these requirements to shareholders through periodic share repurchases. However, the Board has decided that no share repurchases will take place in 2015 in order to maintain the strategic flexibility to invest in the business. FY 2015 Guidance The Company today revises its Total Revenue guidance at CER from that provided on 24 April 2015. Total Revenue in the full year is now expected to decline by low single-digit percent versus the prior guidance of a mid single-digit decline. Core EPS guidance at CER for the year is unchanged and Core EPS is expected to increase by low single-digit percent, reflecting the continued accelerated investment in R&D. The Company also provides the following non-guidance information related to currency sensitivity: Based on current exchange rates1, Total Revenue is expected to decline by high single-digit percent with Core EPS expected to be broadly in line with FY 2014. For additional currency sensitivity information, please see below:   Average Impact Of   Exchang   5% e Rates Weakening Versus In USD Exchange Rate Versus USD ($m)2Currency Primary FY H1 20151 Change Total   Core   Operating Relevance 2014 % Revenue ProfitEUR Product 0.75 0.89 (16) (225) (138) SalesJPY Product 105.87 120.25 (12) (119) (84) SalesCNY Product 6.16 6.22 (1) (115) (49) SalesSEK Costs 6.86 8.37 (18) (6) 114GBP Costs 0.61 0.66 (7) (37) 112Other3 (242) (139) 1 Based on average daily spot rates YTD to the end of June 2015 2 Based on 2014 actual average exchange rates and group currency exposures 3 Other important currencies include AUD, BRL, CAD, KRW and RUB Related Party Transactions There have been no significant related party transactions in the period. Principal Risks and Uncertainties It is not anticipated that the nature of the principal risks and uncertainties that affect the business, and which are set out on pages 205 to 219 of the Annual Report and Form 20-F Information 2014, will change in respect of the second six months of the financial year. In summary, the principal risks and uncertainties listed in the Annual Report and 20-F Information 2014 are: a) Product pipeline risks Failure to meet development targets; difficulties of obtaining and maintaining regulatory approvals for new products; failure to obtain and enforce effective intellectual property protection; delay to new product launches; strategic alliances and acquisitions may be unsuccessful. b) Commercialisation and business execution risks Challenges to achieving commercial success of new products; illegal trade in our products; developing our business in Emerging Markets; expiry or loss of, or limitations on, intellectual property rights; pressures resulting from generic competition; effects of patent litigation in respect of intellectual property rights; price controls and price reductions; economic, regulatory and political pressures; biosimilars; increasing implementation and enforcement of more stringent anti-bribery and anti-corruption legislation; any expected gains from productivity initiatives are uncertain; changes in senior management, failure to attract and retain key personnel and failure to successfully engage with our employees; failure of information technology; failure of outsourcing. c) Supply chain and delivery risks Manufacturing biologics; difficulties and delays in the manufacturing, distribution and sale of our products; reliance on third parties for goods. d) Legal, regulatory and compliance risks Adverse outcome of litigation and/or governmental investigations; substantial product liability claims; failure to adhere to applicable laws, rules and regulations; failure to adhere to laws, rules and regulations relating to anti-competitive behaviour; environmental and occupational health and safety liabilities; misuse of social media platforms and new technology. e) Economic and financial risks Adverse impact of a sustained economic downturn; political and socio-economic conditions; impact of fluctuations in exchange rates; limited third party insurance coverage; taxation; pensions. Condensed Consolidated Statement of Comprehensive Income   For the half year ended 30 June        2015   $m         Restated        2014*  $m   Product sales 11,584  12,870 Externalisation revenue 780  352 Total revenue 12,364  13,222 Cost of   sales (2,336) (2,760)Gross profit 10,028  10,462 Distribution   costs (161) (149)Research   and development expense (2,822) (2,528)Selling,   general and administrative (5,765) (5,784)costsOther   operating income and expense 576  (56)Operating profit 1,856  1,945 Finance income 24  26 Finance expense (537) (467)Share of after tax losses in joint (7) - venturesProfit before tax 1,336  1,504 Taxation (88) (201)Profit for the period 1,248  1,303  Other comprehensive incomeItems that   will not be reclassifiedto profit or lossRemeasurement of the defined   benefit 242  (288)pension liabilityTax on items that will not be   (57) 85 reclassified to profit or loss  185  (203)Items that   may be reclassifiedsubsequently to profit or lossForeign exchange arising on   (11) 64 consolidationForeign exchange arising on   (217) (122)designating borrowings in netinvestment hedgesFair value movements on   derivatives 20  (11)designated in net investment hedgesAmortisation of loss on cash flow   1  1 hedgeNet available for sale (losses)/gains (29) 49   taken to equityTax on items that may be   43  5 reclassified subsequently to profit orloss  (193) (14)Other comprehensive income for the (8) (217)period, net of taxTotal comprehensive income for   the 1,240  1,086 period Profit attributable to:Owners of the Parent 1,247  1,300 Non-controlling interests 1  3   1,248  1,303  Total comprehensive income  attributable to:Owners of the Parent 1,239  1,089 Non-controlling interests 1  (3)  1,240  1,086  Basic earnings per $0.25 Ordinary   $0.99  $1.03 ShareDiluted earnings per $0.25   Ordinary $0.99  $1.03 ShareWeighted average number of   Ordinary 1,263  1,261 Shares in issue (millions)Diluted weighted average number of   1,265  1,263 Ordinary Shares in issue (millions) * 2014 comparatives restated for reclassification of Externalisation revenue (see Note 1) Condensed Consolidated Statement of Comprehensive Income      For the      2015   $m         Restated   2014*  $m   quarter ended 30      June  Product sales 5,836  6,454 Externalisation 471  308 revenueTotal revenue 6,307  6,762 Cost of   sales (1,067) (1,307)Gross profit 5,240  5,455 Distribution   (84) (77)costsResearch   and (1,466) (1,328)development expenseSelling,   general (2,966) (3,058)and administrativecostsOther   operating 199  117 income and expenseOperating profit 923  1,109 Finance income 13  10 Finance expense (276) (253)Share of after tax (2) - losses of jointventuresProfit before tax 658  866 Taxation 38  (69)Profit for the 696  797 period Other comprehensiveincomeItems that   willnot be reclassifiedto profit or lossRemeasurement of 259  (263)the defined  benefitpension liabilityTax on items that (61) 79 will not be  reclassified toprofit or loss  198  (184)Items that   may bereclassifiedsubsequently toprofit or lossForeign exchange 438  9 arising on  consolidationForeign exchange 191  (121)arising on  designatingborrowings in netinvestment hedgesFair value (1) (2)movements on  derivativesdesignated in netinvestment hedgesAmortisation of 1  1 loss on cash flow  hedgeNet available for (48) 47 sale (losses)/gains  taken to equityTax on items that (57) 12 may be  reclassifiedsubsequently toprofit orloss  524  (54)Other comprehensive 722  (238)income for theperiod, net of taxTotal comprehensive 1,418  559 income   for theperiod Profit attributableto:Owners of the 697  796 ParentNon-controlling (1) 1 interests  696  797  Total comprehensiveincome  attributable to:Owners of the 1,418  558 ParentNon-controlling -  1 interests  1,418  559  Basic earnings per $0.55  $0.63 $0.25 Ordinary  ShareDiluted earnings $0.55  $0.63 per $0.25  OrdinaryShareWeighted average 1,264  1,262 number of  OrdinaryShares in issue(millions)Diluted weighted 1,265  1,264 average number of  Ordinary Shares inissue (millions) * 2014 comparatives restated for reclassification of Externalisation revenue (see Note 1) Condensed Consolidated Statement of Financial Position            At 30   Jun      At 31 Dec      At 30 Jun      2015  $m      2014  $m      2014  $m  ASSETSNon-currentassetsProperty, plant 6,134  6,010  6,150 and equipmentGoodwill 11,467  11,550  11,560 Intangible assets 20,486  20,981  21,150 Derivative 471  465  349 financialinstrumentsInvestments in 52  59  70 joint venturesOther investments 448  502  289 Other receivables 957  1,112  1,380 Deferred tax 1,342  1,219  1,387 assets  41,357  41,898  42,335 Current assetsInventories 2,198  1,960  2,249 Trade and other 6,615  7,232  7,817 receivablesOther investments 531  795  819 Derivative 51  21  1 financialinstrumentsIncome tax 450  329  360 receivableCash and cash 3,967  6,360  4,958 equivalents 13,812  16,697  16,204 Total assets 55,169  58,595  58,539 LIABILITIESCurrentliabilitiesInterest-bearing (2,705) (2,446) (2,500)loans andborrowingsTrade and other (10,659) (11,886) (10,304)payablesDerivative   (6) (21) (12)financialinstrumentsProvisions (731) (623) (679)Income tax payable (2,049) (2,354) (2,827) (16,150) (17,330) (16,322)Non-currentliabilitiesInterest-bearing (8,303) (8,397) (7,574)loans andborrowingsDeferred tax (1,582) (1,796) (2,427)liabilitiesRetirement benefit (2,377) (2,951) (2,634)obligationsProvisions (479) (484) (580)Other   payables (7,979) (7,991) (6,950) (20,720) (21,619) (20,165)Total liabilities (36,870) (38,949) (36,487)Net assets 18,299  19,646  22,052 EQUITYCapital andreserves  attributable toequity holders ofthe CompanyShare capital 316  316  316 Share premium 4,281  4,261  4,236 accountOther reserves 2,033  2,021  1,973 Retained earnings 11,649  13,029  15,504   18,279  19,627  22,029 Non-controlling 20  19  23 interestsTotal equity 18,299  19,646  22,052  Condensed Consolidated Statement of Cash Flows      For the half year ended 30         2015  $m            2014   $m   June  Cash flows from operating  activitiesProfit   before tax 1,336  1,504 Finance   income and expense 513  441 Share of   after tax losses in 7  - joint venturesDepreciation,   amortisation and 1,565  1,410 impairment(Increase)/decrease   in working (767) 703 capital and short-term provisionsNon-cash   and other movements (612) 216 Cash   generated from operations 2,042 4,274 Interest   paid (252) (272)Tax   paid (782) (736)Net   cash inflow from operating 1,008  3,266 activitiesCash   flows from investingactivitiesMovement   in short-term 273  34 investments and fixed depositsPurchase   of property, plant and (497) (378)equipmentDisposal   of property, plant and 16  133 equipmentPurchase   of intangible assets (1,222) (1,490)Disposal   of intangible assets 350  - Purchase   of non-current asset (30) (5)investmentsDisposal   of non-current asset 56  - investmentsPayments   to joint ventures -  (70)Upfront   payments on business -  (2,778)acquisitionsPayment   of contingent (239) (449)consideration on businessacquisitionsInterest   received 59  58 Payments   made by subsidiaries -  (10)to non-controlling interestsNet cash outflow from investing (1,234) (4,955)activitiesNet cash outflow before financing (226) (1,689)activitiesCash flows from financing  activitiesProceeds from issue of share 20  254 capitalRepayment of loans (884) (750)Dividends paid (2,357) (2,425)Hedge contracts relating to (43) 25 dividend paymentsRepayment of obligations under (34) (17)finance leasesPayments to acquire non -  (102)-controlling interestMovement in short-term borrowings 910  445 Net cash outflow from financing (2,388) (2,570)activitiesNet decrease in cash and cash   (2,614) (4,259)equivalents in the periodCash and cash equivalents at the 6,164  8,995 beginning of the   periodExchange rate effects (29) 3 Cash and cash equivalents at the 3,521  4,739 end of the   periodCash and cash equivalentsconsists of:Cash and cash equivalents 3,967  4,958 Overdrafts (446) (219) 3,521  4,739  Condensed Consolidated Statement of Changes in Equity Share Share Other Retained Total  Non Total   capi   prem   rese   earning   $m  -   equity   co n t r r o v l t i e l a u s i l m * s n   $m   acco   $m   $m g   $m   in t e r e s u t n s t   $m   $m At 1 Jan 2014 315 3,983 1,966 16,960  23,224  29  23,253 Profit for - - - 1,300  1,300  3  1,303 the periodOther - - - (211) (211) (6) (217)comprehensiveincomeTransfer to - - 7 (7) - -  -otherreservesTransactionswith owners:Dividends - - - (2,395) (2,395) -  (2,395)Issue of 1 253 - - 254  -  254 OrdinarySharesShare-based - - - (143) (143) -  (143)paymentsTransfer from - - - - - (3) (3)non-controllinginterests to  payablesNet movement 1 253 7 (1,456) (1,195) (6) (1,201)At 30 Jun 316 4,236 1,973 15,504  22,029  23  22,052 2014 Share Share Other Retained Total  Non Total   capi   prem   rese   earning   $m  -   equity   co n t r r o v l t i e l a u s i l m * s n   $m   acco   $m   $m g   $m   in t e r e s u t n s t   $m   $m At 1 Jan 2015 316 4,261 2,021 13,029  19,627  19  19,646 Profit for - - - 1,247  1,247  1  1,248 the periodOther - - - (8) (8) -  (8)comprehensiveincomeTransfer to - - 12 (12) -  -  - otherreservesTransactionswith owners:Dividends - - - (2,400) (2,400) -  (2,400)Issue of - 20 - -  20  -  20 OrdinarySharesShare-based - - - (207) (207) -  (207)paymentsNet movement - 20 12 (1,380) (1,348) 1  (1,347)At 30 Jun 316 4,281 2,033 11,649  18,279  20  18,299 2015 * Other reserves include the capital redemption reserve and the merger reserve. Responsibility Statement of the Directors in Respect of the Half-Yearly Financial Report We confirm that to the best of our knowledge: · the condensed set of financial statements has been prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the European Union and as issued by the International Accounting Standards Board; · the half-yearly management report includes a fair review of the information required by: (a) DTR 4.2.7R of the Disclosure and Transparency Rules, being an   indication of important events that have occurred during the first six months   of the financial year and their impact on the condensed set of financial   statements; and a description of the principal risks and uncertainties for   the remaining six months of the year; and(b) DTR 4.2.8R of the Disclosure and Transparency Rules, being related   party transactions that have taken place in the first six months of the   current financial year and that have materially affected the financial   position or performance of the enterprise during that period; and any changes   in the related party transactions described in the last annual report that   could do so. The Board The Board of Directors that served during all or part of the six-month period to 30 June 2015 and their respective responsibilities can be found on pages 28 and 29 of the AstraZeneca Annual Report and Form 20-F Information 2014, with the exception of Cori Bargmann who was elected as Non-Executive Director and appointed as a member of the Science Committee on 24 April 2015. Also on 24 April 2015, Rudy Markham became Senior independent Non-Executive Director, Graham Chipchase became Chairman of the Remuneration Committee and a member of the Nomination and Governance Committee, Bruce Burlington became Chairman of the Science Committee and a member of the Nomination and Governance Committee and Geneviève Berger took on the oversight of sustainability matters on behalf of the Board. Approved by the Board and signed on its behalf by Pascal Soriot Chief Executive Officer 30 July 2015 Independent Review Report to AstraZeneca PLC Introduction We have been engaged by the Company to review the condensed set of Interim Financial Statements in the half-yearly financial report for the six months ended 30 June 2015 (but not for the quarter ended 30 June 2015 as presented in the Condensed Consolidated Statement of Comprehensive Income for the quarter ended 30 June 2015) which comprises Condensed Consolidated Statement of Comprehensive Income, Condensed Consolidated Statement of Financial Position, Condensed Consolidated Statement of Cash Flows, Condensed Consolidated Statement of Changes in Equity and Notes 1 to 6. We have read the other information contained in the half-yearly financial report and considered whether it contains any apparent misstatements or material inconsistencies with the information in the condensed set of financial statements. This report is made solely to the Company in accordance with the terms of our engagement to assist the Company in meeting the requirements of the Disclosure and Transparency Rules ("the DTR") of the UK's Financial Conduct Authority ('the UK FCA"). Our review has been undertaken so that we might state to the Company those matters we are required to state to it in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company for our review work, for this report, or for the conclusions we have reached. Directors' responsibilities The half-yearly financial report is the responsibility of, and has been approved by, the Directors. The Directors are responsible for preparing the half-yearly financial report in accordance with the DTR of the UK FCA. As disclosed in Note 1, the annual financial statements of the Group are prepared in accordance with International Financial Reporting Standards ("IFRSs") as adopted by the European Union ("EU") and as issued by the International Accounting Standards Board ("IASB"). The condensed set of financial statements included in this half-yearly financial report has been prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the EU and as issued by the IASB. Our responsibility Our responsibility is to express to the Company a conclusion on the condensed set of financial statements in the half-yearly financial report based on our review. Scope of review We conducted our review in accordance with International Standard on Review Engagements (UK and Ireland) 2410 Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Auditing Practices Board for use in the UK. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK and Ireland) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Conclusion Based on our review, nothing has come to our attention that causes us to believe that the condensed set of financial statements in the half-yearly financial report for the six months ended 30 June 2015 is not prepared, in all material respects, in accordance with IAS 34 as adopted by the EU and as issued by the IASB, and the DTR of the UK FCA. Antony Cates for and on behalf of KPMG LLP Chartered Accountants 15 Canada Square London E14 5GL 30 July 2015 Notes to the Interim Financial Statements 1      BASIS OF PREPARATION AND ACCOUNTING POLICIES These unaudited condensed consolidated interim financial statements (“interim financial statements”) for the six months ended 30 June 2015 have been prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the European Union (EU) and as issued by the International Accounting Standards Board (IASB). The annual financial statements of the Group are prepared in accordance with International Financial Reporting Standards (IFRSs) as adopted by the EU and as issued by the IASB. Except as detailed below, the interim financial statements have been prepared applying the accounting policies and presentation that were applied in the preparation of the Group’s published consolidated financial statements for the year ended 31 December 2014. Externalisation revenue As announced on 6 March 2015, the Group updated its revenue accounting policy with effect from 1 January 2015. The Group’s business model now includes an increasing level of externalisation activity to create value from the strong science that exists in the pipeline. Historically, reported revenue reflected only product sales, with externalisation revenue forming part of other operating income presented below gross profit. From 1 January 2015 externalisation revenue, alongside product sales, are included in total revenue. Externalisation revenue includes development, commercialisation, partnership and out-licence revenue, such as royalties and milestone receipts, together with income from services or repeatable licences. Income is recorded as externalisation revenue when the Group has a significant ongoing interest in the product and/or it is repeatable business and there is no derecognition of an intangible asset. Disposals of assets and businesses, where the Group does not retain an interest, will continue to be recorded in other operating income. The updated financial presentation reflects the Group’s entrepreneurial approach and provides a clearer picture of this additional revenue stream. The updated revenue accounting policy results in a presentational change to the Statement of Comprehensive Income only, and has no impact on the Group’s net results or net assets. The prior period Condensed Consolidated Statement of Comprehensive Income has been restated accordingly, resulting in $352m of income being reclassified from other operating income to externalisation revenue for the half year ended 30 June 2014, and $308m for the quarter ended 30 June 2014. New accounting standards The Group has adopted the amendments to IAS 19 Employee Benefits, issued by IASB in November 2013 and effective for periods beginning on or after 1 July 2014. The adoption has not had a significant impact on the Group’s profit for the period, net assets or cash flows. There have been no other significant new or revised accounting standards applied in the half year ended 30 June 2015. Legal proceedings The information contained in Note 5 updates the disclosures concerning legal proceedings and contingent liabilities in the Group’s Annual Report and Form 20-F Information 2014. Going concern The Group has considerable financial resources available. As at 30 June 2015 the Group has $4.3bn in financial resources (cash balances of $4.0bn and undrawn committed bank facilities of $3.0bn which are available until April 2020, with only $2.7bn of debt due within one year). The Group’s revenues are largely derived from sales of products which are covered by patents which provide a relatively high level of resilience and predictability to cash inflows, although our revenue is expected to continue to be significantly impacted by the expiry of patents over the medium term. In addition, government price interventions in response to budgetary constraints are expected to continue to adversely affect revenues in many of our mature markets. However, we anticipate new revenue streams from both recently launched medicines and products in development, and the Group has a wide diversity of customers and suppliers across different geographic areas. Consequently, the Directors believe that, overall, the Group is well placed to manage its business risks successfully. On the basis of the above paragraph and after making enquiries, the Directors have a reasonable expectation that the Company and the Group have adequate resources to continue in operational existence for a period of at least 12 months. Accordingly, the interim financial statements have been prepared on a going concern basis. The comparative figures for the financial year ended 31 December 2014 are not the Company’s statutory accounts for that financial year. Those accounts have been reported on by the Group’s auditors and delivered to the registrar of companies. The report of the auditors was (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006. 2    restructuring costs Profit before tax for the half year ended 30 June 2015 is stated after charging restructuring costs of $448m ($235m for the second quarter of 2015). These have been charged to profit as follows: HY   2015 HY   2014 Q2   2015 Q2   2014   $m   $m   $m   $mCost of sales 101 24 58 13Research and 124 190 62 105development expenseSelling, general and 223 266 115 175administrative  costsOther operating - 292 - -income and expenseTotal 448 772 235 293 3    Net DEBT The table below provides an analysis of net debt and a reconciliation of net cash flow to the movement in net debt. At 1 Cash Flow $m  Non Exchange   At   30 Jan 2015 $m  -cashMovements$m Movements$m Jun 2015 $m  Loans due (8,337) -  19  62  (8,256)after oneyearFinance (60) -  12  1  (47)leases dueafter oneyearTotal   (8,397) -  31  63  (8,303)long-termdebt Current (912) 884  -  28  - instalmentsof loansCurrent (48) 34  (47) 1  (60)instalmentsof financeleasesTotal   (960) 918  (47) 29  (60)currentdebt Other   795  (286) 28  (6) 531 investments– currentNet   465  56  (5) -  516 derivativefinancialinstrumentsCash   and 6,360  (2,363) -  (30) 3,967 cashequivalentsOverdrafts (196) (251) -  1  (446)Short-term (1,290) (910) 1  -  (2,199) borrowings 6,134  (3,754) 24  (35) 2,369 Net debt (3,223) (2,836) 8  57  (5,994) Non-cash movements in the period include fair value adjustments under IAS 39. 4    FINANCIAL INSTRUMENTS As detailed in the Group’s most recent annual financial statements, our principal financial instruments consist of derivative financial instruments, other investments, trade and other receivables, cash and cash equivalents, trade and other payables, and interest-bearing loans and borrowings. As indicated in Note 1, there have been no changes to the accounting policies, including fair value measurement, for financial instruments from those disclosed on pages 140 and 141 of the Company’s Annual Report and Form 20-F Information 2014. In addition, there have been no changes of significance to the categorisation or fair value hierarchy of our financial instruments. Financial instruments measured at fair value include $979m of other investments, $1,176m of loans, and $516m of derivatives as at 30 June 2015. The total fair value of interest-bearing loans and borrowings at 30 June 2015, which have a carrying value of $11,008m in the Condensed Consolidated Statement of Financial Position, was $12,039m. Contingent consideration liabilities arising on business combinations have been classified under Level 3 in the fair value hierarchy and movements in fair value are shown below: DiabetesAlliance2015 Other2015 Total2015 Total2014 $m $m $m $mAt 1 January 5,386  1,513  6,899  514 Additions   -  -  -  5,249*throughbusinesscombinationsSettlements (103) (136) (239) (449)Revaluations -  82  82  6 Discount   204  59  263  174 unwindForeign   -  -  -  6 exchangeAt 30 June 5,487  1,518  7,005  5,500  *The preliminary estimate of the fair value of contingent consideration of $5,249m was subsequently revised, in the third quarter of 2014, to $5,169m. 5   legal proceedings and contingent liabilities AstraZeneca is involved in various legal proceedings considered typical to its business, including litigation and investigations relating to product liability, commercial disputes, infringement of intellectual property rights, the validity of certain patents, anti-trust law and sales and marketing practices. The matters discussed below constitute the more significant developments since publication of the disclosures concerning legal proceedings in the Company's Annual Report and Form 20-F Information 2014 (the 2014 Disclosures). Unless noted otherwise below or in the 2014 Disclosures, no provisions have been established in respect of the claims discussed below. As discussed in the 2014 Disclosures, for the majority of claims in which AstraZeneca is involved it is not possible to make a reasonable estimate of the expected financial effect, if any, that will result from ultimate resolution of the proceedings. In these cases, AstraZeneca discloses information with respect only to the nature and facts of the cases but no provision is made. In cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed and which are not subject to appeal, or where a loss is probable and we are able to make a reasonable estimate of the loss, we record the loss absorbed or make a provision for our best estimate of the expected loss. The position could change over time and the estimates that we have made and upon which we have relied in calculating these provisions are inherently imprecise. There can, therefore, be no assurance that any losses that result from the outcome of any legal proceedings will not exceed the amount of the provisions that have been booked in the accounts. The major factors causing this uncertainty are described more fully in the 2014 Disclosures and herein. AstraZeneca has full confidence in, and will vigorously defend and enforce, its intellectual property. Matters disclosed in respect of the first quarter of 2015 and to 24 April 2015. Patent litigation Crestor (rosuvastatin) Patent proceedings outside the US As previously disclosed, in Australia, in 2011 and 2012, AstraZeneca instituted proceedings against Actavis Australia Pty Ltd, Apotex Pty Ltd and Watson Pharma Pty Ltd asserting infringement of three formulation and method patents for Crestor. In March 2013, the Federal Court of Australia held all three patents at issue invalid. AstraZeneca appealed in relation to two patents. In August 2014, the Full Court of the Federal Court of Australia held the two patents invalid. In March 2015, the High Court granted AstraZeneca leave to appeal in relation to one method patent. Daliresp (roflumilast) Patent proceedings in the US In April 2015, AstraZeneca received several Paragraph IV Notices challenging certain patents listed in the FDA Orange Book with reference to Daliresp. AstraZeneca is reviewing the Notices. Faslodex (fulvestrant) Patent proceedings outside the US In March 2015, AstraZeneca was served with a writ of summons by which Actavis Group PTC ehf. and Actavis Italy S.p.A (together, Actavis) commenced invalidity and non-infringement proceedings before a court in Turin, Italy relating to two Faslodex formulation patents, European Patent EP 1250138 and Italian Patent IT 1333490. Losec/Prilosec (omeprazole) Patent proceedings in the US As previously disclosed, in 2008, Apotex Inc. (Apotex) was found to infringe AstraZeneca’s US Patent Nos. 4,786,505 and 4,853,230. In 2013, the US District Court for the Southern District of New York ordered Apotex to pay $76m in damages with an additional sum of $28m in pre-judgment interest, and an unspecified amount of post-judgment interest. Apotex appealed. In April 2015, the US Court of Appeals for the Federal Circuit affirmed the bulk of the damages award, with the exception of a small portion of the award which related to sales post patent expiration during a portion of the paediatric exclusivity period. Patent proceedings outside the US As previously disclosed, in Canada, in 2004, AstraZeneca brought proceedings against Apotex Inc. (Apotex) for infringement of several patents related to Losec. In February 2015, the Federal Court of Canada found that Apotex had infringed AstraZeneca’s Canadian Patent No. 1,292,693. Apotex have appealed. Pulmicort Respules (budesonide inhalation suspension) Patent proceedings in the US As previously disclosed, in October 2014, the US District Court for the District of New Jersey (the District Court) held a trial on the merits in respect of US Patent No. 7,524,834 (the ‘834 Patent) and to determine whether AstraZeneca’s request for permanent injunctive relief against Breath Limited, Apotex, Inc. and Apotex Corp., Sandoz, Inc. and Watson Laboratories, Inc. (together, the Generic Challengers) should be granted. On 13 February 2015, the District Court determined that the ‘834 Patent is invalid and denied the injunction request. Also on 13 February 2015, AstraZeneca filed a motion for an injunction pending an appeal of the District Court’s decision, which was denied on the same day. On 16 February 2015, AstraZeneca appealed the District Court’s decision to the US Court of Appeals for the Federal Circuit (the Court of Appeals) and filed an Emergency Motion for an Injunction Pending Appeal. On 17 February 2015, the Court of Appeals issued an injunction against the Generic Challengers pending submissions by the parties. On 12 March 2015, the Court of Appeals issued an injunction pending appeal. Oral argument in the appeal is scheduled for 4 May 2015. Seroquel XR (quetiapine fumarate) Patent proceedings in the US As previously disclosed, in October and November 2014, AstraZeneca filed patent infringement proceedings against Pharmadax, Inc. and Pharmadax USA, Inc. (together, Pharmadax) in the US District Court for the District of New Jersey. In February 2015, AstraZeneca settled the patent infringement litigation by granting Pharmadax a licence to the Seroquel XR product patent effective from 1 November 2016, or earlier in certain circumstances. In February 2015, AstraZeneca received a Paragraph IV Notice from AB Pharmaceuticals, LLC, the US agent of Macleods Pharmaceuticals, Ltd., (together, Macleods) alleging that the patent listed in the FDA Orange Book with reference to Seroquel XR is invalid, unenforceable and/or is not infringed by Macleods’ proposed generic product. Macleods submitted an Abbreviated New Drug Application (ANDA) seeking to market quetiapine fumarate tablets. In February 2015, AstraZeneca filed a patent infringement lawsuit against Macleods and Macleods Pharma USA, Inc. in the US District Court for the District of New Jersey. Patent proceedings outside the US As previously reported, in March 2013, the Federal Court of Canada dismissed AstraZeneca’s application to prohibit the Canadian Minister of Health from issuing a notice of compliance to Teva Canada Limited (Teva) for its generic quetiapine fumarate product relating to Seroquel XR. Teva subsequently launched its generic Seroquel XR at risk and filed an action seeking section 8 damages arising from these proceedings. In April 2015, AstraZeneca and Teva entered into a settlement agreement ending the ongoing patent litigation between the parties, as well as the section 8 damages action, and allowing Teva to continue selling generic Seroquel XR. Vimovo (esomeprazole magnesium/naproxen) Patent proceedings outside the US In Canada, in January 2015, AstraZeneca received two Notices of Allegation from Mylan Pharmaceuticals ULC. In response, AstraZeneca and Pozen Inc. (the licensee and patent holder, respectively), commenced proceedings in relation to Canadian Patent No. 2,449,098. Commercial litigation Seroquel IR (quetiapine fumarate) As previously disclosed, with regard to insurance coverage for the substantial legal defence costs and settlements that have been incurred in connection with the Seroquel IR product liability claims in the US, related to alleged diabetes and/or other related alleged injuries (which now exceed the total amount of insurance coverage available), an arbitration is ongoing against an insurer in respect of the availability of coverage under an insurance policy. The policy has a coverage limit of $50m. AstraZeneca has not recognised an insurance receivable in respect of this legal action. Synagis (palivizumab) As previously disclosed, in September 2011, MedImmune filed an action against AbbVie, Inc. (AbbVie) (formerly Abbott International, LLC) in the Circuit Court for Montgomery County, Maryland, seeking a declaratory judgment in a contract dispute. AbbVie’s motion to dismiss was granted. In September 2011, AbbVie filed a parallel action against MedImmune in the Illinois State Court, where the case is currently pending. A trial date has been set for 31 August 2015. Toprol-XL (metoprolol succinate) On 30 March 2015, AstraZeneca was served with a state court complaint filed by the Attorney General for the State of Louisiana alleging that, in connection with enforcement of its patents for Toprol-XL, it had engaged in unlawful monopolisation and unfair trade practices, causing the state government to pay increased prices for Toprol-XL. The complaint is very similar to prior class action complaints filed by private parties against AstraZeneca relating to Toprol-XL in 2006 and resolved by settlement in 2012. The State seeks an unspecified amount of trebled damages and pre-judgment interest. AstraZeneca denies these allegations. Matters disclosed in respect of the second quarter of 2015 and to 30 July 2015. Patent litigation Crestor (rosuvastatin) Patent proceedings outside the US As previously disclosed, in 2014, in Japan, Shionogi & Co., Ltd. the licensor of the Crestor patent, received confirmation of a request for trial for patent invalidation in the Japanese Patent Office (JPO). The request was initiated by Teva Pharma Japan Inc. (Teva) and relates to the Crestor substance patent. On 29 June 2015, the JPO dismissed Teva’s claim. A second invalidation action relating to the same patent has been filed by an individual. As previously disclosed, in 2014, in the Netherlands, AstraZeneca received a letter from Resolution Chemicals Ltd. (Resolution) indicating that it had sought marketing authorisation for a rosuvastatin zinc product in the Netherlands. In April 2014, AstraZeneca received a writ of summons from Resolution alleging partial invalidity and non-infringement of the supplementary protection certificate (SPC) related to the Crestor substance patent. On 15 July 2015, the District Court of the Hague determined that the SPC does not extend to zinc salts of rosuvastatin and that Resolution's product does not infringe the SPC. AstraZeneca is considering its response. Daliresp (roflumilast) Patent proceedings in the US As previously disclosed, in April 2015, AstraZeneca received Paragraph IV Notices challenging certain patents listed in the FDA Orange Book with reference to Daliresp. AstraZeneca has received notice from ten companies that each has submitted an Abbreviated New Drug Application (ANDA) seeking to market roflumilast. In May 2015, AstraZeneca filed a patent infringement lawsuit against each of the ten companies in the US District Court for the District of New Jersey. Faslodex (fulvestrant) Patent proceedings in the US As previously disclosed, in June and September 2014 and January 2015, AstraZeneca filed patent infringement lawsuits against Sandoz Inc. and Sandoz International GmbH, Sagent Pharmaceuticals, Inc., and Glenmark Generics, Inc. USA in the US District Court in New Jersey relating to four patents listed in the FDA Orange Book with reference to Faslodex, after those companies sent Paragraph IV notices that they are seeking FDA approval to market generic versions of Faslodex prior to the expiration of AstraZeneca’s patents. In July 2015, AstraZeneca received a Paragraph IV notice from Agila Specialties Inc., on behalf of Onco Therapies Limited, which is also seeking FDA approval to market a generic version of Faslodex prior to the expiration of the same four patents. Patent proceedings outside the US In July 2015, AstraZeneca was served with two nullity complaints, one filed by Hexal AG and the other by ratiopharm GmbH, commencing invalidity proceedings before the Federal Patent Court in Germany, and requesting the revocation of the German part of the Faslodex formulation use patent, EP 1,250,138. Losec/Prilosec (omeprazole) Patent proceedings in the US As previously disclosed, in 2008, Apotex Inc. (Apotex) was found to infringe AstraZeneca’s US Patent Nos. 4,786,505 and 4,853,230 and in 2013, the US District Court for the Southern District of New York (the District Court) ordered Apotex to pay $76m in damages with an additional sum of $28m in pre-judgment interest, and an unspecified amount of post-judgment interest. Apotex appealed. In April 2015, the US Court of Appeals for the Federal Circuit affirmed the bulk of the damages award, with the exception of a small portion of the award which related to sales post patent expiration during a portion of the paediatric exclusivity period. In July 2015, the District Court ordered Apotex to pay $99m to AstraZeneca. The proceeding is now closed and AstraZeneca has recognised the settlement income. Nexium (esomeprazole) Patent proceedings in the US In June 2015, AstraZeneca received a Paragraph IV Notice from HEC Pharm Co., Ltd (HEC) challenging certain patents listed in the FDA Orange Book with reference to Nexium. HEC submitted an Abbreviated New Drug Application (ANDA) seeking to market esomeprazole magnesium capsules. AstraZeneca is reviewing HEC’s notice. In June 2015, AstraZeneca received a Paragraph IV Notice from Lupin Ltd (Lupin) challenging certain patents listed in the FDA Orange Book with reference to Nexium 24HR (OTC). Lupin submitted an ANDA seeking to market OTC esomeprazole magnesium capsules. AstraZeneca is reviewing Lupin’s notice. As previously disclosed, in March 2012, AstraZeneca filed a patent infringement lawsuit against Mylan Laboratories Limited and Mylan Inc. (together, Mylan) in the US District Court for the District of New Jersey. In July 2015, AstraZeneca filed a motion for preliminary injunction against Mylan’s launch of its ANDA version of esomeprazole magnesium capsules. The patents-at-issue are US Patent Nos. 6,369,085 and 7,411,070. Both patents have a date of expiry of 25 May 2018. Patent proceedings outside the US As previously disclosed, in July 2014, in Canada, the Federal Court found Canadian Patent No. 2,139,653 invalid and not infringed by Apotex Inc. On 6 July 2015, AstraZeneca’s appeal was dismissed. As previously disclosed, in July 2014, in Canada, AstraZeneca received a Notice of Allegation from Teva Canada Limited (Teva) alleging either that Teva’s esomeprazole magnesium product would not infringe the patents listed on the Canadian Patent Register in relation to Nexium or, alternatively, that certain of the patents were invalid. AstraZeneca commenced a proceeding in 2014, but has now discontinued its application pursuant to a settlement agreement. Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin and metformin) Patent proceedings in the US In June 2015, Mylan Pharmaceuticals, Inc. filed a petition for an Inter Parties Review with the US Patent Office challenging the validity of the saxagliptin compound patent, US RE44,186, that is listed in the FDA Orange Book for both Onglyza and Kombiglyze XR. Pulmicort Respules (budesonide inhalation suspension) Patent proceedings in the US As previously disclosed, in February 2015, the US District Court for the District of New Jersey (the District Court) determined that the asserted claims of US Patent No. 7,524,834 was invalid. AstraZeneca appealed that decision and on 7 May 2015, the US Court of Appeals for the Federal Circuit affirmed the District Court’s decision and lifted the injunction that was issued pending the appeal. Since 2009, various injunctions were issued in this matter. Damages claims based on those injunctions are expected and a provision has been taken in the first half of 2015. Seroquel XR (quetiapine fumarate) Patent proceedings in the US As previously disclosed, in February 2015, AstraZeneca filed a patent infringement lawsuit against Macleods Pharmaceuticals, Ltd. Macleods Pharma USA, Inc. and AB Pharmaceuticals, LLC. (together, Macleods) in the US District Court for the District of New Jersey. In June 2015, AstraZeneca settled the patent infringement litigation by granting Macleods a license to the Seroquel XR product patent effective from 1 November 2016, or earlier in certain circumstances. Patent proceedings outside the US In Italy, in June 2015, following a challenge to the validity of the formulation patent covering Seroquel XR by Sandoz S.p.A. and Sandoz A/S, the Court of Turin found the Seroquel XR formulation patent invalid. Product liability litigation Nexium (esomeprazole magnesium) As previously disclosed, of the approximately 1,900 plaintiffs who alleged that Nexium caused osteoporotic injuries, such as bone deterioration, loss of bone density and/or bone fractures, approximately 40 claims remained active in California state court and the rest of the claims were dismissed. In June 2015, the California state court granted AstraZeneca’s motion for summary judgment and dismissed the approximately 40 remaining plaintiffs’ claims. In addition, as previously disclosed, approximately 270 plaintiffs have appealed the dismissals of their claims and those appeals remain pending. Commercial litigation Average Manufacturer’s Price qui tam litigation (Streck) AstraZeneca was one of several manufacturers named as a defendant in a lawsuit filed in the US Federal Court in Philadelphia under the qui tam (whistleblower) provisions of the federal and certain state False Claims Acts alleging inaccurate reporting of Average Manufacturer’s prices to the Centers for Medicare and Medicaid Services. The action was initially filed in October 2008 but remained under seal until May 2011. In July 2015, AstraZeneca agreed upon a negotiated settlement to resolve the dispute. A provision for this amount was previously taken. 6. product Sales analysis – h1 2015          World US Europe Established Emerging ROW Markets H1 CER% H1 CER H1 CER% H1 2015$m CER% H1 CER% 2015$m 2015$m   % 2015$m 2015$mRespiratory,Inflammationand Autoimmunity:Symbicort 1,687 -  717 (1) 582 (8) 201 9  187 28 Pulmicort 518 18  108 4  66 (7) 41 (2) 303 37 Tudorza/Eklira 85 n/m  45 n/m  36 n/m  4 n/m  - - Duaklir 7 n/m  - n/m  6 n/m  1 n/m  - - Others 171 20  49 188  46 (7) 10 -  66 4 Total 2,468 9  919 9  736 (3) 257 9  556 30 Respiratory,Inflammation and AutoimmunityCardiovascularandMetabolicdisease:Brilinta/Brilique 275 42  101 60  110 21  17 36  47 80 Onglyza 391 4  211 (16) 71 23  32 30  77 56 Bydureon 263 41  222 35  35 71  3 33  3 200 Byetta 172 8  121 15  30 (13) 10 -  11 33 Farxiga/Forxiga 205 n/m  115 n/m  53 n/m  11 44  26 n/m Legacy:Crestor 2,477 (5) 1,374 (7) 469 (7) 282 (3) 352 5 Seloken/Toprol-XL 378 7  48 (9) 49 (3) 7 (20) 274 14 Atacand 194 (11) 18 (10) 53 (33) 15 (23) 108 8 Others 327 (4) 35 (5) 75 (13) 30 (21) 187 6 Total 4,682 4  2,245 2  945 -  407 (2) 1,085 16 CardiovascularandMetabolic  DiseaseOncology:Iressa 273 (3) - -  66 (5) 68 (11) 139 3 Lynparza 30 n/m  26 n/m  4 n/m  - n/m  - n/m Legacy:Zoladex 409 9  14 27  85 (15) 133 (2) 177 32 Faslodex 333 5  165 2  101 1  25 4  42 32 Casodex 139 (5) 1 (67) 15 (18) 66 (14) 57 17 Arimidex 126 (9) 7 (22) 25 (27) 40 (15) 54 14 Others 71 23  13 -  15 13  29 79  14 (11)Total Oncology 1,381 5  226 15  311 (7) 361 (4) 483 18 Infection,Neuroscienceand  Gastrointestinal:Nexium 1,291 (27) 479 (49) 143 (10) 272 (6) 397 (1)Seroquel XR 526 (7) 353 2  113 (25) 14 (30) 46 10 Synagis 270 (28) 160 (38) 110 (6) - -  - n/m Losec/Prilosec 181 (6) 12 (7) 48 (12) 39 (17) 82 6 FluMist/Fluenz 21 75  21 110  - -  - n/m  - - Movantik/Moventig 4 n/m  4 n/m  - n/m  - n/m  - n/m Others 760 (8) 106 (28) 195 (13) 141 1  318 (1)Total Infection, 3,053 (18) 1,135 (34) 609 (14) 466 (7) 843 - Neuroscience and GastrointestinalTOTAL PRODUCT 11,584 (2) 4,525 (9) 2,601 (5) 1,491 (2) 2,967 14 SALES 7. product Sales analysis – Q2 2015          World US Europe Established Emerging ROW Markets Q2 CER% Q2 CER Q2 CER% Q2 2015$m CER% Q2 CER% 2015$m 2015$m   % 2015$m 2015$mRespiratory,Inflammationand Autoimmunity:Symbicort 842 -  375  (1) 276 (9) 102 24  89 16 Pulmicort 232 19  56  8  28 (15) 21 5  127 44 Tudorza/Eklira 55 n/m  35  n/m  18 n/m  2 n/m  - n/m Duaklir 5 n/m  -  -  4 n/m  1 n/m  - - Others 91 32  37  n/m  21 (16) 7 60  26 (18)Total 1,225 11  503  16  347 (3) 133 23  242 20 Respiratory,Inflammation and AutoimmunityCardiovascularandMetabolicdisease:Brilinta/Brilique 144 38  55  57  56 21  9 38  24 59 Onglyza 208 (7) 113  (22) 34 (5) 18 25  43 38 Bydureon 140 29  116  22  19 53  2 50  3 - Byetta 82 (1) 53  -  15 (22) 6 14  8 60 Farxiga/Forxiga 129 n/m  78  n/m  29 n/m  8 n/m  14 n/m Legacy:Crestor 1,310 (3) 760  (1) 226 (9) 150 (4) 174 (1)Seloken/Toprol-XL 184 6  21  (28) 24 (3) 4 -  135 16 Atacand 99 (13) 7  (22) 23 (38) 8 (9) 61 4 Others 156 (4) 15  (25) 36 (13) 15 (26) 90 12 Total 2,452 4  1,218  3  462 (3) 220 (1) 552 14 CardiovascularandMetabolic DiseaseOncology:Iressa 129 (1) -  -  31 (5) 36 10  62 (4)Lynparza 21 n/m  18  n/m  3 n/m  - n/m  - n/m Legacy:Zoladex 215 14  8  60  41 (17) 71 2  95 41 Faslodex 172 9  82  (4) 52 10  13 15  25 50 Casodex 69 (5) 1  (50) 7 (18) 34 (13) 27 20 Arimidex 64 (6) 4  -  12 (25) 21 (7) 27 8 Others 37 20  7  -  7 13  16 90  7 (30)Total Oncology 707 9  120  17  153 (4) 191 4  243 20 Infection,Neuroscienceand  Gastrointestinal:Nexium 647 (27) 254  (44) 69 (14) 144 (9) 180 (16)Seroquel XR 264 (8) 184  2  50 (30) 7 (18) 23 4 Synagis 66 40  (2) n/m  68 51  - -  - n/m Losec/Prilosec 85 (9) 5  (17) 22 (15) 20 (14) 38 3 FluMist/Fluenz 14 180  14  180  - -  - -  - - Movantik/Moventig 1 n/m  1  n/m  - -  - -  - - Others 375 (11) 59  (19) 90 (18) 70 (13) 156 (2)Total Infection, 1,452 (17) 515  (28) 299 (12) 241 (10) 397 (8)Neuroscience and GastrointestinalTOTAL PRODUCT   5,836 (1) 2,356  (3) 1,261 (5) 785 -  1,434 9 SALES ASTRAZENECA DEVELOPMENT PIPELINE 30 JUNE 2015 Phase III / Pivotal Phase II / Registration NMEs and significant additional indications Submission dates shown for assets in Phase III and beyond. As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time. †    US and EU dates correspond to anticipated acceptance of the regulatory filing. #    Partnered product. +----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|  Compound   |  Mechanism   |  Area Under |  Date |  Estimated || | |Investigation   |Commenced|Filing†   || | | |Phase   | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|  US   |  EU   |  Japan  |  China   |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|Respiratory, ||Inflammation ||and Autoimmunity |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|anifrolumab# |IFN-alphaR mAb |SLE |Q3 20151 |2019 |2019 |2019 | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|benralizumab#CALIMA |IL-5R mAb |severe asthma |Q4 2013 |H2 2016 |H2 2016 |N/A |N/A ||SIROCCO ZONDA BISE | | | | | | | ||BORAGREGALE | | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|benralizumab#TERRANOVA|IL-5R mAb |COPD |Q3 2014 |2018 |2018 |N/A |N/A ||GALATHEA | | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|brodalumab |IL-17R mAb |psoriasis |Q3 2012 |2015++ |2015++ | | ||  AMAGINE-1,2,3 | | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|brodalumab AMVISION |IL-17R mAb |psoriatic |Q1 2014 |++ |++ | | ||-1,2 | |arthritis | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|lesinurad |selective uric |chronic |Q4 2011 |Filed |Filed | | ||  CLEAR 1,2 |acid |treatment of | | | | | ||  CRYSTAL |reabsorption |patients | | | | | || |inhibitor (URAT |with gout | | | | | || |-1) | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|PT003 GFF PINACLE |LABA / LAMA |COPD |Q2 2013 |Q3 2015 |H1 2016 |2017 |2017 |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|PT010   |LABA   / LAMA / |COPD |Q3 20151 |2018 |2018 |2018 |2019 || |ICS | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|tralokinumabSTRATOS |IL-13 mAb |severe asthma |Q3 2014 |2018 |2018 |2018 | ||1,2TROPOS | | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|Cardiovascular   and ||Metabolic Disease |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|Brilinta/Brilique2 |P2Y12 receptor |arterial thrombosis | |Launched |Launched |Filed |Launched|| |antagonist | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|Epanova# |omega-3 |severe | |Approved | |2017 |2019 || |carboxylic |hypertriglyceridaemia | | | | | || |acids | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|Farxiga/Forxiga3 |SGLT-2 |type-2 diabetes | |Launched |Launched |Launched|Filed || |inhibitor | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|roxadustat# OLYMPUS |hypoxia |anaemia in CKD/ESRD |Q3 2014 |2018 |N/A |N/A |H2 2016 ||ROCKIES |-inducible | | | | | | || |factor prolyl | | | | | | || |hydroxylase | | | | | | || |inhibitor | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|Oncology |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|AZD9291AURA 2,3 |EGFR tyrosine |≥2nd-line advanced |Q2 2014 |Filed   |Filed |Q3 2015 |2017 || |kinase |EGFRm T790M NSCLC | |4(Breakthrough| | | || |inhibitor | | |designation) | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|AZD9291FLAURA |EGFR tyrosine |1st-line advanced |Q1 2015 |2017 |2017 |2017 |2020 || |kinase |EGFRm NSCLC | | | | | || |inhibitor | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|Caprelsa |VEGFR / EGFR |medullary thyroid | |Launched |Launched |Filed |Filed || |tyrosine kinase|cancer | | | | | || |inhibitor with | | | | | | || |RET kinase | | | | | | || |activity | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|cediranibICON 6 |VEGFR tyrosine |PSR ovarian cancer |Q2 2007 | |Filed5(Orphan| | || |kinase | | | |  Drug) | | || |inhibitor | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|durvalumab (MEDI4736)#|PD-L1 mAb |stage III NSCLC |Q2 2014 |2017 |2020 |2020 | ||  PACIFIC | | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|durvalumab (MEDI4736)#|PD-L1 mAb |3rd-line NSCLC |Q1 2014 |H1 2016(Fast |2017 |2017 | ||  ATLANTIC¶ | | | |Track) | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|durvalumab   |PD-L1   mAb + |3rd-line   NSCLC |Q2 2015 |2017 |2017 |2017 | ||(MEDI4736)# |CTLA-4 mAb | | | | | | ||+tremelimumab | | | | | | | ||  ARCTIC | | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|durvalumab   |PD-L1   mAb |2nd-line   SCCHN (PD |Q1 2015 |H2 2016 |H2 2016 |H2 2016 | ||(MEDI4736)# | |-L1 positive) | | | | | ||  HAWK¶ | | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|durvalumab   |PD-L1   mAb + |2nd-line   SCCHN (PD |Q2 2015 |2017 |2017 |2017 | ||(MEDI4736)# |CTLA-4 mAb |-L1 negative) | | | | | ||+ tremelimumab | | | | | | | ||  CONDOR¶ | | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|moxetumomab pasudotox#|anti-CD22 |hairy cell leukaemia |Q2 2013 |2018 |2018 | | || |recombinant | | | | | | || |  immunotoxin | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|selumetinib# |MEK inhibitor |2nd-line KRASm NSCLC |Q4 2013 |2017 |2017 | | ||  SELECT-1 | | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|selumetinib# |MEK inhibitor |differentiated |Q3 2013 |2018 |2018 | | ||  ASTRA | |thyroid cancer | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|tremelimumab¶   |CTLA-4   mAb |mesothelioma |Q2 2014 |H1 2016(Orphan|H2 2016 |H2 2016 | ||DETERMINE | | | |Drug) | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|Infection, ||Neuroscience ||and Gastrointestinal |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|CAZ AVI#RECLAIM |cephalosporin/be |serious |Q1 2012 |N/A |Filed | |2017 || |ta lactamase |infections | | | | | || |inhibitor | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|CAZ AVI# REPROVE |cephalosporin/ |hospital |Q2 2013 |N/A |Filed | |2017 || |beta lactamase |-acquired | | | | | || |inhibitor |pneumonia/ | | | | | || | |ventilator | | | | | || | |-associated | | | | | || | |pneumonia | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+|Zinforo# |extended |pneumonia/skin| |N/A |Launched |N/A |Filed || |spectrum |infections | | | | | || |cephalosporin | | | | | | || |with affinity | | | | | | || |to   penicillin | | | | | | || |-binding | | | | | | || |proteins | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+| | | | | | | | | |+----------------------+---------------+---------+--------------+---------+--------------+-------------+--------+--------+ #    Partnered product. ¶    Registrational Phase II/III study. ++  Amgen recently announced the termination of its co-development and commercialisation agreement with AstraZeneca for brodalumab; AstraZeneca is proceeding with the transfer of the programme from Amgen and will communicate additional decisions in due course.     1    First patient dosed July 2015. 2    Brilinta in the US; Brilique in rest of world. 3    Farxiga in the US; Forxiga in rest of world. 4    AZD9291 filed in Q2. US regulatory submission acceptance anticipated in Q3 2015. 5    Cediranib regulatory submission accepted in Q3 2015. Phases I and II NMEs and significant additional indications +------------------+---------------+---------------+---------+---------+-------+++-+|Compound |Mechanism |Area   Under |Phase |Date |Estimated || | |Investigation | |Commenced|Filing || | | | |Phase | |+------------------+---------------+---------------+---------+---------+-------+++-+|US |EU |Japan |China |+------------------+---------------+---------------+---------+---------+-------+++-+|Respiratory, ||Inflammation and ||Autoimmunity |+------------------+---------------+---------------+---------+---------+-------+++-+|abediterol |LABA |asthma/COPD |II |Q4 2007 | ||| ||(AZD0548) | | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD7624 |inhaled P38 |COPD |II |Q4 2014 | ||| || |inhibitor | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD9412# |inhaled   |asthma/COPD |II |Q1 2010 | ||| || |interferon | | | | ||| || |beta | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|mavrilimumab# |GM-CSFR mAb |rheumatoid |II |Q1 2010 | ||| || | |arthritis | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI-551# |CD19 mAb |neuromyelitis |II |Q1 2015 | ||| || | |optica2 | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI2070# |IL-23 mAb |Crohn’s disease|II |Q1 2013 | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|abrilimumab |alpha(4)beta(7)|Crohn’s disease|II |Q4 2012 | ||| ||(MEDI7183)# |mAb |/ ulcerative | | | ||| || | |colitis | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI9929# |TSLP mAb |asthma |II |Q2   2014| ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|PT010 |LABA/LAMA/ICS |asthma |II |Q2   2014| ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|RDEA3170 |selective   |chronic |II |Q3 2013 | ||| || |uric acid |treatment of | | | ||| || |reabsorption |patients | | | ||| || |inhibitor |with   | | | ||| || |(URAT-1) |hyperuricaemia | | | ||| || | |or gout | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|sifalimumab# |IFN-alpha mAb |SLE3 |II |Q3 2008 | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|tralokinumab |IL-13 mAb |IPF |II |Q4 2012 | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|tralokinumab |IL-13 mAb |atopic |II |Q1 2015 | ||| || | |dermatitis | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD1419# |TLR9 agonist |asthma |I |Q3   2013| ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD7594 |inhaled SGRM |asthma/COPD |I |Q3 2012 | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD7986 |DPP1 |COPD |I |Q4 2014 | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD8999 |MABA |COPD |I |Q4 2013 | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI4920 |anti-CD40L-Tn3 |primary |I |Q2 2014 | ||| || |fusion |Sjögren’s | | | ||| || |protein |syndrome | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI5872# |B7RP1 mAb |SLE |I |Q4 2008 | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI7836 |IL-13 mAb-YTE |asthma |I |Q1 2015 | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|Cardiovascular ||and ||Metabolism |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD4901 |NK3 receptor |polycystic |II |Q2 2013 | ||| || |antagonist |ovarian | | | ||| || | |syndrome | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI0382 |GLP-1/glucagon |diabetes / |I |Q1 2015 | ||| || |dual |obesity | | | ||| || |agonist | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI6012 |LCAT |ACS |I |Q1 2012 | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI8111 |Rh-factor II |trauma / |I |Q1 2014 | ||| || | |bleeding | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|Oncology |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD1775# |WEE-1 inhibitor|ovarian cancer |II |Q4 2012 | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD2014 |mTOR serine/ |solid tumours |II |Q1 2013 | ||| || |threonine | | | | ||| || |kinase | | | | ||| || |inhibitor | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD4547 |FGFR tyrosine |solid tumours |II |Q4 2011 | ||| || |kinase | | | | ||| || |inhibitor | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI-551# |CD19 mAb |CLL / DLBCL |II |Q1 2012 | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI-573# |IGF mAb |metastatic |II |Q2 2012 | ||| || | |breast cancer | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|selumetinib# |MEK inhibitor |2nd-line KRAS |II |Q1 2013 | ||| || | |wt NSCLC | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD5363# |AKT kinase |breast cancer |II |Q1 2014 | ||| || |inhibitor | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|  Compound   |  Mechanism   |  Area Under |  Phase  |  Date |  Estimated|| | |Investigation  | |Commenced|Filing   || | | | |Phase   | |+------------------+---------------+---------------+---------+---------+-------+++-+|  US   |  EU   |  Japan   |  China  |+------------------+---------------+---------------+---------+---------+-------+++-+|durvalumab |PD-L1 mAb |solid tumours |II |Q3 2014 | ||| ||(MEDI4736)# | | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|durvalumab   |PD-L1   mAb + |gastric   |II |Q2 2015 | ||| ||(MEDI4736)# + |CTLA-4 |cancer | | | ||| ||tremelimumab |mAb | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|moxetumomab |anti-CD22 |pALL |II |Q3 2014 | ||| ||  pasudotox# |recombinant | | | | ||| || |immunotoxin | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|savolitinib/voliti|MET tyrosine |papillary renal|II |Q2 2014 | ||| ||nib |kinase |cell | | | ||| ||(AZD6094)# |inhibitor |carcinoma | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD3759 |EGFR tyrosine |advanced EGFRm |I |Q4 2014 | ||| || |kinase |NSCLC | | | ||| || |inhibitor | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD5312# |androgen |solid tumours |I |Q2 2014 | ||| || |receptor | | | | ||| || |inhibitor | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD6738 |ATR serine / |solid tumours |I |Q4 2013 | ||| || |threonine | | | | ||| || |kinase | | | | ||| || |inhibitor | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD8186 |PI3 kinase beta|solid tumours |I |Q2 2013 | ||| || |inhibitor | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD8835 |PI3 kinase |solid tumours |I |Q4 2014 | ||| || |alpha | | | | ||| || |inhibitor | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD9150# |STAT3 inhibitor|haematological |I |Q1 2012 | ||| || | |malignancies | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD9291 + |EGFR tyrosine |advanced EGFRm |I |Q3 2014 | ||| ||(durvalumab |kinase |NSCLC | | | ||| ||(MEDI4736)# or |inhibitor + (PD| | | | ||| ||selumetinib#   or |-L1 mAb | | | | ||| ||volitinib#)TATTON |or | | | | ||| || |MEK inhibitor | | | | ||| || |or   MET | | | | ||| || |tyrosine kinase| | | | ||| || |inhibitor) | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD9496 |selective |ER+ breast |I |Q4 2014 | ||| || |oestrogen |cancer | | | ||| || |receptor | | | | ||| || |downregulator | | | | ||| || |(SERD) | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|durvalumab |PD-L1 mAb |NSCLC |I |Q3 2014 | ||| ||(MEDI4736)# |  + (EGFR | | | | ||| ||after (AZD9291 or |tyrosine | | | | ||| ||Iressa |kinase | | | | ||| ||or (selumetinib# |inhibitor or | | | | ||| ||  |MEK | | | | ||| ||+docetaxel) or |inhibitor or | | | | ||| ||tremelimumab) |CTLA-4 | | | | ||| || |mAb) | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|durvalumab |PD-L1 mAb |solid tumours |I |Q3 2014 | ||| ||(MEDI4736)# | | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|durvalumab |PD-L1 mAb + PD |solid tumours |I |Q2 2014 | ||| ||(MEDI4736)# |-1 mAb | | | | ||| ||+ MEDI0680 | | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|durvalumab |OX40 agonist + |solid tumours |I |Q2 2015 | ||| ||(MEDI4736)# |PD-L1 | | | | ||| ||+ MEDI6383# |mAb | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|durvalumab |PD-L1 mAb + |solid tumours |I |Q3 2014 | ||| ||(MEDI4736)# |murine OX40 | | | | ||| ||+ MEDI6469# |agonist | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|durvalumab |PD-L1 mAb+ BRAF|melanoma |I |Q1 2014 | ||| ||(MEDI4736)# |inhibitor + MEK| | | | ||| ||+ dabrafenib + |inhibitor | | | | ||| ||trametinib1 | | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|Iressa + |PD-L1 mAb+ EGFR|NSCLC |I |Q2 2014 | ||| ||durvalumab |tyrosine kinase| | | | ||| ||(MEDI4736)# |inhibitor | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|durvalumab |PD-L1 mAb + |solid tumours |I |Q4 2013 | ||| ||(MEDI4736)# |CTLA-4 mAb | | | | ||| ||+ tremelimumab | | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI0562# |humanised OX40 |solid tumours |I |Q1 2015 | ||| || |agonist | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI-565# |CEA BiTE mAb |solid tumours |I |Q1 2011 | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI0639# |DLL-4 mAb |solid tumours |I |Q2 2012 | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI0680 |PD-1 mAb |solid tumours |I |Q4 2013 | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI3617# |ANG-2 mAb |solid tumours |I |Q4 2010 | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI-551# |CD19 mAb + PD-1|DLBCL |I |Q4 2014 | ||| ||+MEDI0680 |mAb | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI-551# + |CD19 mAb + CD20|haematological |I |Q2 2014 | ||| ||rituximab |mAb |malignancies | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI6383# |OX40 agonist |solid tumours |I |Q3 2014 | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI6469# |murine OX40 |solid tumours |I |Q1 2006 | ||| || |agonist | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI6469# + |murine OX40 |solid tumours |I |Q1 2015 | ||| ||rituximab |agonist + | | | | ||| || |CD20 mAb | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI6469# |murine OX40 |solid tumours |I |Q4 2014 | ||| ||+tremelimumab |agonist + | | | | ||| || |CTLA-4 mAb | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|Infection, ||Neuroscience ||and ||Gastrointestinal |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD3241 |myeloperoxidase|multiple system|II |Q2 2012 | ||| || |inhibitor |atrophy | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD3293# |beta-secretase |Alzheimer’s |II |Q4 2014 | ||| || |inhibitor |disease | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD5213 |histamine-3 |Tourette’s |II |Q4 2013 | ||| || |receptor |syndrome / | | | ||| || |antagonist |neuropathic | | | ||| || | |pain | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD5847 |oxazolidinone |tuberculosis |II |Q4 2012 | ||| || |anti | | | | ||| || |-bacterial | | | | ||| || |inhibitor | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|AZD8108 |NMDA antagonist|suicidal |I |Q4 2014 | ||| || | |ideation | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|CXL# |beta lactamase |MRSA |II |Q4 2010 | ||| || |inhibitor / | | | | ||| || |cephalosporin | | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI1814 |amyloid beta |Alzheimer’s |I |Q2 2014 | ||| || |mAb |disease | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI4893 |MAb binding to |hospital |II |Q4 2014 |(Fast  ||| || |S. |-acquired | | |Track) ||| || |aureus   toxin |pneumonia / | | | ||| || | |serious S. | | | ||| || | |aureus | | | ||| || | |infection | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI8897# |RSV mAb-YTE |passive RSV |II |Q1 2015 |(Fast  ||| || | |prophylaxis | | |Track) ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|ATM AVI# |monobactam/ |targeted |I |Q1 2015 | ||| || |beta |serious | | | ||| || |lactamase |bacterial | | | ||| || |inhibitor |infections | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI-550 |pandemic |pandemic |I |Q2 2006 | ||| || |influenza |influenza | | | ||| || |virus vaccine |prophylaxis | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI3902 |anti-Psl/PcrV |prevention of |I |Q3 2014 |(Fast  ||| || | |nosocomial | | |Track) ||| || | |pseudomonas | | | ||| || | |pneumonia | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI7510 |RSV sF+GLA-SE |prevention of |I |Q2 2014 | ||| || | |RSV disease in | | | ||| || | |older adults | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+|MEDI8852 |influenza A mAb|influenza A |I |Q1 2015 | ||| || | |treatment | | | ||| |+------------------+---------------+---------------+---------+---------+-------+++-+ #    Partnered product. 1    MedImmune-sponsored study in collaboration with Novartis. 2    Neuromyelitis optica now lead indication. Multiple sclerosis Phase I study continuing. 3    SLE project stopped but molecule under evaluation for alternative indications. Significant Life-Cycle Management +-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|  Compound   |  Mechanism  |  Area Under |  Date Commenced Phase   |  Estimated || | |Investigation   | |Filing†   |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|  US   |  EU   |  Japan   |  China  |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Respiratory, ||Inflammation and ||Autoimmunity |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Duaklir   |LAMA/LABA |COPD | |2018 |Launched|2018 |2018 ||Genuair# | | | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|SymbicortSYGMA |ICS/LABA |as needed use in |Q4 2014 |N/A |2018 | |2019 || | |mild asthma | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Symbicort1 |ICS/LABA |breath actuated | |2018 | | | || | |Inhaler asthma/COPD | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Cardiovascular ||and Metabolism |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Brilinta/Brilique|P2Y12 |outcomes study in |Q4 2012 |2017 |2017 |2017 |2018 ||2   EUCLID |receptor |patients with | | | | | || |antagonist |peripheral artery | | | | | || | |disease | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Brilinta/Brilique|P2Y12 |prevention of vaso |Q4 2014 |2020 |2020 | | ||2   HESTIA |receptor |-occlusive crises in | | | | | || |antagonist |paediatric patients | | | | | || | |with   sickle cell | | | | | || | |disease | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Brilinta/Brilique|P2Y12 |outcomes study in |Q4 2010 |Filed |Filed |Q4 2015 |2017 ||2 |receptor |patients with prior | |(Priority | | | ||  PEGASUS- |antagonist |myocardial | |Review) | | | ||  TIMI 54 | |infarction | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Brilinta/Brilique|P2Y12 |outcomes study in |Q1 2014 |H1 2016 |H1 2016 |H2 2016 |2017 ||2   SOCRATES |receptor |patients with stroke | | | | | || |antagonist |or TIA | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Brilinta/Brilique|P2Y12 |outcomes study in |Q1 2014 |2018 |2018 |2018 |2018 ||2   THEMIS |receptor |patients with type-2 | | | | | || |antagonist |diabetes and CAD, | | | | | || | |but   without a | | | | | || | |previous history of | | | | | || | |MI or stroke | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Bydureon Dual |GLP-1 |type-2 diabetes | |Launched |Launched|Approved | ||  Chamber Pen |receptor | | | | | | || |agonist | | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Bydureon EXSCEL |GLP-1 |type-2 diabetes |Q2 2010 |2018 |2018 |2018 | || |receptor |outcomes study | | | | | || |agonist | | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Bydureon weekly |GLP-1 |type-2 diabetes |Q1 2013 |Q4 2015 |Q4 2015 | | ||  suspension |receptor | | | | | | || |agonist | | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Epanova STRENGTH |omega-3 |outcomes study in |Q4 2014 |2020 |2020 |2020 |2020 || |carboxylic |statin-treated | | | | | || |acids |patients at high CV | | | | | || | |risk, with | | | | | || | |persistent   | | | | | || | |hypertriglyceridemia | | | | | || | |plus low HDL | | | | | || | |-cholesterol | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Epanova/Farxiga/F|omega-3 |Non-alcoholic fatty |Q1 2015 | | | | ||orxiga3 |carboxylic |liver disease/non | | | | | || |acids/ SGLT-2|-alcoholic | | | | | || |inhibitor |steatohepatitis   | | | | | || | |(NASH) | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Farxiga/Forxiga3 |SGLT-2 |type-2 diabetes |Q2 2013 |2020 |2020 | | ||  |inhibitor |outcomes study | | | | | ||  DECLARE- | | | | | | | ||  TIMI 58 | | | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Farxiga/Forxiga3 |SGLT-2 |type-1 diabetes |Q4 2014 |2018 |2017 |2018 | ||  |inhibitor | | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Kombiglyze |DPP-4 |type-2 diabetes | |Launched |Launched| |Filed ||XR/Komboglyze4 |inhibitor/ | | | | | | || |metformin FDC| | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Onglyza SAVOR |DPP-4 |type-2 diabetes |Q2 2010 |Filed |Launched| |Q4 2015 ||-TIMI 53 |inhibitor |outcomes study | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|saxagliptin/dapag|DPP-4 |type-2 diabetes |Q2 2012 |Filed |Filed | | ||liflozin FDC |inhibitor/ | | | | | | || |SGLT-2 | | | | | | || |inhibitor FDC| | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Xigduo |SGLT-2 |type-2 diabetes | |Launched |Launched| | ||XR/Xigduo5 |inhibitor/ | | | | | | || |metformin FDC| | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Oncology |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Caprelsa |VEGFR/EGFR tyrosine|differentiated |Q2 2013 |H1 2016 |H1 2016 |H1 2016 | || |kinase inhibitor |thyroid cancer | | | | | || |with RET kinase | | | | | | || |activity | | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|FaslodexFALCON |oestrogen receptor |1st-line |Q4 2012 |H2 2016 |H2 2016 |H2 2016 |2017 || |antagonist |hormone | | | | | || | |receptor +ve | | | | | || | |advanced | | | | | || | |breast cancer | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Iressa |EGFR   tyrosine |EGFRm NSCLC | |Approved6 |Launched |Launched|Launched|| |kinase inhibitor | | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Lynparza |PARP inhibitor |1st-line BRCAm |Q3 2013 |2017 |2017 |2017 | ||(olaparib) SOLO | |ovarian cancer | | | | | ||-1 | | | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Lynparza |PARP inhibitor |2nd-line or |Q3 2013 |H1 2016 |H1 2016 |H2 2016 | ||(olaparib) SOLO | |greater BRCAm | | | | | ||-2 | |PSR ovarian | | | | | || | |cancer, | | | | | || | |maintenance   | | | | | || | |monotherapy | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Lynparza |PARP inhibitor |gBRCA PSR |Q1 2015 |2018 | | | ||(olaparib) SOLO | |ovarian cancer | | | | | ||-3 | | | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Lynparza |PARP inhibitor |2nd-line |Q3 2013 | | |2017 | ||(olaparib) GOLD | |gastric cancer | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Lynparza |PARP inhibitor |gBRCA adjuvant |Q2 2014 |2020 |2020 |2020 | ||(olaparib) | |triple | | | | | ||OlympiA | |negative | | | | | || | |breast   | | | | | || | |cancer | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Lynparza |PARP inhibitor |gBRCA |Q2 2014 |H2 2016 |H2 2016 |H2 2016 | ||(olaparib) | |metastatic | | | | | ||OlympiAD | |breast cancer | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Lynparza |PARP inhibitor |pancreatic |Q1 2015 |2017 |2017 |2017 | ||(olaparib) POLO | |cancer | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Lynparza |PARP inhibitor |prostate |Q3 2014 | | | | ||(olaparib) | |cancer | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Infection, ||Neuroscience and ||Gastrointestinal |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Diprivan# |sedative and |conscious | |N/A |Launched |Filed |Launched|| |anaesthetic |sedation | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Entocort |glucocorticoid |Crohn’s | |Launched |Launched |Q3 |N/A || |steroid |disease / | | | |2015 | || | |ulcerative | | | | | || | |colitis | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|linaclotide# |GC-C receptor |irritable | |N/A |N/A |N/A |Q4 2015 || |peptide agonist|bowel | | | | | || | |syndrome | | | | | || | |with | | | | | || | |constipation | | | | | || | |  (IBS-C) | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Nexium |proton pump |stress ulcer | | | | |2017 || |inhibitor |prophylaxis | | | | | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+|Nexium |proton pump |paediatrics | |Launched |Launched |H2 | || |inhibitor | | | | |2016 | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+| || | | | | | || ||| |||| | |+-----------------++------------+--+---+----------------+-------------+-----------------------++---------+++------++++-------+--------+ #    Partnered product. 1    Development of a new BAI device is ongoing. 2    Brilinta in the US; Brilique in rest of world. 3    Farxiga in the US; Forxiga in rest of world. 4    Kombiglyze XR in the US; Komboglyze in the EU. 5    Xigduo XR in the US; Xigduo in the EU. 6    Approved by FDA in July 2015. Faslodex 500 mg approved in China in Q2 for the treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer (replaces 250mg dose). Terminations (discontinued projects between 1 April and 30 June 2015) +---------+------------+---------------+------------------------------------+|NME   / |Compound |Reason   for |Area   Under Investigation ||Line | |Discontinuation| ||Extension| | | |+---------+------------+---------------+------------------------------------+|NME |selumetinib#|Safety/efficacy|uveal melanoma || |SUMIT | | |+---------+------------+---------------+------------------------------------+|NME |tenapanor   |Safety/efficacy|ESRD-Pi/CKD   with T2DM || |(AZD1722)# | | |+---------+------------+---------------+------------------------------------+|LCM |Nexium |Regulatory |refractory reflux   oesphagitis (JP)|+---------+------------+---------------+------------------------------------+ Completed Projects / Divestitures +-------------+---------------------------+-------------+-----+--------+--------+++|Compound |Mechanism |Area   Under |Phase|Estimated || | |Investigation| |Filing |+-------------+---------------------------+-------------+-----+--------+--------+++|US |EU |Japan |China|+-------------+---------------------------+-------------+-----+--------+--------+++|Neuroscience |+-------------+---------------------------+-------------+-----+--------+--------+++|Movantik/Move|oral peripherally-acting mu|opioid | |Launched|Launched||||ntig#1 |-opioid receptor antagonist|-induced | | | |||| | |constipation | | | |||+-------------+---------------------------+-------------+-----+--------+--------+++ #    Partnered product. 1    Movantik in the US; Moventig in EU. Shareholder Information +--------------------------+|Announcements and Meetings|+--------------------------+ Announcement of nine months and third   quarter results 5   November 2015Announcement of full year and fourth   quarter results 4   February 2016 +---------+|Dividends|+---------+ Future dividends will normally be paid as follows:   First Announced   with half year and secondinterim quarter results and paid in September  Second Announced   with full year and fourth  interim quarter results and paid in March The record date for the first interim dividend for 2015, payable on 14 September 2015, will be 14 August 2015. Ordinary Shares listed in London and Stockholm will trade ex-dividend from 13 August 2015. American Depositary Shares listed in New York will trade ex-dividend from 12 August 2015. +-------------+|ADR Programme|+-------------+ AstraZeneca announced an intended ratio change to its NYSE-listed sponsored Level 2 American Depositary Receipt (ADR) programme on 26 June 2015. The prior ratio was one American Depositary Share (ADS) per one Ordinary Share. Effective from 27 July 2015 the new ratio became two ADSs per one Ordinary Share. There was no change to the underlying Ordinary Shares. ADS holders at the close of business New York time on the record date, 22 July 2015, received a distribution of one additional ADS for every ADS held. The new ADSs were distributed on 24 July 2015. No action was required by ADS holders to effect this change. +----------+|Trademarks|+----------+ Trademarks of the AstraZeneca group of companies and of companies other than AstraZeneca appear throughout this document in italics. AstraZeneca, the AstraZeneca logotype and the AstraZeneca symbol are all trademarks of the AstraZeneca group of companies. Trademarks of companies other than AstraZeneca that appear in this document include Daliresp, a trademark of Takeda GmbH; Duaklir Genuair, Duaklir, Eklira, Tudorza and Tudorza Pressair, trademarks of Almirall, S.A.; Epanova, a trademark of Chrysalis Pharma AG; Imbruvica, a trademark of Pharmacyclics, Inc.; Zinforo, a trademark of Forest Laboratories; Zydelig, a trademark of GILEAD SCIENCES IRELAND UC; and Zytiga, a trademark of Johnson & Johnson. +----------------------------+|Addresses for Correspondence|+----------------------------+ Registrar   US   Registered   Swedish   CentralandTransfer   DepositaryCitibank   Office2 SecuritiesOfficeEquiniti Shareholder Kingdom DepositoryEuroclear  LimitedAspect ServicesPO Box StreetLondonW2 Sweden ABPO Box 191SE 43077ProvidenceRI 6BDUK -101  HouseSpencer 02940 23 StockholmSweden  RoadLancingWe -3077USAst SussexBN996DAUKTel   Tel: +44 (0)207 500 Tel: +44 (0)20 Tel: +46 (0)8 402 9000(freephone in 2030or +1 877 248 7604 8000UK): 4237  0800 389 (1 877-CITI-ADR)/E1580Tel   -mail:(outside UK): citiadr@citi.com  +44 (0)121415 7033 +------------------------------------------------------------+|Cautionary Statements Regarding Forward-Looking   Statements|+------------------------------------------------------------+ In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and AstraZeneca undertakes no obligation to update these forward-looking statements. We identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things: the loss or expiration of, or limitations to, patents, marketing exclusivity or trademarks, or the risk of failure to obtain and enforce patent protection; the risk of substantial adverse litigation/government investigation claims and insufficient insurance coverage; effects of patent litigation in respect of IP rights; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the risk that strategic alliances and acquisitions, including licensing and collaborations, will be unsuccessful; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any delays in the manufacturing, distribution and sale of any of our products; the impact of any failure by third parties to supply materials or services; the risk of failure of outsourcing; the risks associated with manufacturing biologics; the risk of delay to new product launches; the difficulties of obtaining and maintaining regulatory approvals for products; the risk of failure to adhere to applicable laws, rules and regulations; the risk of failure to adhere to applicable laws, rules and regulations relating to anti-competitive behaviour; the risk that new products do not perform as we expect; failure to achieve strategic priorities or to meet targets or expectations; the risk of an adverse impact of a sustained economic downturn; political and socio-economic conditions; the risk of environmental liabilities; the risk of occupational health and safety liabilities; the risk associated with pensions liabilities; the risk of misuse of social medial platforms and new technology; the risks associated with developing our business in emerging markets; the risk of illegal trade in our products; the risks from pressures resulting from generic competition; the risk of failure to successfully implement planned cost reduction measures through productivity initiatives and restructuring programmes; economic, regulatory and political pressures to limit or reduce the cost of our products; the risk that regulatory approval processes for biosimilars could have an adverse effect on future commercial prospects; the impact of failing to attract and retain key personnel and to successfully engage with our employees; the impact of increasing implementation and enforcement of more stringent anti-bribery and anti-corruption legislation; and the risk of failure of information technology and cybercrime. Nothing in this presentation / webcast should be construed as a profit forecast.

Goodspeed mobile Wi-Fi adds 12 new countries to its roaming-free zone

Uros (http://uros.com/?utm_source=press_release&utm_medium=cision&utm_campaign=12_vodafone_countries) today announces it has added 12 new countries to its Goodspeed mobile internet (https://goodspeed.io/?utm_source=press_release&utm_medium=cision&utm_campaign=12_vodafone_countries) service coverage. The service that offers affordable mobile data helping companies overcome their connectivity challenges now covers the majority of the globe and enhances its presence in Africa in particular. This announcement follows a recent partnership with Vodafone to increase the Goodspeed mobile Wi-Fi footprint. The first stage of the agreement has now been implemented with 12 new destinations available on Goodspeed; Albania, Malta, Romania, Turkey, Democratic Republic of the Congo, Ghana, Kenya, Lesotho, Mozambique, South Africa, Tanzania and New Zealand. In the new African destinations and New Zealand, Goodspeed users can now consume up to 500 MB of data a day for a flat rate of £8.20 (or $13.99), and in the new European destinations for £4.90 (or $7.99). Goodspeed’s fixed and affordable fees guarantee predictable mobile data costs for companies whose mobile employees depend on a data connection to stay productive when travelling. The secure personal Wi-Fi connection also ensures the company data is kept inside the business even when the staff is on the go. Tommi Uhari, CEO of Uros, comments: “By enhancing Goodspeed’s offering on such a large scale it is a huge acceleration in our campaign to put an end to mobile connectivity issues. I’m especially excited that we can now offer our service in large parts of Africa which is the fastest growing mobile market in the world, and where roaming fees have been checkered.” The service is enabled by the Goodspeed hotspot, which can accommodate and switch automatically between ten SIM cards. The device and destination SIM cards can be purchased from goodspeed.io (https://goodspeed.io/?utm_source=press_release&utm_medium=cision&utm_campaign=12_vodafone_countries) and through Goodspeed direct sales channels, including Business Sales and official Goodspeed distributors before travelling.

Enea signs 3 MEUR service deal with a global telecom company

STOCKHOLM, Sweden, July 30, 2015. Enea (NASDAQ OMX Nordic: ENEA) has signed a new service agreement with a leading telecom company valued at 3 MEUR over a period of 3 years. The customer, who is a global telecom provider has selected Enea as vendor based on Enea’s capabilities to deliver best services in automated and manual testing solutions. Enea’s Professional Services team, located in Romania, has delivered high quality services during a long relation lasting for more than 10 years, which have positioned them as main vendor for customers’ testing and acceptance division. They have provided this customer with a complex services package over a large range of technologies including specialized engineering expertise, flexible delivery models and the strength of onsite program management. “We have a good relationship with this customer since many years back. I am glad to see that the customer selected Enea based on our capabilities to deliver best services in automated and manual testing solutions which requires personnel with specialized engineering expertise.” said Anders Lidbeck, President and CEO for Enea.” This information is such that Enea AB (publ) is to publish in accordance with the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication on July 30, 2015 at 10.30 CET. For more information visit www.enea.com/investors or contact: Anders Lidbeck, President & CEOE-mail: anders.lidbeck@enea.com Sofie Sarhed, Investor RelationsPhone: +46 70 971 40 05E-mail: sofie.sarhed@enea.com About Enea Enea is a global supplier of Linux and real-time operating system solutions, including middleware, tools, databases, and world class services, with a vision to enable communication everywhere. As a trusted and respected player in the embedded software eco system, Enea has for more than four decades delivered value and helped customers develop and maintain ground-breaking products. Every day, more than three billion people around the globe rely on Enea’s technologies in a wide range of applications in multiple verticals – from Telecom and Automotive, to Medical and Avionics. Enea has offices in Europe, North America and Asia, and is listed on NASDAQ OMX Nordic Exchange Stockholm AB. For more information please visit www.enea.com or contact us at info@enea.com Enea®, Enea OSE®, Netbricks®, Polyhedra® and Zealcore® are registered trademarks of Enea AB and its subsidiaries. Enea OSE®ck, Enea OSE® Epsilon, Enea® Element, Enea® Optima, Enea® Optima Log Analyzer, Enea® Black Box Recorder, Enea® LINX, Enea® Accelerator, Polyhedra® Lite, Enea® dSPEED Platform, Enea® System Manager and Embedded for Leaders(TM) are unregistered trademarks of Enea AB or its subsidiaries. Any other company, product or service names mentioned above are the registered or unregistered trademarks of their respective owner. © Enea AB 2015.

UN Report Warns Borneo’s Orangutans Face Severe Threats from Land Cover and Climate Change

Over 80 percent of the orangutan’s remaining habitat in Borneo could be lost by the year 2080 if the island’s current land-use policies remain intact, according to a new United Nations report led by Liverpool John Moores University’s Professor Serge Wich. The Future of the Bornean Orangutan: Impacts of Change in Land Cover and Climate (download (http://www.unep.org/pdf/Borneo-Report-Executive-Summary.pdf)), which was published by the United Nations Environment Programme (UNEP) and Liverpool John Moores University, in collaboration with the Great Apes Survival Partnership (GRASP), states that the massive conversion of Borneo’s forests for agricultural development – primarily oil palm – will leave the endangered orangutans fragmented and facing extinction in a number of areas. In addition, the environmental impact of climate change exacerbated by the deforestation of Borneo could result in severe floods, temperature rises, reduced agricultural productivity and other negative effects. The report was presented at the GRASP Regional Meeting – Southeast Asia, held on Borneo in Kota Kinabalu, Malaysia. “The current policies for land conversion on Borneo are simply unsustainable,” said Professor Serge Wich. “Our models show that the effects will worsen over time, leading to greater and greater loss of suitable land, not just for orangutans, but for the human population as well.” Borneo is Asia’s largest island and is jointly ruled by three nations: Malaysia and Brunei in the north, and Indonesia in the south. Borneo’s deforestation rate has been among the world’s highest for over two decades, and 56 percent of the protected tropical lowland forests – an area roughly the size of Belgium – was lost between 1985 and 2001. The Future of the Bornean Orangutan uses different climate and land-cover scenarios for the years 2020, 2050 and 2080 and models the individual and combined effect of both factors on the orangutan habitat. In each, dramatic rises in temperature brought on by deforestation and the loss of land cover cause serious damage to the island’s biodiversity, with the combined model showing an even more pronounced impact than either factor alone. UNEP Executive Director Achim Steiner urged adoption of programmes that measure the natural capital of a region and offer payment for ecosystem services to mitigate these threats. “Now, it is time to utilize these approaches and divert from an unsustainable pathway to development,” he wrote in the report’s foreword. “It is clear that a future without sustainable development will be a future with a different climate and, eventually, without orangutans, one of our closest relatives.” An estimated 55,000 Bornean orangutans remain in the wild, split into three distinct subspecies. But orangutans’ solitary nature and slow reproductive rates leave them particularly vulnerable to forest loss. Models incorporating projected changes to climate and to land cover indicate that 68-81% of the current orangutan habitat might be lost by 2080. Among the report’s recommendations to curb the impact of agricultural conversion are: 1.) Immediate identification and protection of priority orangutan populations and habitats, 2.) Connection of key orangutan sites through the creation of corridors, so as to ensure the species’ mobility and viability, 3.) conversion to more sustainable methods of agricultural use for palm oil and other crops, and 4.) support for REDD+ and other forest protection programmes. Report: The Future of the Bornean Orangutan: Impacts of Change in Land Cover and Climate (download (http://www.unep.org/pdf/Borneo-Report-Executive-Summary.pdf)) Watch the Borneo report book launch in Kota Kninabalu during the GRASP regional meeting https://www.youtube.com/watch?v=IvoIFZ6_dXs Interview contact details:  Professor Serge Wich   s.a.wich@ljmu.ac.uk  

Neal’s Yard Holidays Has Christmas All Wrapped up with Festive Wellness Retreats

For the health conscious in search of an energising end to 2015 and an invigorating start to 2016, a Neal’s Yard Holidays retreat (http://www.nealsyardholidays.com/Activity/view/christmas-new-year-retreats) is just what the doctor ordered. Holistic and hand-picked, a festive selection of Christmas and New Year getaways are available to book now, replacing seasonal debauchery with rest and revitalisation in beautiful spots around the world. Available at a range of locations, each retreat includes leading wellness experts and life coaching, all set to fabulous surroundings. With over 23 years experience handpicking yoga getaways, health detox retreats and wellbeing escapes across the globe, Neal’s Yard Holidays has an in-depth understanding of what makes a retreat shine. In the lead up to the festive season the team of health and wellness experts has curated a collection of Christmas and New Year breaks that will have guests feeling nurtured, nourished and wonderfully rebalanced.  “The festive season is typically a fun and busy time however for the mind, body and spirit it can also be incredibly stressful. To help our clients enjoy the winter months with utter calmness and composure, we’ve cherry picked a selection of retreats that replace Christmas chaos with peace, tranquillity and a restored sense of wellness,” says Ulrike Spire, director of Neal’s Yard Holidays. For those in search of South East English sun, three and four night Sussex Yoga, Detox and Relaxation Breaks (http://www.nealsyardholidays.com/Holiday/view/yoga-detox-and-relaxation-breaks-in-sussex-uk) are guaranteed to have guests glowing. Held in the market town of Arundel, the Raw Horizons programme is run by leading international wellness expert and life coach, Claudia Jones. The transforming experiences are designed to create inner harmony, build self-esteem, pinpoint paths to happiness, enrich the soul and rejuvenate the body. At just a one and a half hour train trip from London and a fifty minute ride from Gatwick airport, the Sussex Downs retreat is perfectly positioned for locals and South East visitors alike. Also featured from Raw Horizons are two or five night North Yorkshire retreats (http://www.nealsyardholidays.com/Holiday/view/yoga-detox-and-relaxation-breaks-in-north-yorkshire-uk) with Dr Claire Maguire. Combining yoga and meditation with the energy of wholesome food and powerful life coaching, the retreats gift guests with the opportunity to relax, transform and revitalize to create life changing results. Those wanting to swap egg nog for Om will love the two night AdventureYogi retreat held in Oxfordshire. Guests are put up in a beautiful manor house where they’ll enjoy nourishing meals and sumptuous surrounds accompanied by twice daily yoga, meditation and massage sessions.  For Brits wanting to escape the chilly winter weather Spanish Yoga and Pilates retreats (http://www.nealsyardholidays.com/Holiday/view/yoga-pilates-and-surf-holidays-on-fuerteventura-spain) from Azul Wellbeing are the perfect pick-me-up. With a backdrop of dramatic volcanos and stunning sandy beaches, sun-drenched Fuerteventura is an idyllic location to enjoy organic food, holistic therapies, Ayurvedic consultations and of course, daily surf sessions. The wellbeing gurus at Azul also offer rejuvenating weeklong beach yoga retreats featuring intimate class sizes, world-class instruction and invigorating massage treatments that will have guests heading back home with a sun kissed summer glow.   To find out more about the Christmas and New Year retreats offered by Neal’s Yard Holidays, visit: http://www.nealsyardholidays.com/

New Director appointments at recently expanded GoldMoney

GoldMoney promotes two new Jersey Directors following its acquisition by BitGold Canada. The new roles come as the completed acquisition sets the framework for the first global, full-reserve and gold-based financial services business. Katy Millington has been appointed Director of GoldMoney’s Jersey-based entities and General Counsel of GoldMoney Group, which includes both the BitGold and GoldMoney subsidiaries respectively. Previously, Katy held the role of Legal Counsel and Head of Compliance for GoldMoney,  since she joined the company in 2013. Prior to this she was an Associate with Collas Crill, Jersey, and Steptoe & Johnson LLP’s London office, where she worked within the dispute resolution & regulatory teams. Katy says the new GoldMoney Group is good for customers, Jersey and staff, “The acquisition by BitGold allows us to continue serving our valued clients while benefitting from our Canadian parent’s innovative technology. I am so excited to be a Director at this fantastic time for our business; we are currently recruiting and our development can only be a good contributor to Jersey’s global reputation as the newly enhanced company expands its international reach.” Kerry Sharman has also been appointed Director of GoldMoney’s Jersey-based entities and Head of Operations for the Jersey-based business. Kerry was formerly Head of Finance and Risk with GoldMoney, but his new role will also encompass dealing, settlements, and information technology. He has been at GoldMoney for nearly three years and came to the company with vast investment experience. “This is a dynamic industry and one which is expanding worldwide as people look for alternative methods to preserve their wealth. The timing of the BitGold deal couldn’t be better and I am really looking forward to working with the team here and our new colleagues in Canada, and taking the business forward.” Before joining GoldMoney, Kerry was a financial controller for Ashburton and Gartmore Fund Managers, and worked with UBS AG with responsibiliies including financial accounting. Roy Sebag, GoldMoney’s CEO said, “We have made these promotions from within the legacy company to provide for stability and continuity. Both Kerry and Katy have an excellent track record and I’m pleased that they will keep a steady hand on the Jersey business as we forge ahead with our joint global plans.”  


Britain’s largest energy provider, British Gas, is to fit Michelin CrossClimate tyres to its fleet of 13,000 commercial vehicles. Fleet Manager Colin Marriott tested the tyre at its launch event in Geneva, comparing the new technology to Michelin’s summer and winter ranges as well as some competitors’ all-season tyres. He says: “I was impressed by the performance of the CrossClimate tyres. On dry roads there was absolutely no doubt they performed as well as Michelin’s summer tyres, and they outperformed the winter tyres and all-season tyres by some margin.” He adds: “It was a very easy decision for us to fit these tyres, due to the quality of the product.” British Gas will be asking OEMs to supply CrossClimate tyres on its new vehicles where possible. All replacement tyres will be fitted by ATS Euromaster, which has already hailed the tyre as a ‘true game-changer’ for the UK fleet sector. The CrossClimate offers the benefits of a summer tyre for dry or wet braking, total mileage and energy efficiency, while also boasting the traction and braking performance of a winter tyre on cold and snow-covered roads – making it perfect for the UK’s often unpredictable weather. After being evaluated by three independent European testing organisations – TÜV SÜD, Dekra Test Centre and UTAC CERAM –­ the CrossClimate tyre has obtained Three Peak Mountain Snow Flake (3PMSF) approval, meaning it can be used in countries that require special winter equipment at clearly defined times of the year. The tyre has also earned the top ‘A’ rating for wet braking on European tyre labels and ‘C’ for rolling resistance, with a noise rating of 68 decibels. With a V-shaped tread and self-blocking 3D sipes, the tyre is designed to optimise traction in snow. Described as a “claw” effect, the vertical and lateral waves of the sipes give the tread blocks greater rigidity, while also benefiting longevity, steering precision and general dry road performance due to its ability to resist heat build-up. The CrossClimate tyre is currently available in 23 dimensions, covering 76% of all car and car-derived van tyres in sizes from 15 to 17 inches, with Michelin to launch additional sizes next year. Andy Fern, Michelin’s Head of Fleet, says: “By fitting CrossClimate, motorists can drive safely the entire year without needing to change tyres. CrossClimate fitments address an increasingly urgent need among business motorists to feel safer when faced with unstable, unpredictable weather.” ends About Michelin (www.michelin.co.uk) Michelin, the leading tyre company, is dedicated to sustainably improving the mobility of goods and people by manufacturing, distributing and marketing tyres for every type of vehicle. It also offers innovative business support services, digital mobility services and publishes travel guides, hotel and restaurant guides, maps and road atlases. Headquartered in Clermont-Ferrand, France, Michelin is present in 170 countries, has 112,300 employees and operates 68 production plants in 17 countries. The Group also has a Technology Centre, responsible for research and development, with operations in Europe, North America and Asia. (www.michelin.com) For further press information please contact: David Johnson, Michelin Press OfficeTel: + 44 (0) 1782 402341      Email: d.johnson@uk.michelin.com James Keeler or Andy Hemphill, Garnett Keeler PR, Inver House, 37-39 Pound Street,Carshalton, Surrey, SM5 3PGTel: +44 (0)20 8647 4467   Fax: +44 (0)20 8544 4711   E-mail: james.keeler@garnettkeeler.com / andy.hemphill@garnettkeeler.com MICHF/220/15

BioGaia’s oral health probiotic reduces Candida in the elderly

After 12 weeks of intervention with two lozenges per day of Lactobacillus reuteri Prodentis there was a statistically significant reduction of 53 per cent in the proportion of patients that had high Candida counts in both saliva and plaque in the probiotic group whereas there was no difference in the placebo group. Candida a common problemOral candidosis, or Candida-associated stomatitis, is common among the elderly and is often associated with factors such as antibiotic treatment, an impaired immune system, neglected oral hygiene and smoking. In frail elderly patients the condition may be more or less chronic or frequently recurrent and may require long-term or repeated antifungal medication with the risk of resistant strains. Furthermore, the long-term effects of antifungal drugs on the oral microbiota are unclear. ”As Candida affects a large number of our elderly population the new and positive results could make BioGaia’s oral health probiotic ProDentis an attractive alternative to conventional antifungal drugs”, says Peter Rothschild, President, BioGaia. The study was published in Journal of Dental Research (http://jdr.sagepub.com/content/early/2015/07/22/0022034515595950.abstract) 22 July 2015. Study facts are found here (http://www.biogaia.com/sites/biogaia.com/files/Study_facts_Twetman_2015.pdf). Latest press releases from BioGaia2015-06-30 Number of shares in BioGaia2015-06-24 BioGaia subsidiary IBT takes rapid steps in development of a drug for premature infants2015-06-12 BioGaia evaluates the possibility of a separate listing of Infant Bacterial Therapeutics AB BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 30 July 2015, 01:00 pm CET.

Major Partner Museums funding creates cultural jobs for the Humber Region

Funding released to the Humber Museums Partnership as part of Arts Council England’s Major Partner Museums programme is helping to create seventeen new roles for the Humber region. The seventeen roles, spread across different projects at the Ferens Art Gallery, Wilberforce House Museum, Hull Maritime Museum, The Treasure House in Beverley, The North Lincolnshire Museum and Normanby Hall in North Lincolnshire, will help further develop the Humber’s region’s reputation for cultural excellence in the build-up to the City of Culture in 2017. Hull, along with local authority run museums and historic houses across the East Riding of Yorkshire and North Lincolnshire, form the Humber Museums Partnership. Last year the partnership achieved Major Partner Museums status  & funding following its highly successful £1 million ‘Joining Up The Humber Museums’ initiative, which saw collaborative exhibitions, roadshows and educational projects taking place right across the Humber region. “Everyone working in the cultural sector knows that centrally-funded budgets are facing real cuts, and so those managing museums and historic collections need to look to work smartly to ensure that they continue to deliver world-class cultural experiences.  Our work as part of the Joining Up The Humber Museums Partnership demonstrated that we can do this on a region-wide scale, so we were delighted to receive the Major Partnership Museums accolade from Arts Council England.  Under the banner of the Humber Museums Partnership, this brings more funding to our region to enable continued collaboration and an even greater depth of community involvement in the stunning collections held across the region,” comments Director of Cultural Services for Hull Culture & Leisure, Simon Green. The amount to be released as part of the package is still to be confirmed, as funds available to Arts Council England will be reviewed in the coming months following the first budget of the new government.  However, funding is secure for these seventeen roles for curatorial staff and technicians for a full year, with the option to renew once the Arts Council England funding is confirmed. For more information on the roles, please search for ‘Hull’ on www.museumsjobs.com ENDS Notes to editors:  Humber Museums Partnership are one of 21 Major Partner Museums announced by Arts Council England to receive funding of £22.6 million in the year 2015/16.  For further media information or photographs, please contact: Jay Commins Pyper York Limited Tel:         01904 500698 Email:    jay@pyperyork.co.uk

Takoma Park/Silver Spring Becomes First Community College Campus in the Nation to Earn "Green Seal" Certification

Montgomery College's Takoma Park/Silver Spring Campus has been awarded Green Seal certification for cleaning services, becoming the first community college in the country to ever earn certification under the GS-42 standard for Commercial and Institutional Cleaning Services. Green Seal is the nation's premier environmental organization and the original "Green Seal of Approval.""We are so proud to have received this certification because it aligns our cleaning operations with one of our College values, sustainability," said Terrence Evelyn, director of facilities on the Takoma Park/Silver Spring Campus.Green Seal's certification process involves an in-depth review of the cleaning service's processes, procedures, and purchasing records. It also includes an on-site audit of facilities cleaned by the service. Periodic monitoring is required to maintain certification."We now recognize the significant role each custodian plays in protecting the health and well-being of the students, faculty and staff," Evelyn said. "There has been a positive change in the overall motivation and outlook of each custodian as training, environmental and procedural changes are implemented."Certification means that a cleaning service has been evaluated according to Green Seal's science-based standard, without bias or conflict of interest. Cleaning services qualifying for certification must meet environmental and health requirements for cleaning operations, cleaning techniques, waste reduction and environmentally responsible procurement, as well as requirements for communications and training. More information on the GS-42 standard can be found at this link.About Green SealThe original "Green Seal of Approval" was founded in 1989 to help safeguard the health of people and the planet. As an independent, science-based standards developer and certification body, Green Seal identifies products and services that are environmentally responsible, and provide public education for creating a more sustainable world. Call 202-872-6400 for more information, or visit www.GreenSeal.org for links to all Green Seal standards and certified products and services. About Montgomery CollegeMontgomery College is a public, open admissions community college with campuses in Germantown, Rockville, and Takoma Park/Silver Spring, plus workforce development/continuing education centers and off-site programs throughout Montgomery County, Md. The College serves nearly 60,000 students a year, through both credit and noncredit programs, in more than 130 areas of study.

WoodWing announces extensive support for new Adobe Digital Publishing Solution

 (http://www.woodwing.com/pr/WoodWing_PR_DPS_NationalTheatre_Quantas_300.jpg) At Adobe´s DPS release event in New York, Qantas in Australia and the National Theatre in London already showcased stunning apps created with Inception and DPS (click to enlarge) The digital publishing requirements of publishers and brands have continued to evolve over the past five years since the innovation of digital publishing in 2010. Key drivers for this trend include the reader´s desire for more attractive and interactive content, an ever-increasing variety of digital devices and the need to optimize the ROI in digital publishing. Rebuilt from the ground up, the new Adobe Digital Publishing Solution addresses these needs. Apps created using Adobe’s new DPS deliver high-impact, interactive content to audiences in a uniquely intuitive way. Readers get instant access to the content they want and designers maintain complete control over how the content is displayed. The apps run on smartphones and tablets using all of the major mobile operating systems: iOS, Android and Windows. In addition, Adobe expanded the tools that publishers and brands can use to create stunning content including InDesign-based workflows, as well as HTML design tools. Inception and Enterprise support the new DPS WoodWing’s recently announced cloud-based HTML5 authoring tool Inception enables publishers and brands to quickly and easily create responsive HTML5 content in an article-based approach for optimal reader-friendly presentation on any device. Once the article is designed, content providers can publish it directly via Adobe Digital Publishing Solution. Inception is currently available as a public beta (http://www.woodwing.com/en/node/4714), which includes the basic feature set. The final version is scheduled to debut around the end of the third quarter. Many publishers and brands worldwide have chosen WoodWing’s multichannel publishing system Enterprise to efficiently produce content for print, Web, tablets and smartphones, as well as social media, in one integrated Adobe InDesign-based workflow. WoodWing Enterprise has long supported the original Adobe Digital Publishing Suite, and that tradition will continue with Enterprise version 9.6’s support for the new Adobe Digital Publishing Solution. Users will be able to mix content from Enterprise and Inception in a single app. “Adobe and WoodWing have worked closely together for many years to define how publishers and brands publish their content on smartphones and tablets,” said Nick Bogaty, senior director, head of digital publishing at Adobe. “We are delighted that this fruitful cooperation continues in the context of the all-new Adobe Digital Publishing Solution.” “We see the industry is moving towards article-based publishing. The new DPS from Adobe is leading the industry with article-based publishing in mobile apps, to increase publishing frequency, shorten cycles and increase engagement. It clearly extends the range of options and the quality of results in the field of digital publishing. Users will achieve tremendous efficiency gains and their readers will benefit from the significantly higher appeal and timeliness of the content of their apps,” said the Roel-Jan Mouw, CEO of WoodWing Software. “Our solutions and tools will support our customers to further amplify these advancements and to seamlessly integrate digital publishing in their daily workflows.”

Hearthstone Communities Launches New Brand Image and Website

Woodstock, IL – Hearthstone Communities has launched a new refreshed brand image, website and messaging to create more awareness about the organization’s 100 year history in senior care and retirement living. Hearthstone enlisted Bild & Company’s marketing expertise to help them emphasize their high quality of care, dedicated close-knit family spirit and “going the extra mile” approach through original imagery and real stories.  “The Hearthstone history and stories about our stellar care and our amazing staff and residents is what makes us so unique.  Now the new brand thoroughly reflects our high quality values and services,” said Terry Eagan, President and CEO.  Originally founded a century ago as an orphanage, Hearthstone Communities is a not-for-profit, faith-based organization dedicated to providing the highest and most compassionate level of care towards seniors. Located on a 14-acre campus in Woodstock, Illinois this Continuing Care Retirement Community (CCRC) offers a home-like, neighborhood feel with a variety of senior living options that range from Independent Living to long-term nursing. It also offers a unique integrated program with children through the well-respected Hearthstone Early Learning Center. Bild & Company’s Chief Branding Officer, Jennifer Ruyle, spearheaded the rebranding project with a focus on stronger messaging and original photography of staff and residents that would connect with families looking for trusted care and compassion.  “The tagline, ‘You’ll feel at home here’ really embodies the feel of how the staff nurtures every resident and provides a family atmosphere- just like at home,” Ruyle said.  Along with a refreshed logo and tagline, the brand initiative includes a new fully mobile optimized website (http://bit.ly/hearthstone-pr ), which makes it easy for the user to find the residential lifestyle or level of care they want and learn more.  One area of the site features stories and videos showcasing the residents and staff and their experiences with Hearthstone. These real stories offer potential residents and their families’ insight into the positive experiences at the community. For questions regarding Hearthstone Communities, email Dick Hattan at hattand@hearthstonewoodstock.org or call 815-321-4028. Or contact Jennifer Ruyle with Bild & Company at jruyle@tracibild.com. ###

Consumer Reports Provides Incomplete Picture of Auto Insurance

CHICAGO, IL – The following statement by the Property Casualty Insurers Association of America (PCI) is in response to “Consumer Reports” recent study on car insurance rates. The following statement can be attributed to David Snyder, PCI’s vice president of policy development and research. “The auto insurance industry serves the driving public well by providing a highly competitive and pro-consumer marketplace that gives consumers many options to choose from. As a result, if you don’t like your quote or the cost of your insurance, you can always shop around for a better price and we encourage consumers to do so. “One of the benefits of shopping around is that if consumers have questions or concerns about how their price was determined, their agent or company can walk them through the process and discuss ways to adjust the price and coverage offerings. “It’s also important for consumers to understand that what Consumer Reports calls “socioeconomic factors” are not that at all, but rather different ways to predict the likelihood of someone having an accident or filing a claim other than just relying on state motor vehicle records which are plagued by many omissions and unreported events. For example, just think about that person that sped by you on the freeway but didn’t get pulled over, or that ticket that doesn’t go on your record because you completed an “online safe driving” course. It’s also important to note that insurance scores are a strong predictor of the likelihood of someone having an accident or filing a claim and insurers’ real-world data as well as numerous studies have repeatedly proven that. These studies also show that the vast majority of consumers benefit from the use of this kind of factor, that’s why nearly all regulators allow it in their states. “Unlike many other prices consumer pay for goods and services, auto insurance prices are heavily regulated by each state. There are laws governing insurers’ use of each underwriting and rating factor, especially credit, in determining insurance prices. Almost every state regulates to ensure that rates are not excessive, inadequate or unfairly discriminatory to protect the consumer.“Usage-based insurance is used to provide more precise information about the way people drive. It is now allowing the collection and use for pricing of actual vehicle usage data and insurers are increasingly using it. This is something that benefits consumers because prices will help measure the risk of loss. PCI would like to see Consumer Reports endorse some of the great things insurers are doing to help consumers instead of simply criticizing the industry. “It’s seem odd that Consumer Reports is criticizing one of the most pro-consumer and competitive markets – which provides dozens of choices for all drivers. Do they want to remake this market so it resembles a non-competitive one-size fits all market, which we believe would hurt consumers? “PCI welcomes the questions raised by Consumer Reports, and our highly competitive and regulated industry has nothing to hide.  We look forward to Consumer Reports reaching out to us in the future to avoid misconceptions of our industry and how we do business.” 

Tactivo follow-up order from NHS Foundation Trust

Tactivo is used for secure mobile access to healthcare systems and delivered as part of an integrated solution provided by Precise Biometrics´ partner Isosec Ltd. The Trust has chosen to expand their number of Tactivo smart card readers, enabling more staff swift and secure access to relevant patient data, reporting and information exchange on iPad devices. The solution allows care providers to spend more time with patients while ensuring instant access to patient information. This increases care quality and reduces time spent on administration. "We are pleased to see that this NHS Trust is following up on their previous order from May. This shows their confidence and commitment to Tactivo for convenient and secure mobile access to information systems and resources. The solution increases employee flexibility and efficiency, while ensuring a high level of security by utilizing two-factor authentication", says Håkan Persson, CEO of Precise Biometrics. The healthcare system is accessed through two-factor login using a smart card, Tactivo, iPad and Isosec’s mobile authentication software (MIA). For more information about secure mobility for healthcare and mobile smart card readers, please visit; http://precisebiometrics.com/smart-card-reader/healthcare-solutions/ For more information about National Health Services and Trusts in the UK, please visit; http://www.nhs.uk/NHSEngland/thenhs/about/Pages/overview.aspx About Tactivo Tactivo is a product portfolio of form-fitted smart card readers that provides convenient and secure access to restricted resources from mobile devices. Tactivo reduces workload for caregivers, increasing productivity, ensuring a more efficient way of working and allow staff to spend more time with patients. Tactivo is available for iPad, iPhone and Android.

Interim report January – June 2015

April–June, year-on-year · Gross cash collections increased 36 per cent to SEK 834m (615) · Total revenue increased 34 per cent to SEK 537m (401) · EBIT totalled SEK 161m (132) · The EBIT margin was 30 per cent (33) · Profit before tax totalled SEK 52m (56) · Portfolio acquisitions totalled SEK 665m (897) · Basic earnings per share totalled SEK 0.53 (0.79) Diluted earnings per share totalled SEK 0.51 (0.66)1) 30 June, year-on-year · The carrying value of acquired loans2) increased 22 per cent to SEK 9,040m (7,386) · Gross 120-month ERC (Estimated Remaining Collections) increased26 per cent to SEK 15,316m (12,182) · The total capital ratio improved to 15.28 per cent (12.74) · The CET1 ratio was 12.58 per cent (9.24) · Financial net amounted to an expense of SEK 109m (expense: 76) and was charged with an expense of SEK 4m (expense: 7) related to currency and interest hedges Subsequent events · Hoist Finance acquired an extensive and diversified loan portfolio on 1 July 2015 for a total investment of SEK 1,256m 1) Includes effect of 983,913 outstanding warrants. 2) Including run-off consumer loan portfolio and portfolios held in joint venture. Statement by the CEO Continued stable earnings trend and high market activity Hoist Finance continued its stable growth with a good earnings trend during the second quarter of 2015. Gross as well as net revenue from acquired loan portfolios was the highest ever, as was total revenue. EBIT was up 22 per cent year-on-year. The EBIT margin was impacted by the rise in legal collections during the quarter, particularly in the UK. This has increased costs in the short term according to plan. High market activity and the single largest acquisition to date The second quarter was primarily distinguished by high market activity with negotiations and acquisitions in multiple markets, including the acquisitions of loan portfolios in Poland, Italy and Germany. Major efforts were also focused on preparing for the significant Compello acquisition in the UK. All of these portfolios will generate revenue as of the third quarter. We are very pleased to have completed its single largest transaction to date on July 1st with the acquisition of debt management company Compello Holdings. The acquisition includes a diversified banking portfolio, comprised of over one million overdue loans from 19 financial institutions and an established collection platform with 178 employees. At 30 June 2015 the portfolio had estimated collections (ERC) of approximately SEK 2,823m over 120 months. This acquisition is highly consistent with our strategy to develop and strengthen our position in key markets. It also enables us to increase our operational capacity and thereby consolidate our market position among core banking customers in the UK. The acquisition will not give rise to any acquisition goodwill, as the entire purchase price is related to the debt portfolios. The total investment is SEK 1,256 million. Overall, Hoist Finance has thus far this year acquired portfolios valued at SEK 2.5 billion, including Compello, which is well in line with our target for 2015. A growing market The supply of non-performing consumer loans is expected to remain strong due to the growing need of many European banks to divest loan portfolios. Although the market remains competitive, we have not seen any discernible changes in pricing during the year. We have, however, seen greater pricing harmonisation between countries. Strategy for continued profitable growth In line with our successful strategy, we will continue to ensure long-term profitable growth. Our strategy is based on wide geographical presence, a focused acquisition model based on well-structured processes, and long-term instalment plans founded on fair and amicable settlements. As always, we focus on deepening our relationships with partners in existing markets and following them into new markets, while also working to strengthen our position as a permanent work-out unit for the largest international banks. We also actively evaluate various opportunities to enter new European markets. Another important component of Hoist Finance’s strategy is to have well-diversified financing through deposits from the public as well as the bond market. Hoist Finance’s capital adequacy was considerably strengthened through the new share issues conducted in 2014 and in conjunction with the IPO in 2015. As a credit market company Hoist Finance is well versed in what it means to operate in a regulated environment with internal governance, risk management and control, and is thus able to meet its partners’ high standards.  Outlook With a strong financial position and over 20 years’ experience, and as leading partner to many international banks, Hoist Finance is well positioned to capitalise on the growing market. We also see good acquisition opportunities during the remainder of the year. Accordingly, our assessment is that we will achieve or exceed our indicated acquisition volumes for 2015 – ie, volumes in line with or higher than recent years. Jörgen Olsson CEO Hoist Finance AB (publ) A teleconference for investors, analysts and media will be held at 09.00 AM (CET). Jörgen Olsson, CEO and Pontus Sardal, CFO will present and comment the report. Visit our website: http://ir.hoistfinance.com/ for link to the audiocast and the presentation material. Dial-in details for the conference call: SE: +46 8 566 426 62 UK: +44 203 428 14 13 US: +1 855 831 59 44 The presentation and the report will be available on www.hoistfinance.com after the publication. For further information please contact : Anne Rhenman Eklund, Group Head of Communications and IR Hoist Finance Phone: +46 (0)8 555 177 45 The information in this interim report has been published pursuant to the Swedish Securities Market Act and/or Swedish Financial Instruments Trading Act. This information was submitted for publication on 31 July 2015 at 8.00 A.M. (CET). Hoist Finance AB (publ) (the “Company” or the “Parent”) is the parent company of the Hoist Finance group of companies (“Hoist Finance”). The Company’s wholly owned subsidiary, Hoist Kredit AB (publ) (“Hoist Kredit”) is a regulated credit market company. Hence, Hoist Finance produces financial statementsin accordance with the guidance and format set forth in the Swedish Annual Accounts Act for Credit Institutions and Securities Companies. In order to assess the operational performance of the debt purchasing and collection operations and to facilitate comparison with our competitors, Hoist Finance supplements its statutory financial statements with an operating income statement. The operating income statement is prepared based on the accounting and valuation principles used in the statutory financial statements, with no amendments or adjustments thereto.

CMS growth in the USA continues

April – June 2015Revenue for the second quarter increased to SEK 3,944 million (3,319). Organic growth was 1 percent (4) and real growth was 6 percent (14). Loomis operating income (EBITA)[1] amounted to SEK 397 million (333) and the operating margin was 10.1 percent (10.0). Income before taxes amounted to SEK 320 million (303) and income after taxes was SEK 236 million (222). Earnings per share before and after dilution amounted to SEK 3.14 (2.95). Cash flow from operating activities amounted to SEK 206 million (387), equivalent to 52 percent (116) of operating income (EBITA). January – June 2015Revenue for the first half of 2015 amounted to SEK 7,786 million (6,196). Organic growth was 2 percent (4) and real growth was 11 percent (9). Loomis operating income (EBITA)[1] amounted to SEK 741 million (575) and the operating margin was 9.5 percent (9.3). Income before taxes amounted to SEK 601 million (513) and income after taxes was SEK 442 million (373). Earnings per share before and after dilution amounted to SEK 5.87 (4.95). Cash flow from operating activities amounted to SEK 501 million (398), equivalent to 68 percent (69) of operating income (EBITA). “We have taken several steps forward over the past quarter and the CMS growth in the USA contributes strongly to the Group’s total growth. The acquisition of the retail cash handling operations from Cardtronics in the UK will positively impact growth in Europe. Our margin-enhancing activities, performed in accordance with the Loomis model, continue to yield results both in the USA and in Europe”, states Loomis President and CEO Jarl Dahlfors. [1] Earnings Before Interest, Taxes, Amortization of acquisition-related intangible fixed assets, Acquisition-related costs and revenue and Items affecting comparability. 7.31.2015 Jarl DahlforsPresident and CEOCell number: +46 70 607 20 51Email: jarl.dahlfors@loomis.com Anders HakerCFOCell number: +46 70 810 85 59Email: anders.haker@loomis.com Loomis offers secure and effective comprehensive solutions for the distribution, handling, storage and recycling of cash and other valuables. Loomis’ customers are banks, retailers and other companies. Loomis operates through an international network of around 400 branches in more than 20 countries. Loomis employs around 21,000 people and had revenue in 2014 of SEK 13.5 billion. Loomis is listed on NASDAQ OMX Stockholm Large-Cap list. Loomis AB discloses the information provided herein pursuant to the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08.00 am CEST on July 31st, 2015.

Stena Line disagrees with Commission’s decision to allow State aid for the Femern A/S undersea tunnel project

Stena Line is a provider of maritime transport links between mainland Europe and the Scandinavian Peninsula. “The existence of 9 ferry routes between 14 different ports is based on established interconnectivity needs and fair competition. The market is more than adequately served by these ferry routes. All the State’s involvement achieves is an extra 8 billion € cost for the taxpayers. A fixed undersea tunnel link between Rødby and Puttgarden supported by unjustified State aid creates an un-level playing field and distorts competition with the well-functioning ferry services which have been provided for many years. It also goes against the principle of shifting transport away from road,” says Carl-Johan Hagman, CEO Stena Line. Stena Line notes that the Commission’s Press Release does not confirm whether the payment of State aid has taken place, but simply states that if State aid is involved, the aid can be approved.  In doing so, the Commission seems to be taking an approach which is entirely out of touch with well-established case-law of the Union Courts and the practice of the European Commission, such as the Øresund Commission Decision, which confirms that public financing for commercially exploited infrastructure is subject to the State aid rules. In addition to the above, the Commission does not seem to have prescribed a timeframe for the State aid. “The idea of open-ended State aid without time limits, for a project of this magnitude, simply makes no sense. This provides the operators of the tunnel with the ability to use the State aid to dump their State-subsidised prices, thereby squeezing out competitors such as ferry operators,” Hagman said. Stena Line awaits the publication of the full Decision and will consider to challenge the Decision before the Union courts in Luxembourg. No doubt other affected operators will be doing likewise.

Notice for Nurminen Logistics Plc’s Extraordinary General Meeting

Nurminen Logistics Plc                               Stock Exchange Release 31 August 2015 at 1 p.m.    Notice is given to the shareholders of Nurminen Logistics Plc to the Extraordinary General Meeting to be held on Monday, 24 august 2015 at 1:00 p.m. at the address Satamakaari 24, 00980 Helsinki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 12:00 noon. At the Extraordinary General Meeting, the following matters will be considered: 1. Opening of the meeting 2. Calling the meeting to order 3. Election of persons to scrutinize the minutes and to supervise the counting of votes 4. Recording the legality of the meeting 5. Recording the attendance at the meeting and adoption of the list of votes 6. Resolution on the remuneration of the Chairman of the Board of Directors Shareholders of the company who represent in total approximately 65.4 % of the voting rights of the company’s shares, propose to the General Meeting that the remuneration of the Chairman of the Board will be EUR 10,000 per month plus car benefit with the maximum value of EUR 1,600 per month and telephone benefit in addition to the remuneration agreed upon in the Annual General Meeting on 7 April 2015. The compensation has been defined according to the importance of the job and its time use. The Annual General Meeting of Shareholders on 7 April 2015 resolved that for the Chairman of the Board remuneration level will be as follows: annual remuneration of EUR 40,000 and a meeting fee of EUR 1,000 per meeting for the Board and Board Committee meetings. Thus the remuneration of the Chairman of the Board would comprise of annual remuneration of EUR 40,000, monthly remuneration of EUR 11,620 and a meeting fee of EUR 1,000 per meeting. 7. Resolution on the number of members of the Board of Directors and election of members of the Board of Directors Shareholders of the company who represent in total approximately 65.4 % of the voting rights of the company’s shares, propose to the General Meeting that the number of members of the Board of Directors will be five until the end of the next Annual General Meeting and thus complementing the Board of Directors with one member. Shareholders of the company who represent in total approximately 65.4 % of the voting rights of the company’s shares, propose to the General Meeting Olli Pohjanvirta to be elected as a Board Member according to his consent and to be chosen as the Chairman of the Board of Directors. The Chairman’s duties include, in addition to managing the Board of Directors, promoting projects in line with the company’s strategy, especially in the rail transport market as well as taking care of financing and investor relations. The current Chairman of the Board of Directors Tero Kivisaari would continue as a Member of the Board of Directors. 8. Closing of the meeting Documents of the General Meeting The proposals of the shareholders and Board of Directors relating to the agenda of the Extraordinary General Meeting, as well as this notice are available on Nurminen Logistics Plc’s website at www.nurminenlogistics.com. The minutes of the meeting will be available on the above-mentioned website as no later than Monday, 7 September 2015. Instructions for the participants in the General Meeting The right to participate and registration Each shareholder, who is registered on 12 August 2015 in the shareholders’ register of the company held by Finnish Central Securities Depository Ltd., has the right to participate in the General Meeting. A shareholder, whose shares are registered on his/her personal Finnish book-entry account, is registered in the shareholders’ register of the company. A shareholder, who wants to participate in the General Meeting, shall register for the meeting no later than 19 August 2015 at 10:00 a.m. by giving a prior notice of participation. The notice must arrive at the Company by the above mentioned deadline. Such notice can be given: a) by e-mail: yhtiokokous@nurminenlogistics.comb) by telephone:+358 10 545 2132 (on working days from 9:00 a.m. to 4:00 p.m.)c) by regular mail to Nurminen Logistics Plc, Extraordinary General Meeting, Satamakaari 24, FI-00980 Helsinki, Finland. In connection with the registration, a shareholder shall notify his/her name, personal identification number, address, telephone number and the name and personal identification number of a possible assistant or proxy representative. The personal data given to Nurminen Logistics Plc is used only in connection with the General Meeting and with the processing of related registrations. Proxy representative and powers of attorney A shareholder may participate in the General Meeting and exercise his/her rights at the meeting by way of proxy representation. A proxy representative shall produce a dated proxy document or otherwise in a reliable manner demonstrate his/her right to represent the shareholder at the General Meeting. When a shareholder participates in the General Meeting by means of several proxy representatives representing the shareholder with shares at different securities accounts, the shares by which each proxy representative represents the shareholder shall be identified in connection with the registration for the General Meeting. Possible proxy documents should be delivered in originals to Nurminen Logistics Plc, AGM, Satamakaari 24, FI-00980 Helsinki, Finland, before the last date for registration. Holders of nominee registered shares A holder of nominee registered shares, who wants to participate in the General Meeting, must have been entered into the shareholders’ register of the company on the record date of the meeting, 12 August 2015. The right to participate in the General Meeting requires, in addition, that the shareholder on the basis of such shares has been registered into the temporary shareholders’ register held by Euroclear Finland Ltd. at the latest by 19 August 2015 by 10 a.m. As regards nominee registered shares this constitutes due registration for the General Meeting.A holder of nominee registered shares is advised to request necessary instructions regarding the issuing of proxy documents and registration for the General Meeting from his/her custodian bank. The account management organization of the custodian bank shall register a holder of nominee registered shares, who wants to participate in the General Meeting, to be temporarily entered into the shareholders’ register of the company as described above at the latest by the time stated above. Other instructions and information Pursuant to chapter 5, section 25 of the Companies Act, a shareholder who is present at the General Meeting has the right to request information with respect to the matters to be considered at the meeting. On the date of this notice, 31 July 2015, the total number of shares in Nurminen Logistics Plc is 14,574,410 and the total numbers of votes is 14,474,410. In Helsinki, 31 July 2015 NURMINEN LOGISTICS PLCThe Board of Directors DISTRIBUTIONNASDAQ OMX HelsinkiMajor Mediawww.nurminenlogistics.com Nurminen Logistics is a listed company established in 1886 that offers logistics services. The company provides high-quality railway transports, project transport services, special transports and forwarding and cargo handling services to its customers. The main market areas of Nurminen Logistics are Finland, Russia and its neighbouring countries.

Summer arrival for Santa Special tickets behind seasonal chill?

The reason behind this week’s unseasonably chilly weather may have been revealed by staff at the North Yorkshire Moors Railway – a cold blast from the North Pole, as Father Christmas arrived to drop off tickets for this year’s Santa Specials, which go on sale tomorrow, 1 August 2015. “As Santa’s annual global expeditions normally take place in the middle of winter, we don’t tend to feel the blast of North Pole air that he brings with him, but his arrival in the middle of summer seems to have created a temporary drop in temperature,” comments marketing manager, Danielle Ramsey.  “Holidaymakers in the region need not worry, though, as now he’s dropped off the Santa Specials tickets, he’s heading back home to supervise the elves making this year’s crop of Christmas presents, so we’re hoping that normal summer weather conditions will resume from tomorrow!” The first of the North Yorkshire Moors Railway’s Santa Specials will leave the platform just 120 days after the tickets are released for sale, and with many travellers making their Santa Special trip part of their annual festival celebrations, key services are expected to book up fast! “Every year, we hear about the nightmare before Christmas faced by parents who spend hours waiting in line to see Father Christmas in shopping centres around the country – our Santa Specials avoid all of the queuing, as children take their turn to visit his special carriage during the journey, and of course, there’s the added benefit of enjoying a comfortable ride through the autumnal colours of the North York Moors National Park,” adds Danielle.  “Indeed, from 2015, we’ll be introducing special collectors’-edition Santa Hats for all children riding on the trains – a unique souvenir of their trip!” The round trip takes around an hour, and includes delicious mince pies, warming hot drinks (and a little alcoholic tipple for grown-ups!).  Children receive a trail sheet, colouring pencils and a drink of juice, and will be given a present by Santa himself when they visit his special carriage during the journey. Services depart from Pickering on 28 and 29 November, 5, 6, 12, 13, 19 and 20 December with services at 9.45am, 11.20am, 1.40pm and 3.15pm.  Passengers can also travel from Grosmont on 28 and 29 November, 5, 12, 19, 20 and 21 December and from Whitby on 6 & 13 December.  Tickets are £16 per person.  Special Santa Trains – where some of Santa’s elves who have finished their quotas of toymaking early will be entertaining passengers en route - will also run on 21 December from Pickering and 22 December from Grosmont, priced at £20 per person.  Tickets can be booked online from 1 August 2015 at www.nymr.co.uk, or by calling 01751 472508. ENDS For further media information or photographs, please contact: Jay Commins Pyper York Limited Tel:         01904 500698 Email:    jay@pyperyork.co.uk

Major League Baseball Players Alumni Association Brings Legends for Youth Baseball Clinic Series to Chicago

Colorado Springs, Colo. – Local youth will have an opportunity to play with their big league heroes at the Major League Baseball Players Alumni Association (MLBPAA) Legends for Youth baseball clinic series on Monday, August 3rd, 2015. In partnership with the Lincoln Park Baseball Academy and Mizuno, the free clinic features former Major League Baseball players who will teach baseball skills, drills and life lessons for approximately 200 local youth. Players attending* include former All-Star Bill “Soup” Campbell and 10-year MLB veteran Dan Pasqua, as well as Gene Hiser, Tom Klawitter, Jerry Kutzler, Gordy Lund, John Martin and Jack Perconte. The clinic will take place at the Baseball Stadium at Devon and Kedzie, running from 6:00 p.m. to 8:00 p.m., located at 6404 N. Kedzie, Chicago, IL 60645. Alumni players will train at stations including pitching, catching, base running and life skills. Registration will begin at 5:30 p.m. The evening will conclude with an autograph session for children in attendance. To register for this clinic, please visit www.baseballalumni.com. Registration is required. For more information regarding the clinic, please contact Nikki Warner, Director of Communications, at (719) 477-1870, ext. 105 or visit www.baseballalumni.com. *Clinicians subject to change. About The Major League Baseball Players Alumni Association (MLBPAA) MLBPAA was founded in 1982 with the mission of promoting baseball, raising money for charity and protecting the dignity of the game through its Alumni players. The MLBPAA is headquartered in Colorado Springs, CO with a membership of more than 7,400, of which approximately 5,600 are Alumni and active players. Alumni players find the MLBPAA to be a vital tool to become involved in charity and community philanthropy. Follow @MLBPAA for Twitter updates. About Legends for Youth Clinics MLBPAA’s Legends for Youth clinics impact more than 15,000 children each year, allowing them the unique opportunity to interact with and learn from players who have left a lasting impact on the game of baseball. The MLBPAA has reached children across America and internationally in Australia, Canada, the Dominican Republic, Nicaragua, the United Kingdom and Venezuela, through the Legends for Youth clinic series. To donate to this program, visit baseballalumni.com/donate (http://www.baseballalumni.com/donate). The official hashtag of the Legends for Youth clinic series is #LFYClinic. ###

Merseyside to benefit from Police Knowledge Fund

The College of Policing, the Higher Education Funding Council for England (HEFCE) and the Home Office launched the £10m Police Knowledge Fund earlier this year to encourage collaboration between academia and police forces in order to increase evidence-based knowledge, skills and problem solving approaches within policing. Liverpool John Moores University will be working in partnership with Merseyside Police and the OPPC for Merseyside to deliver a programme entitled ‘Embedding evidence based practice in public protection and crime prevention: a multi-disciplinary partnership.’ This will run as part of the University’s new Centre for Advanced Policing Studies, due to be launched in September. The programme will focus on providing support for victims, protecting vulnerable people and maintaining public safety, with specialisms offered in child exploitation, effective crime prevention and hate crime. Research knowledge relating to cyber-crime, computer forensics and CCTV will be embedded in each of these specialisms. In addition to LJMU tutors, practitioners from Merseyside Police will be seconded on a part time basis to assist with the delivery of the 20-month-long programme. Dr Joe Yates, Director of LJMU’s School of Humanities and Social Studies, who led the funding bid for the University, commented: “As a modern civic university, LJMU continuously strives to deliver research which has a demonstrable impact on society, and this funding, secured by working in partnership with OPCC and Merseyside Police, will enable us to collectively explore new and innovative ways to respond to challenges faced in policing today. While locally focussed, the collaboratively developed project is designed to have impact nationally and internationally. By further developing expertise in computer forensics, cyber-crime and CCTV, the project aims to enhance the evidence base from which the Police can draw on for effective crime prevention and to counteract child exploitation and hate crime. Over many years LJMU has worked with the Police to develop and deliver training programmes, and this new project, and the forthcoming launch of the Centre for Advanced Policing Studies, recognises the success of our working relationship, and gives us the opportunity to enhance it further.” LJMU Vice-Chancellor, Professor Nigel Weatherill, added: “This is an excellent example of the University working in partnership with leading organisations to address key challenges we face in society and we are delighted to have received the support of the College of Policing, HEFCE and the Home Office for this innovative project.” Merseyside’s Police Commissioner Jane Kennedy said: “I am delighted that out of 72 bids, the proposal jointly submitted by LJMU, Merseyside Police and my office was successful. Merseyside Police is always striving to improve and better the service it offers to the people of Merseyside, particularly to victims of crime and vulnerable people, and this partnership is yet another example of how we are leading the way in collaboration and innovation. “The Force already has a close working relationship with LJMU, but with the help of this funding we will have the opportunity to further pool resources and knowledge in order to find new ways to prevent crime and protect our communities. This partnership will enable us to use evidence-based research to increase our knowledge and understanding of the issues our police service faces and improve our responses. I would like to congratulate everyone who worked on this bid and I look forward to seeing the results of this partnership working in the future.”

Welcome to the Annual General Meeting of shareholders of Elekta AB (publ)

NotificationShareholders who wish to attend the Meeting shall:-             be registered in the register of shareholders maintained by Euroclear Sweden AB not later than Wednesday, August 26, 2015; and-             notify the Company of their intention to attend (along with notification of the number of any representatives) no later than on Wednesday, August 26, 2015, preferably before 4:00 pm to: Internet:  www.elekta.comMail:       Elekta AB (publ)               “Annual General Meeting”               Box 7842               SE-103 98 StockholmPhone:    +46 (0) 8 402 92 80 In providing notification of attendance, shareholders must state their name/company name, national identification number/corporate registration number, address, telephone number and the registered number of shares held. Proxy, shares registered in the name of a nominee etceteraShareholders represented by proxy must issue a power-of-attorney for the representative and the original power-of-attorney should be submitted at the same time as the notification. Forms of power-of-attorney in Swedish and English are available on the company’s web site, www.elekta.com. If the power-of-attorney is issued by a legal entity, a verified copy of the registration certificate or corresponding document for the legal entity must be appended. The power-of-attorney and the registration certificate may not be older than one year. However, a longer period of validity may be specified on the power-of-attorney, although not longer than five years from the date of issue. Personal data obtained from notifications, proxies and the register of shareholders kept by Euroclear Sweden AB will be used for the necessary registration and preparation of the voting list for the Meeting. Shareholders whose shares are registered in the names of nominees must temporarily re-register the shares in their own names in the shareholders’ register maintained by Euroclear Sweden AB in order to participate in the Annual General Meeting. Such re-registration, so called voting right registration, must be completed not later than Wednesday, August 26, 2015, which means that shareholders in sufficient time prior to this date must instruct the nominee to carry out such action. The financial statements, the auditor’s report, the auditor’s statement pursuant to Chapter 8 section 54 of the Swedish Companies Act and the Board’s complete proposals for decisions in accordance with points 10 (including the Board’s reasoned statement in accordance with Chapter 18 Section 4 of the Swedish Companies Act), 18, 19 and 20 a) (including the Board’s reasoned statement in accordance with Chapter 19 Section 22 of the Swedish Companies Act), of the agenda will be available on the Company’s website, www.elekta.com, and at the Company’s head office at Kungstensgatan 18 in Stockholm as of Tuesday, August 11, 2015 and will be distributed to shareholders upon request and notification of postal address. The Nomination Committee’s proposals and reasoned statement and details of all proposed members of the Board of Directors will be available on the Company’s website from the date of issue of this notice. All of the above documentation will also be presented at the Annual General Meeting. The total number of shares in the Company amounts to 382,828,775 shares, whereof 14,250,000 shares of series A and 368,578,775 shares of series B, representing a total of 511,078,775 votes. The series A shares carries ten votes and the series B shares carries one vote. The Company holds 1,541,368 series B shares, which may not be represented at the general meeting. The information pertains to the circumstances as per the time of issuing this notice. The shareholders present at the Annual General Meeting have a right to request information regarding the matters on the agenda or the Company’s financial situation in accordance with Chapter 7 Section 32 of the Swedish Companies Act (2005:551). Agenda1.   Opening of the Meeting;2.   Election of the Chairman of the Meeting;3.   Preparation and approval of the list of shareholders entitled to vote at the Meeting;4.   Approval of the agenda;5.   Election of one or two minutes-checkers;6.   Determination of whether the Meeting has been duly convened;7.   Presentation of the Annual Report and the Auditors’ Report and the consolidated accounts and the Auditors’ Report for the Group;8.   Address by the President and Chief Executive Officer and report on the work of the Board of Directors and Committees of the Board of Directors by the Chairman of the Board;9.   Resolution concerning adoption of the balance sheet and income statement and the consolidated balance sheet and consolidated income statement;10. Resolution concerning approval of the disposition of the Company’s earnings as shown in the balance sheet adopted by the Meeting;11. Resolution concerning the discharge of the members of the Board of Directors and the President and Chief Executive Officer from personal liability;12. Report on the work of the Nomination Committee;13. Determination of the number of members and any deputy members of the Board of Directors;14. Determination of the fees to be paid to the members of the Board of Directors and the auditors;15. Election of Board members and any deputy Board members;16. Election of Auditor;17. Resolution regarding guidelines for remuneration to executive management;18. Resolution regarding     a) Performance Share Plan 2015     b) transfer of own shares in conjunction with the Performance Share Plan 2015;19. Resolution regarding     a) transfer of own shares in conjunction with the Performance Share Plan 2014     b) authorization for the Board of Directors to decide upon transfer of own shares in conjunction with the Performance Share Plan 2013 and 2014;20. Resolution regarding     a) authorization for the Board of Directors to decide upon acquisition of own shares     b) authorization for the Board of Directors to decide upon transfer of own shares;21. Appointment of the nomination committee;22. Proposed resolutions by shareholder Thorwald Arvidsson regarding:       a) amendment of section 5, paragraph 2 in the articles of association       b) removal of section 12 in the articles of association       c) instruction to the Board of Directors to write to the Government       d) instruction to the Board of Directors to establish a shareholders’ association       e) instruction to the Board of Directors regarding shareholder representatives in the Company’s Board of Directors        f) instruction to the Company’s Nomination Committee regarding the proposed candidates’ ethical standard;23. Closing of the Meeting Proposals by the Board, the Nomination Committee and individual shareholdersPoint 2 – Chairman of the MeetingThe nomination committee proposes Bertil Villard, attorney at law, as Chairman of the Meeting. Point 10 – Disposition of the Company’s earningsThe Board of Directors proposes that of the Company’s unappropriated earnings, SEK 1,971,134,244 an amount representing SEK 0.50 per share, should be distributed as dividend to the shareholders and that the remaining unappropriated earnings should be carried forward. Record day for the dividends is proposed to be Thursday, September 3, 2015. If the Meeting resolves in accordance with the proposal, payment through Euroclear Sweden AB is estimated to be made on Tuesday, September 8, 2015. Points 13 to 16 – Election of the Board of Directors and Auditor and remuneration to the Board of Directors and the AuditorsThe Nomination Committee proposes that the Board of Directors shall consist of nine (eight) members, without deputy members. It is proposed that remuneration shall be paid to the Board at a total of SEK 4,295,000 (3,710,00) of which SEK 1,075,000 (1,040,000) to the Chairman of the Board, SEK 460,000 (445,000) to each of the external members of the Board, and remuneration for committee work at a total of SEK 660,000 (unchanged), of which SEK 90,000 (unchanged) shall be paid to the Chairman of the Company’s Executive Compensation Committee and SEK 50,000 (unchanged) to any other member of said committee, SEK 200,000 (unchanged) shall be paid to the Chairman of the Company’s Audit Committee and SEK 110,000 (unchanged) to any other member of said committee. No board fees or remuneration for committee work shall be paid to members of the Board that are employed by the Company. Remuneration to the Auditor is proposed to be paid according to an approved account. The Nomination Committee proposes that each of Luciano Cattani, Laurent Leksell, Siaou-Sze Lien, Tomas Puusepp, Wolfgang Reim, Jan Secher and Birgitta Stymne Göransson are re-elected as members of the Board, and that Annika Espander Jansson and Johan Malmqvist are elected as new members of the Board, for the time until the end of the next annual general meeting in 2016. Hans Barella has declined re-election. Laurent Leksell is proposed to be re-elected Chairman of the Board. The Nomination Committee proposes that PwC, with Authorized Public Accountant Johan Engstam as auditor in charge, is elected as Auditor for the period until the end of the annual general meeting in 2016. Proposal from shareholder The shareholder Thorwald Arvidsson proposes that the directors of the Board, under no circumstances, shall be entitled to invoice their remunerations from another physical or legal person. Point 17 – Resolution regarding guidelines for remuneration to executive managementThe Board of Directors proposes that the Annual General Meeting on September 1, 2015 approve the following guidelines for remuneration and other terms of employment for the executive management of the Group. The guidelines will be valid for employment agreements entered into after the Annual General Meeting and for any changes made to existing employment agreements thereafter. It is proposed that the Board be given the ability to deviate from the below-stated guidelines in individual cases where specific reasons or requirements exist. The guidelines in the following proposal are in principle unchanged compared to the guidelines which were proposed by the Board of Directors and approved by the Annual General Meeting on August 28, 2014. GuidelinesIt is of fundamental importance to Elekta and its shareholders that the guidelines for remuneration and other terms of employment for the executives of the Group attract, motivate and retain competent employees and managers, both in the short and long-term. To achieve this goal, it is important to ensure fairness and internal equity, while maintaining market competitiveness in terms of the structure, scope and level of executive compensation within Elekta. Employment conditions for executive management should comprise a balanced mix of fixed salary, a variable salary component, annual incentive, long-term incentives, pension and other benefits, as well as notice and severance payments, where applicable. Total target cash compensationTotal target cash compensation, (fixed plus variable salary components), should be competitive in the geographic market where the executive is resident or work. The level of total target compensation should be reviewed annually to ensure that it is above market median and within the third quartile for similar positions in that market. Market medians are established with the assistance of external compensation benchmarking. Since compensation should be performance-driven, the target annual variable salary component should account for a relatively high portion of the total target compensation. Compensation componentsThe Group compensation system comprises various forms of compensation. This ensures well-balanced remuneration, thereby strengthening and underpinning short and long-term objective setting and achievement. Fixed salaryExecutive Management’s fixed salary shall be individual and based on the content and responsibility of the position, the individual’s competence and experience in relation to the role held, as well as the geography in which the position is based. Variable salaryIn addition to a fixed salary, Executive Management also has a variable salary component. The variable component is structured as a portion of the total cash remuneration package and is primarily related to the achievement of common Group financial performance goals. The Key Performance Indicators (KPIs) for variable salary components shall primarily be related to the outcome of specific financial and functional objectives within the Group compensation and benefit system. The size of the variable salary component depends on the position held and may amount to between 30 percent and 70 percent of the fixed salary for on-target performance. Performance against fixed targets and payment for results achieved are measured quarterly. Quarterly payments against variable salary components are capped at 100 percent. The goals for the variable salary component are established annually by the Board so as to sustain the business strategy and objectives. Other KPIs may be used to drive focus on non-financial objectives of particular interest. Annual incentiveFor performance related to financial goals within the variable salary plan exceeding 100 percent of the target, there is the opportunity for additional compensation called annual incentive. The annual incentive entails a potential to earn a maximum of 60 percent of the target variable salary component. Accordingly, the maximum payout level for the sum of the variable salary component and the annual incentive is capped at a 160 percent of the original target for variable compensation. The plan also contains a minimum performance level or threshold under which no variable salary or annual incentive will be paid out at all. Equity-based long-term incentive programsThe Board also uses long-term incentives to ensure alignment between shareholder interests and executive management, senior managers and other key colleagues. On an annual basis, the Board of Directors evaluates whether an equity-based long-term incentive program should be proposed to the Annual General Meeting. In order to strengthen long-term thinking in decision-making and ensure achievement of long-term objectives, while also covering situations where equity-based solutions may be inappropriate or precluded by law, the Board may also selectively decide on other types of non-equity-based long-term incentive programs. Monetary long-term incentives should only be used as remuneration in special circumstances and be in line with practice in each market. They must also require continued employment in the Group. Retention measuresIn order to ensure long-term engagement and retention of key staff in connection with the acquisition of new business, the divestment of operations or other transitional activities, an additional annual incentive with a deferred payment of 12–24 months may or may not be applied. This deferred incentive requires continued employment until an agreed future date for any payment to be made and is applied only in special and rare circumstances, which means that it is not part of any ordinary executive remuneration scheme. The deferred incentive should never exceed 50 percent of the contractual annual variable salary component and shall in other aspects comply with the Group bonus plan. PensionsWhen establishing new pension agreements, senior executives who are entitled to pension benefits should only be enrolled in defined-contribution schemes. The standard retirement age for Swedish citizens is 65 years while other executives follow the rules of their respective countries of residence. The main guideline is that the size of pension contributions be based only on the fixed salary. Certain individual adjustments may occur based on local market practice. Other benefitsBenefits such as company cars and health, medical and sickness-related insurance schemes, should be of a more limited value compared with other items of the compensation package and in line with the market practice for the respective geographic market. Notice periods and severance agreementsPeriods of notice in Elekta follow local labor legislative requirements in the geographies in which they are based. Senior executives generally have notice periods of between 6 and 12 months. In the event of a material change of control, the President and CEO shall have the right to terminate the employment with 6 months’ notice within 120 days, and the President and CEO shall be entitled to severance payment equal to 12 months employment including all employment benefits except for annual incentives and company car. Severance agreements entitling executives to lump sum payments will in principle not be signed. Preparation and decision processDuring the year, Elekta’s Executive Compensation & Capability Committee (ECCC) provided the Board with recommendations regarding principles for formulating the Group’s remuneration system and remuneration of senior executives and senior managers. The recommendations covered formulation of the bonus system, distribution between fixed and variable remuneration and the size of any salary increases. The ECCC also proposed criteria for assessing the performance of senior executives and senior managers. Any decisions on remuneration for the CEO have been taken by the Board in its entirety. The Board has discussed the proposals from the ECCC and its motion to the Annual General Meeting is based on the recommendation submitted. Elekta’s ECCC comprises the Chairman of the Board and three independent Board members. The President and CEO attend the committee’s meetings. The Group Vice President Human Resources acts as the ECCC secretary. Point 18 a) – Resolution on a Performance Share Plan 2015Performance Share Plan 2015 (“PSP 2015”) including the Board of Directors’ proposal for resolutions on implementation of a performance share plan and transfer of treasury shares. BackgroundLong-term variable compensation is an integral part of Elekta’s remuneration strategy and Elekta has, for a number of years, resolved on a long-term incentive program in the form of a performance-based share program for key employees within the Elekta Group. The Board of Directors has carried out a review of the Performance Share Plan 2014 (“PSP 2014”) in order to ensure that it continues to meet its stated objectives, i.e. to create involvement by key employees regarding possibilities and risk in the Company’s development and to ensure that they share the objective to generate profitable growth. It was also intended to motivate key employees to continued employment in the Group. The completed review resulted in the conclusion that there is a need to implement a long-term incentive plan also this year. The long-term incentive program proposed by the Board of Directors to be implemented during 2015, relating to the financial years 2015-2017 and that may result in so-called performance shares being received during 2018, i.e. PSP 2015, is further described below. The PSP 2015 is limited to the President and CEO and Executive Management, in total eleven (11) employees including the President and CEO. The purpose of the PSP 2015 is to encourage and improve long-term value creation in alignment with shareholders’ interests, the Company’s business strategy and financial targets as well as to focus on restoring lost shareholder value. Main changes compared to the Performance Share Plan 2014In order to strengthen the link to long-term company performance, as well as to simplify and to align the program with market trends, the following main changes are proposed to the PSP 2015 as compared to the PSP 2014:•                     the employee group eligible for participation in the PSP 2015 has been limited to the President and CEO and Executive Management of the Company;•                     an EPS (Earnings Per Share) target is introduced instead of the Group Business Volume and EBITA targets in order to more closely align the management and shareholders’ interests. In addition, a three year performance period is introduced for the EPS target in order to focus on long-term Group performance, whereas the performance period for the pervious targets was measured and earned out by one-third each financial year during the performance period. Proposal for a Performance Share Plan 2015The Board of Directors proposes that the Annual General Meeting resolves on the implementation of the PSP 2015. In order to implement the PSP 2015, the Board of Directors proposes that no more than in total 475,000 series B shares in Elekta may be used in the PSP 2015 to be transferred to employees in the Elekta Group and, that up to 30 per cent of these shares may be sold on Nasdaq Stockholm in order to cover, inter alia, social contribution costs. The Board of Directors proposes that the Annual General Meeting resolves in accordance with the proposals set out below. Implementation of the Performance Share Plan 2015The PSP 2015 shall be offered to individuals with most impact on long-term company performance; i.e. the President and CEO and Executive Management, all in all eleven (11) employees. The Board of Directors will determine a maximum value for the PSP 2015 per individual denominated in SEK. The maximum value for the President and CEO is the same as in the PSP 2014 and amounts to SEK 2,700,000, and for other members of the Group Management to SEK 1,350,000 respectively. The total sum of the maximum value for all participants in the PSP 2015 will not exceed SEK 16,200,000 excluding social contribution costs. Each participant’s maximum value shall be converted into a number of shares, based on the average closing share price of the Elekta series B share on Nasdaq Stockholm during a period of ten trading days before the day the participants are offered to participate in the program. The total number of shares that are covered by the PSP 2015 and all shares covered by outstanding incentive programs, will not exceed five (5) per cent of the total number of outstanding shares in the Company. Participants in the PSP 2015 will be granted a conditional award over performance shares, which is a right to receive a specific number of such shares at a future date, provided the relevant conditions are met. The total number of shares that can be received is dependent on the degree of fulfilment of one financial target, EPS Growth over the 3-year Performance Period. The Board of Directors establishes the minimum and maximum level for the performance target. For the PSP 2015, the 2015 PSP award will vest if the compound annual growth rate of EPS is between 32 per cent and 41 per cent comparing 2017 financial results to 2014. The performance target shall be adjusted at the occurrence of events affecting the number of outstanding shares in the Company, or unforeseen material events affecting the Elekta Group´s operations or otherwise affecting the performance targets and deemed relevant by the Board of Directors. Should the Company decide on changes to the company’s accounting principles or decide on restructuring costs the Board may decide on changes to the PSP 2015 performance targets. The receipt of shares normally requires that the persons covered by the PSP 2015 are employed in the Elekta Group. If all conditions included in the PSP 2015 are met, receipt of shares shall be made free of charge three years after an agreement has been entered into and following approval by the Board of Directors. Before the number of shares to be received are finally determined, the Board of Directors shall examine whether the allotment is reasonable considering the Company’s financial results and position, conditions on the stock market and other circumstances, and if not, as determined by the Board of Directors, reduce the number of shares to be allotted to the lower number of shares deemed appropriate by the Board of Directors. The participants shall not provide any consideration for their rights under the program. Participants shall at receipt of shares receive cash compensation for any cash dividend paid out for the three financial years 2015-2017. The number of shares included in the proposal may be recalculated by the Board of Directors due to changes in the capital structure, such as a bonus issue, a consolidation or a split of shares, new issue or reduction of the share capital or similar measures. The Board of Directors, or a committee established by the Board for this purpose, will be responsible for the detailed drafting and management of the PSP 2015, within the scope of the principal conditions and guidelines as specified. The Board of Directors shall thereupon be entitled to make adjustments to meet specific rules or market conditions abroad. The Board shall also be entitled to make other adjustments provided that there are substantial changes in the Elekta Group or its business environment which would signify that conditions for allocation in accordance with the PSP 2015 are no longer appropriate. Participation in the PSP 2015 assumes that such participation is legally possible and suitable and that the administrative costs and financial efforts are reasonable in the opinion of the Board of Directors. In order to reduce the economic risk upon the increase of the share price during the term of the performance shares and in order to secure the ability to deliver shares, Elekta intends to acquire and transfer own shares in accordance with points 20 a) and 18 b). Costs of Performance Share Plan 2015Assuming maximum allotment under the PSP 2015 and a share price of SEK 50, a maximum of 421,200 series B shares are required to fulfil commitments under the program (including social security costs), corresponding to approximately 0.11 per cent of the total number of outstanding shares. The number of shares covered by existing and outstanding incentive programs amounts to 1,742,714 shares, corresponding to approximately 0.46 per cent of the total number of outstanding shares. Assuming maximum allotment of shares under the PSP 2015 and a share price of SEK 50, the costs, including social security costs and the financing cost for repurchased own shares, are estimated at approximately SEK 21,060,000. Hedging actionsIn order to secure delivery under the PSP 2015, the Board of Directors proposes under point 18 b), that no more than 475,000 series B shares may be transferred to employees in the Elekta Group and, moreover that a portion of the shares also may be transferred at Nasdaq Stockholm in order to cover inter alia social contribution costs. If the proposal to transfer repurchased shares to program participants would not be approved by the Annual General Meeting, the Board of Directors will consider other means to meet the delivery undertakings under the PSP 2015. Preparation of the proposalThe proposal has been prepared by the company’s Executive Compensation Committee in consultation with the Board. The resolution to propose the PSP 2015 to the Annual General Meeting has been taken by the Board of Directors. Outstanding incentive programs in ElektaFor a description of Elekta’s on-going share related incentive programs reference is made to note 5 in Elekta’s annual report for 2014/2015. Majority requirementA valid resolution in respect of the Board of Directors’ proposal at a general meeting requires that the resolution be supported by shareholders with more than half of the votes cast or, in the event of a tied vote, through the chairman exercising his casting vote. Point 18 b) – Resolution regarding transfer of own shares in conjunction with the Performance Share Plan 2015The Board proposes that the Meeting resolves on transfer of own shares in the Company and authorization for the Board as a result of the Performance Share Plan 2015 on the following terms.i)        No more than 475,000 shares of series B can be transferred with deviation from the shareholders’ preferential rights.ii)       Right to acquire shares shall be granted to such individuals within the Elekta group covered by the terms and conditions for the Performance Share Plan 2015. Further, subsidiaries within the Elekta group shall have the right to acquire shares free of consideration and such subsidiaries shall be obligated to immediately transfer free of consideration shares to their employees covered by the terms of the Performance Share Plan 2015.iii)      The employee shall have the right to receive shares during the period when the employee is entitled to receive shares in accordance with the terms of the Performance Share Plan 2015.iv)      Employees covered by the terms of the Performance Share Plan 2015 shall subject to certain conditions, receive shares of series B free of consideration.v)      The Board is authorized, during the period until the next Annual General Meeting to decide, on one or more occasions, to transfer no more than 142,500 shares on Nasdaq Stockholm, in order to cover certain payment, mainly social security payment. The transfer may be executed by waiving the shareholders’ preferential rights and at a price within the so-called spread (see above) at the time of the decision regarding the transfer and in accordance with the rules of Nasdaq Stockholm at any given time. The reasons for deviation from the shareholders’ preferential rights and the base for determination of the transfer price are as follows. The base for determination of the transfer prices is evident from the Board’s proposal under the relevant heading above. The transfer of own shares forms part of the implementation of the Performance Share Plan 2015. The Board considers it an advantage for the Company and its shareholders that the employees are shareholders in the Company. In order for the Meeting’s resolution in accordance with the proposal under this point 18 b) to be valid, shareholders representing at least nine tenths of the votes cast as well as the shares represented at the meeting must be in favor of the proposal. Point 19 a) – Resolution regarding the transfer of own shares in conjunction with the Performance Share Plan 2014The Annual General Meeting 2014 did not approve the Board’s proposal regarding transfer of own shares in conjunction with the Performance Share Plan 2014, despite that the Annual General Meeting previously approved the plan itself. The Board, however, believes that this is the most cost efficient way to fulfill the company’s obligations, and thus therefor proposes again that the Meeting resolves on transfer of own shares in the Company and authorization for the Board as a result of Performance Share Plan 2014 on the following terms.i)        No more than 1,139,600 shares of series B can be transferred with deviation from the shareholders’ preferential rights.ii)       Right to acquire shares shall be granted to such individuals within the Elekta group covered by the terms and conditions for the Performance Share Plan 2014. Further, subsidiaries within the Elekta group shall have the right to acquire shares free of consideration and such subsidiaries shall be obligated to immediately transfer free of consideration shares to their employees covered by the terms of the Performance Share Plan 2014.iii)      The employee shall have the right to receive shares during the period when the employee is entitled to receive shares in accordance with the terms of the Performance Share Plan 2014.iv)      Employees covered by the terms of the Performance Share Plan 2014 shall subject to certain conditions, receive shares of series B free of consideration.The Board has set the targets for the 2014 Performance Share Plan as follows. Under the 2014 Performance Share Plan, the targets are set annually and are measured and earned by one-third each financial year during the financial year 2014/2015 until financial year 2016/2017. The targets for the 2015/2016 financial year are disclosed in the table below: The reasons for deviation from the shareholders’ preferential rights and the base for determination of the transfer price are as follows. The transfer of own shares forms part of the implementation of the Performance Share Plan 2014 that was resolved upon at last year’s Annual General Meeting. The Board considers it an advantage for the Company and its shareholders that the employees are shareholders in the Company. In order for the Meeting’s resolution in accordance with the proposal under this point 19 a) to be valid, shareholders representing at least nine tenths of the votes cast as well as the shares represented at the meeting must be in favor of the proposal. Point 19 b) – Resolution regarding authorization for the Board to decide upon the transfer of own shares in conjunction with the Performance Share Plan 2013 and 2014The Board proposes that the Meeting authorize the Board during the period until the next Annual General Meeting to decide, on one or more occasions, on the transfer of not more than 286,800 shares on Nasdaq Stockholm, with reference to the Performance Share Plan 2013 and 2014, to cover certain expenditures, mainly social security contributions. Transfers may be executed at a price that is within the so-called spread (see above) at the time of the decision regarding the transfer and in accordance with the rules of Nasdaq Stockholm at any given time. The resolution of the Meeting in accordance with the Board’s proposal pursuant to this point 19 b) must be supported by shareholders representing at least two-thirds of the votes cast and the shares represented at the Meeting. Point 20 a) – Resolution regarding authorization for the Board to decide upon acquisition of own sharesThe Board proposes that the Meeting authorize the Board during the period until the next Annual General Meeting to decide, on one or more occasions, on the acquisition of a maximum number of own shares so that, after the purchase, the Company holds not more than five percent of the total number of shares in the Company. Such shares shall be purchased on Nasdaq Stockholm at a price that is within the registered price interval (spread) at any given time, meaning the interval between the highest bid price and the lowest ask price, and in other respects in accordance with the rules of Nasdaq Stockholm at any given time. The purpose of the repurchase of own shares is firstly to align the Company’s capital structure to the Company’s capital requirements and, where appropriate, to enable share transfers in conjunction with the financing of company acquisitions and other types of strategic investments and acquisitions. An additional objective is to facilitate hedging of costs and delivery in relation to the Performance Share Plan 2015 proposed under point 18. The resolution of the Meeting in accordance with the Board’s proposal pursuant to this point 20 a) must be supported by shareholders representing at least two-thirds of the votes cast and the shares represented at the Meeting. Proposal from shareholderThe shareholder Mahamed Abdi proposes that acquisition of own shares shall be made of not more than ten per cent of the total number of shares in the Company. Point 20 b) – Resolution regarding authorization for the Board to decide upon the transfer of own sharesThe Board proposes that the Meeting authorize the Board during the period until the next Annual General Meeting to decide, on one or more occasions, on the transfer of shares in the Company. The shares may only be transferred in conjunction with the financing of company acquisitions and other types of strategic investments and acquisitions, and the transfers may not exceed the maximum number of treasury shares held by the Company at any given time. Transfer of own shares shall be made either on Nasdaq Stockholm or in another manner. In conjunction with the acquisition of companies or operations, transfer of own shares may be made with deviation from the shareholders’ preferential rights and at a price that is within the so-called spread (see above) at the time of the decision regarding the transfer and in accordance with the rules of Nasdaq Stockholm at any given time. Payment for shares transferred in this manner may be made in cash or through a non-cash issue or offsetting of claims against the Company, or on other specific terms. The reason for the Board’s authorization to waive the shareholders’ preferential rights is, where appropriate, to be able to transfer shares in conjunction with the financing of any company acquisitions and other types of strategic investments and acquisitions in a cost-efficient manner. The resolution of the Meeting in accordance with the Board’s proposal pursuant to this point 20 b) must be supported by shareholders representing at least two-thirds of the votes cast and the shares represented at the Meeting. Point 21 – Appointment of the Nomination CommitteeThe Nomination Committee proposes that the procedure for appointment of Nomination Committee for the Annual General Meeting 2016 shall be arranged in accordance with the following: The Chairman of the Board shall, before the end of the second quarter of the financial year, contact the four largest holders of voting rights, besides the or those shareholders the Chairman of the Board may represent, which may appoint one person each that, together with the Chairman of the Board, shall constitute the Nomination Committee until the end of the next Annual General Meeting, or, where applicable, until a new Nomination Committee has been appointed. Where shareholders refrain from their respective right to appoint a member to the Nomination Committee, the right to appoint a member to the Nomination Committee shall pass on to the thereafter largest holder of voting rights which not yet have appointed or have had the right to appoint a member to the Nomination Committee. Euroclear Sweden AB’s list of shareholders on the last banking day in September and other reliable information being provided the company on such date, shall form the basis of the assessment of which holders of voting rights being the largest. Unless the Nomination Committee unanimous resolves to appoint another member as the Chairman of the Nomination Committee, the Chairman of the Nomination Committee shall be the member of the Nomination Committee being appointed by the largest holder of voting rights. The Nomination Committee shall be entitled to, following a unanimous resolution hereof, appoint a person as co-opt member to the Nomination Committee. Such co-opted member does not participate in the Nomination Committee’s resolutions. The names of the members of the Nomination Committee and the names of those having appointed them, shall be made public as soon as they have been appointed, however no later than six months before the next Annual General Meeting. No remuneration shall be paid to the members of the Nomination Committee. If any of the shareholders having appointed a member to the Nomination Committee sells its shares in the company before the Nomination Committee has fulfilled its assignment, the member that has been appointed by such a shareholder shall, if the Nomination Committee so resolves, be replaced by a member to be appointed by the shareholder at that time being the largest shareholder following the shareholders being represented in the Nomination Committee. If any of the members of the Nomination Committee ceases to represent the shareholder having appointed that member, before the assignment of the Nomination Committee has been fulfilled, that member shall be replaced, if the shareholder so wishes, by a new representative appointed by that shareholder. The Nomination Committee is entitled to, if deemed appropriate and besides a co-opted member possibly appointed in accordance with above, co-opt a member to the Nomination Committee who is appointed by a shareholder who after the constituting of the Nomination Committee, has come to be among the four largest holders of voting rights. Such co-opted member does not participate in the Nomination Committee’s resolutions. The Nomination Committee shall execute its assignment in accordance with the Swedish Corporate Governance Code (Sw. Svensk kod för bolagsstyrning) and other applicable rules. The assignment includes inter alia to present proposals on:i)        Chairman at Annual General Meeting;ii)       Chairman and other members of the Board of Directors;iii)      remuneration to non-executive members;iv)      remuneration to the Company’s auditor and election of auditor; andv)      where so deemed necessary, proposal to amend the instructions for the Nomination Committee. Point 22 – Proposed resolutions by shareholder Thorwald Arvidsson regarding the following:The shareholder Thorwald Arvidsson has requested that the following items shall be addressed at the Annual General Meeting. Point 22 a) – Amendment of section 5 paragraph 2 in the articles of associationAmendment of section 5, paragraph 2 in the articles of association, to reflect that both Class A shares and Class B shares shall carry one vote each. Point 22 b) – Removal of section 12 in the articles of associationIf the resolution in accordance with point 22 a) above is passed, it is proposed that section 12 of the articles of association is removed. Point 22 c) – Instruction to the Board of Directors to write to the GovernmentInstruction to the Board of Directors to write to the Government requesting the repeal of provisions in the Swedish Companies Act allowing for different voting rights for different classes of shares and that a pre-emptive obligation is enforced in public limited liability companies. Point 22 d) – Instruction to the Board of Directors to establish a shareholders’ associationInstruction to the Board of Directors to take appropriate actions in order to, if possible, establish a shareholders’ association for the company’s shareholders. Point 22 e) – Instruction to the Board of Directors regarding shareholder representatives in the Company’s Board of DirectorsInstruction to the Board of Directors to prepare a proposal of a procedure for preparing small- and medium-sized shareholders representation in the Company’s Board of Directors. Point 22 f) – Instruction to the Company’s Nomination Committee regarding the proposed candidates’ ethical standardInstruction to the Company’s Nomination Committee to specifically regard questions connected with the proposed candidates’ ethical standard. Stockholm in July, 2015The Board of Directors of Elekta AB (publ) # # # For further information, please contact:Johan Andersson, Director, Investor Relations, Elekta ABTel: +46 702 100 451, e-mail: johan.andersson@elekta.comTime zone: CET: Central European TimeGert van Santen, Group Vice President Corporate Communications, Elekta ABTel: +31 653 561 242, e-post: gert.vansanten@elekta.comTime zone: CET: Central European TimeThe above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on August 3, 2015.About ElektaElekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.

Precise Biometrics signs license agreement with ELAN

The license agreement will generate royalty revenue based on sales of fingerprint sensors from ELAN that includes Precise BioMatch Mobile. Royalty revenues are volume dependant and cannot be forecasted at this point. The agreement also includes a limited initial fixed fee for the right to integrate and use Precise BioMatch Mobile and for support & maintenance, which will be recognized starting from the third quarter 2015.”The agreement with ELAN further strengthens our position as the leading supplier of software for fingerprint authentication for mobile devices. We welcome ELAN as a partner and appreciate the trust they put in us by selecting our products”, says Håkan Persson, CEO of Precise Biometrics. In a recent market analysis of fingerprint biometrics for mobile devices, Frost & Sullivan praised Precise BioMatch Mobile for providing superior fingerprint authentication for smartphones and tablets. As a result, Precise Biometrics was awarded (http://precisebiometrics.com/news/2015/04/frost-sullivan-awards-leader-in-fingerprint-biometrics/) the “2015 Global Frost & Sullivan Award for Customer Value Leadership in fingerprint biometrics for mobile devices”.Precise BioMatch Mobile provides easy integration of fingerprint matching functionality for smartphones and tablets, and is optimized for small touch sensors in mobile environments through a unique patented hybrid algorithm. The software offers fast, accurate, and secure verification of the user’s identity, creating a convenient user experience for consumers when unlocking their mobile device or authenticating to services, while delivering enhanced security.For more information about ELAN, please visit http://www.emc.com.tw/eng/

Medivir announces that Janssen has started a phase I study to evaluate the effect of simeprevir and odalasvir on AL-335 pharmacokinetics

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies (Janssen) has started a phase I clinical trial to evaluate the potential effect of simeprevir and odalasvir (also known as ACH-3102), on the pharmacokinetics of AL-335 in healthy volunteers.This phase I study is an open-label, two-group study of simeprevir, odalasvir, a hepatitis C virus (HCV) NS5A inhibitor, and of AL-335, a nucleotide-based HCV polymerase inhibitor. The primary objective of the study is to investigate the potential effect of simeprevir and odalasvir on the pharmacokinetics of AL-335 when administered in combination to healthy volunteers.Approximately 150 million people are chronically infected with HCV globally*. When left untreated, HCV causes progressive liver disease in many of those who are chronically infected, and this can lead ultimately to cirrhosis, hepatocellular carcinoma and a requirement for liver transplantation. However, combinations of antiviral agents, including e.g. a protease inhibitor such as simeprevir, have shown the potential to be curative and convenient regimens for patients infected with HCV.Further information about the study can be found at www.clinicaltrials.govFor further information, please contact:Ola Burmark, CFO Medivir AB, mobile: +46 (0)725-480 580.Medivir is required under the Securities Markets Act to make the information in this press release public.The information was submitted for publication at 8.30 CET on 3 August 2015.About Simeprevir (OLYSIO®)Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen Sciences Ireland UC and Medivir AB and indicated for the treatment of chronic hepatitis C infection as a component of a combination antiviral treatment regimen. Simeprevir efficacy has been established in HCV genotype 1 and HCV genotype 4 infected patients with compensated liver disease, including cirrhosis. Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB retains marketing rights for simeprevir in these countries under the marketing authorization held by Janssen-Cilag International NV. In November 2013, simeprevir was approved by the U.S. Food & Drug Administration and, in May 2014, it was granted marketing authorisation by the European Commission. Subsequent marketing authorisations have followed in several other countries around the world. Indications vary by market.About MedivirMedivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List. *http://www.who.int/mediacentre/factsheets/fs164/en/

Evolution launches exclusive Live Casino offering for Marathonbet

The complete range of Evolution generic tables have already gone live, with Live Roulette, Immersive Roulette, Live Baccarat, Live Blackjack and Live Casino Hold’em all now available to players on desktop. Mobile access for these games will be added in September, while Evolution’s online live dealer version of SHFL’s Three Card Poker will join the desktop line-up. In addition, Marathonbet.com will launch a dedicated Live Blackjack table in the coming weeks. All of these live games, which are hosted at Evolution’s Latvia studios, are available to the vast majority of Marathonbet.com’s player base. Completing the extended Marathonbet.com Live Casino rollout will be a number of native speaking dealer services including London Roulette, Deutsches Roulette and Sports Roulette. Thereafter, Marathonbet.com will also use Evolution Live Casino services to expand into regulated markets. Marathonbet has grown significantly in recent years and gained high levels of brand awareness through its investment in sports, notably as Shirt Sponsors for Hibernian as well as Fulham and Dynamo Kiev in the past. They recently announced a three-year deal with Liverpool FC to become the club’s new Regional Betting Partner, in addition to being Official Betting Partners of Tottenham Hotspur and Derby County. Commenting on his company’s decision to select Evolution as its Live Casino provider, Christian Melin, Online Casino Manager at Marathonbet said: “We wanted to work with the market leader, to have premium content and to offer our players a great experience across multiple devices. Our Live Casino is already gaining strong momentum and attracting a high number of unique players. We are confident these numbers will increase even more when we launch our and dedicated Live Blackjack table and mobile product.  Jens von Bahr, CEO of Evolution, commented: “Marathonbet are especially strong in sportsbook, a vertical proven to be a perfect pairing with Live Casino in terms of cross-selling potential and conversions. With Marathonbet looking to drive further growth in regulated markets and to maximise brand awareness, this is a really exciting partnership that will capitalise on the full breadth of the Evolution Live Casino offering.”

Cansteiner Launches Kickstarter Campaign to Create Ultimate Drinking Vessel

Corporate merchandise just got fresher thanks to the launch of an innovative new product that makes cracking open a can of beer smarter, simpler and markedly more stylish. Designed for discerning drinkers, the Cansteiner transforms any 12 oz. can into the ultimate beverage vessel. To fast-track the product to beer drinkers across the globe Cansteiner founders have launched a 30 day Kickstarter campaign aiming to raise $50,000 in 30 days. Nothing says style quite like the mighty stein and for beer drinkers determined to sip with swagger, it’s a superlative accessory. Featuring an interchangeable handle and base, Cansteiner can be secured to any 12 oz. can in a matter of seconds.  Just one snap and users can enjoy their beverage in a refreshing new way. And thanks to the easy grip handle Cansteiner ensures that drinkers don’t spill a drop. As friends are fumbling with stubby holders, suffering from chilly fingers or worse, warming beer with their own hands, Cansteiner owners can enjoy ice cold beverages while looking cool, calm and collected.  While the product has been designed with beer drinkers in mind the Cansteiner lends itself to all manner of beverage. From ales and lagers to coolers and soft drinks, owners can stein any can, at any time, on any occasion. Just like beer brings people together, and so does the Cansteiner. Whether it’s a corporate party or a summer BBQ with family and friends, Cansteiner brings a lively German beer hall atmosphere that will have ‘prosts’ flying in from all angles. For corporate promoters in search of utterly unique merchandise opportunities, Cansteiner is a fresh new opportunity. The company has already secured a bulk order from a high profile Fortune 500 corporation and is expecting to fill an influx of additional orders as the Cansteiner word starts to spread. Justin Saul, VP of marketing said, “Forget pens, caps and backpacks. Cansteiner offers corporate promoters the chance to hand out what the people really want – novelty beer drinking accessories that are both fun and functional!” What started off as an endeavor to build a fun accessory for themselves quickly turned into a lucrative business plan with the potential to take off. Since then the founders have been working towards building a better product, and the Kickstarter campaign is set to fuel this desire. $20,000 will fund the development of rubber inserts for the sides and bottom which will foster an even more comfortable grip. They’ll also allow for greater customization by giving drinkers the option of picking an accent color that complements their personality. Hitting the $30,000 mark will allow Cansteiner to develop a novel new pop top. Drinkers will then be able to pop the top with their thumb and watch their can fly across the room. At $50,000 founders will be able to roll out a flip down lid that will transform any can into a traditional stein!  Should the campaign go above and beyond expectations Cansteiner plans to introduce a range of additional colours. It the future it also has its sights set on manufacturing modular add ons that can be used to help people with disabilities enjoy drinks as they should.  With a patent currently pending, Cansteiner will soon enjoy market exclusivity. To find out more about Cansteiner and join the ‘clip and sip’ revolution, view the Kickstarter campaign http://bit.ly/cansteiner or visit the website http://www.cansteiner.com